<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
      <journal-title-group>
        <journal-title>Nature Communications</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2041-1723</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31541099</article-id>
      <article-id pub-id-type="pmc">6754503</article-id>
      <article-id pub-id-type="publisher-id">12333</article-id>
      <article-id pub-id-type="doi">10.1038/s41467-019-12333-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Agricultural land-uses consistently exacerbate infectious disease risks in Southeast Asia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0204-451X</contrib-id>
          <name>
            <surname>Shah</surname>
            <given-names>Hiral A.</given-names>
          </name>
          <address>
            <email>h.shah16@imperial.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9682-8002</contrib-id>
          <name>
            <surname>Huxley</surname>
            <given-names>Paul</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2097-5465</contrib-id>
          <name>
            <surname>Elmes</surname>
            <given-names>Jocelyn</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8382-0674</contrib-id>
          <name>
            <surname>Murray</surname>
            <given-names>Kris A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution>MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, </institution><institution>School of Public Health, Imperial College London, </institution></institution-wrap>London, UK </aff>
        <aff id="Aff2"><label>2</label>Grantham Institute&#x2014;Climate Change and the Environment&#x2014;Imperial College London, London, UK </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution>Department of Global Health and Development, </institution><institution>London School of Hygiene and Tropical Medicine, </institution></institution-wrap>London, UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>20</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2019</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>4299</elocation-id>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>3</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>8</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2019</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Agriculture has been implicated as a potential driver of human infectious diseases. However, the generality of disease-agriculture relationships has not been systematically assessed, hindering efforts to incorporate human health considerations into land-use and development policies. Here we perform a meta-analysis with 34 eligible studies and show that people who live or work in agricultural land in Southeast Asia are on average 1.74 (CI 1.47&#x2013;2.07) times as likely to be infected with a pathogen than those unexposed. Effect sizes are greatest for exposure to oil palm, rubber, and non-poultry based livestock farming and for hookworm (OR 2.42, CI 1.56&#x2013;3.75), malaria (OR 2.00, CI 1.46&#x2013;2.73), scrub typhus (OR 2.37, CI 1.41&#x2013;3.96) and spotted fever group diseases (OR 3.91, CI 2.61&#x2013;5.85). In contrast, no change in infection risk is detected for faecal-oral route diseases. Although responses vary by land-use and disease types, results suggest that agricultural land-uses exacerbate many infectious diseases in Southeast Asia.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">Here, Shah et al. perform a meta-analysis and show that people who live or work in agricultural land in Southeast Asia are on average 1.7 times more likely to be infected with a pathogen than controls, suggesting that agricultural land-use increases infectious disease risk.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Ecological epidemiology</kwd>
        <kwd>Infectious diseases</kwd>
        <kwd>Epidemiology</kwd>
        <kwd>Risk factors</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par3">Agricultural land-use and land-use change, including agricultural intensification and the conversion of forests, wetlands and grasslands into forest monocultures, crops and pasture, has led to major increases in the production of food, timber, housing and other commodities<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Although delivering economic and social benefits, these human activities have also resulted in substantial negative socio-ecological consequences, such as increased CO<sub>2</sub><sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>, air pollutant emissions<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, loss of biodiversity<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref></sup>, modifications in surface fluxes of heat and water vapour resulting in changing regional weather patterns<sup><xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref></sup>, degradation of air and water quality<sup><xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref></sup> and a decrease in the supply of renewable fresh water<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p>
      <p id="Par4">This trade-off between the considerable costs and benefits at stake places the agricultural sector at the heart of global sustainability, health and environmental frameworks (e.g., Sustainable Development Goals, Paris Agreement, Aichi Biodiversity Targets), and makes simultaneous achievement of key targets a formidable challenge<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.</p>
      <p id="Par5">While the impacts of agricultural land-use activities is relatively well characterised in some sectors (e.g., carbon emissions accounting frameworks<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, biodiversity loss<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>), less well established are the potential impacts on human health, where the majority of existing research signposts towards the health impacts of occupational pesticide, chemical and heavy metal exposure<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. In particular, the evidence linking human-induced land-use changes and infectious disease risk outcomes in humans, many of which are related to agriculture<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x2013;<xref ref-type="bibr" rid="CR32">32</xref></sup>, has not been systematically evaluated or quantified.</p>
      <p id="Par6">Numerous case studies support a link between agricultural land-use or land-use change and infectious disease risks<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. For example, irrigation-based agriculture and rural development can expand breeding habitats of <italic>Culex</italic> vectors and has led to Japanese encephalitis virus establishing a secondary cycle in domestic pig populations where it amplifies and spills over into human populations<sup><xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR36">36</xref></sup>. Deforestation and associated environmental changes may facilitate the transmission of <italic>Plasmodium knowlesi</italic> (cause of zoonotic malaria) to humans in Malaysian Borneo<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>; expansion and changes in agricultural practices are associated with the emergence of Nipah Virus in Malaysia<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and increased <italic>Leptospira</italic> infections and fatalities in Thailand have been observed in open habitats such as rice fields that are prone to flooding<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
      <p id="Par7">In addition, a number of theoretical modelling studies and meta-analyses suggest potentially generalisable links between land-use or land-use change and biodiversity loss (a key outcome of land-use change, albeit not necessarily specific to agricultural activities<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>), some of which may be linked to increases in disease risk. For example, Guo et al.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> find a general increase in host or vector community competence associated with land-use changes. Rohr et al.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> report that agricultural drivers are associated with &gt;25% of emerging infectious diseases and &gt;50% of emerging zoonotic infectious diseases in humans. Faust et al.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> highlight changing host population densities and edge effects as mechanisms that could drive disease emergence in converted landscapes. Civitello et al.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> show that host diversity inhibits parasite abundance (e.g., infection prevalence for microparasites, mean parasite load for macro-parasites, density of infected vectors for vector-borne parasites or percent diseased tissue for plant parasites) and therefore suggest that a generalisable &#x2018;dilution effect&#x2019; may modulate disease risk across a number of disease systems. However, the extent to which these effects extend to human infectious diseases remain highly contentious<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, and few studies focus on specific land-use types.</p>
      <p id="Par8">Here, we test for a generalisable or net impact of occupational or residential exposure to agricultural land-use on the risk of infectious disease in humans in Southeast Asia (SE Asia) via a systematic review and meta-analysis approach, following PRISMA reporting standards for medical and epidemiological evidence syntheses.</p>
      <p id="Par9">A global review was deemed infeasible due to the vast collection of citations that would require double review to achieve PRISMA standards (~50,000 citations). We considered a narrower focus on SE Asia (defined here as the ASEAN region, including, Vietnam, Cambodia, Laos PDR, Thailand, Myanmar, Malaysia, Indonesia, Singapore, Philippines, East Timor and Brunei) as an appropriate model system given its combination of biologically diverse landscapes<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, differing land-uses<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> and because it is considered a zoonotic, parasitic and emerging disease hotspot area<sup><xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. Specifically, we quantified an overall association between where people live or work in SE Asia and disease risk, finding that those in agricultural land are on average almost twice as likely to be infected with a pathogen than controls (odds ratio (OR) 1.74, confidence interval (CI) 1.47&#x2013;2.07, <italic>p</italic>&#x2009;&lt;&#x2009;0.001). We also report consistent associations between forest monoculture agriculture (oil palm and rubber) and a number of specific diseases of differing ecologies and epidemiologies, while accounting for potential effects of publication bias and both within and between-study confounding. Although responses clearly vary by land-use and disease types, generalisable results from this and further studies will help identify co-management opportunities for health and the environment.</p>
    </sec>
    <sec id="Sec2" sec-type="results">
      <title>Results</title>
      <sec id="Sec3">
        <title>Regional analysis</title>
        <p id="Par10">The search strategy returned 15,426 potentially relevant publications in total, 58 of which met the inclusion criteria for full text analysis (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Of these, 34 mutually exclusive studies were included in the regional meta-analysis and a total of 37 mutually exclusive studies were included in the multiple subgroup analyses. Studies spanned five countries (Thailand&#x2009;=&#x2009;11, Malaysia&#x2009;=&#x2009;10, Vietnam&#x2009;=&#x2009;9, Philippines&#x2009;=&#x2009;2, Lao PDR&#x2009;=&#x2009;2), two designs (cross-sectional&#x2009;=&#x2009;27, case&#x2013;control&#x2009;=&#x2009;7) and were assessed as being of varying quality using two study quality tools (Office of Health Assessment and Translation (OHAT)&#x2014;definitely low risk of bias&#x2009;=&#x2009;2, probably low risk of bias&#x2009;=&#x2009;25, probably high risk of bias&#x2009;=&#x2009;10 and National Heart, Lung, and Blood Institute (NHLBI)&#x2014;good&#x2009;=&#x2009;7, fair&#x2009;=&#x2009;23, poor&#x2009;=&#x2009;4). A total of 80 effect estimates were extracted consisting of 26 infectious diseases and 12 different exposures. All included studies were in English and no studies were found to be in any other language. Full details of sample characteristics for each study including analysis groups are presented in Supplementary Data&#xA0;<xref rid="MOESM5" ref-type="media">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA diagram. A flow chart of the study selection process</p></caption><graphic xlink:href="41467_2019_12333_Fig1_HTML" id="d29e416"/></fig></p>
        <p id="Par11">Overall, occupational or residential exposure to agricultural land-use was consistently associated with increased infectious disease risks, but effects varied widely among studies, differing disease groups and agricultural types. A regional analysis of 34 mutually exclusive crude odds ratios from 34 studies demonstrated that people exposed to agricultural land either occupationally or residentially were at a 74% increased risk of being infected with a pathogen than those unexposed (OR 1.74, CI 1.45&#x2013;2.05, <italic>p</italic>&#x2009;&lt;&#x2009;0.001, <italic>E</italic>&#x2009;=&#x2009;2.01, Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Although a larger number of positive studies were included within our sample data set, as shown in the funnel plot (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>), linear regression tests and the trim and fill analyses (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) highlighted no evidence of publication bias on the overall effect size. High between-study heterogeneity (<italic>I</italic><sup>2</sup>&#x2009;=&#x2009;83.8%) was nevertheless observed, indicating considerable variability in effects among studies.<fig id="Fig2"><label>Fig. 2</label><caption><p>Regional meta-analysis. Regional meta-analysis of mutually exclusive risk estimates to determine the association between occupational or residential exposure to agricultural land-use and infectious disease prevalence. Exposure to 'agriculture' is defined as a category where a person indicates they work or live in or near agriculture regardless of the type of agriculture. Square points show the crude odds ratio for each study, solid diamonds show the pooled meta-analysis estimates and error bars are defined as the 95% confidence interval. Note: <italic>Q</italic>, the Cochrane <italic>Q-</italic>test. Df, degrees of freedom. <italic>p</italic>, <italic>p</italic>-value. <italic>I</italic><sup>2</sup>, test for heterogeneity. RE, random effects</p></caption><graphic xlink:href="41467_2019_12333_Fig2_HTML" id="d29e465"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Funnel plot for the regional meta-analysis. A plot of the logarithmic risk estimates vs. the precision (standard error) for each study, with adjustment using the trim and fill method. Closed circles denote identified studies and their summary measures, respectively. Open circles represent missing studies after adjustment for funnel plot asymmetry and the summary measure incorporating hypothetical studies, respectively. Key areas of statistical significance have been superimposed on the funnel, and the plot is now centred at zero. The yellow zones show effects between <italic>p</italic>&#x2009;=&#x2009;0.10 and <italic>p</italic>&#x2009;=&#x2009;0.05, and the orange zones show effects between <italic>p</italic>&#x2009;=&#x2009;0.05 and <italic>p</italic>&#x2009;=&#x2009;0.01. Effects in the white zone are greater than <italic>p</italic>&#x2009;=&#x2009;0.10 and effects in the grey zones are smaller than <italic>p</italic>&#x2009;=&#x2009;0.01. A <italic>Z</italic>-test was conducted to calculate <italic>p-</italic>values</p></caption><graphic xlink:href="41467_2019_12333_Fig3_HTML" id="d29e499"/></fig></p>
        <p id="Par12">To assess the impact for within study confounding, a meta-analysis of 17 mutually exclusive adjusted odds ratios from 17 studies was conducted suggesting that people exposed to agricultural land either occupationally or residentially were similarly at significantly increased risk of being infected with a pathogen than those unexposed (OR 1.46, CI 1.11&#x2013;1.92, <italic>p</italic>&#x2009;&lt;&#x2009;0.001, Supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). Tests of the potential effect of unmeasured confounders suggested that an excluded variable(s) would have to have a minimum odds ratio of 2.03 with both the exposure and outcome to fully explain away the pooled result (<italic>E</italic>&#x2009;=&#x2009;2.03).</p>
      </sec>
      <sec id="Sec4">
        <title>Subgroup analyses</title>
        <p id="Par13">To evaluate the impact of between-study confounding, we examined the influence of a range of additional study and sample characteristics on effect size and direction, including study type and methodology, socio-demographic characteristics (gender, whether children were included in the sample population, and rural vs. urban), both study quality assessments and study location. In this test, associations consistent with the overall positive effect were observed irrespective of study and sample characteristics (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>), strengthening confidence that the pooled result is robust to a range of measured and, by extension, unmeasured confounders. In addition, the significant heterogeneity observed among studies in the regional pooled analysis (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) does not suggest the presence of systematic bias from unmeasured confounders.<fig id="Fig4"><label>Fig. 4</label><caption><p>Sensitivity analysis of the regional meta-analysis. A priori subgroups based on study characteristics to test the sensitivity of the regional meta-analysis. Results suggest that subgroups based on study characteristics do not significantly alter the direction of the association between occupational or residential exposure to agricultural land-use and infectious disease prevalence. Circle points show the pooled subgroup estimates and error bars are defined as the 95% confidence interval. Note: <italic>n</italic>, number of studies included in each pooled estimate. CI, confidence intervals. OHAT, Office of Health Assessment and Translation. NHLBI, National Heart, Lung and Blood Institute</p></caption><graphic xlink:href="41467_2019_12333_Fig4_HTML" id="d29e533"/></fig></p>
        <p id="Par14">Nevertheless, one effect modifier/confounder variable (study setting) exhibited a divergence in effect sizes between groups, suggesting a possible interaction with the main effect of agricultural exposure. Here, the effect of agricultural exposure on infection was more than twice as strong in studies in urban than in rural settings, preserving the possibility that the pooled effect is vulnerable to the effect of unmeasured confounders, albeit here insufficient to explain away the pooled result. In addition, a single subgroup indicated a lack of significant association (studies based in Lao PDR). However, given the effect sizes and direction for these groups did not deviate considerably from the pooled effect, we considered this more likely due to small sample size than evidence of potential confounding. Finally, low heterogeneity for some stratum specific covariates alongside consistent effect sizes indicates that the source of heterogeneity is likely coming from elsewhere, warranting the use of further subgroup analyses to scrutinise the pooled result and to test our hypotheses on differences in effect between agricultural types and disease groups.</p>
        <p id="Par15">Further subgroup analysis was performed using mutually exclusive estimates based on common exposure types (Figs.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig6" ref-type="fig">6</xref>) and for specific disease classes (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>). Consistent associations between agricultural exposure and infection were again evident. For the non-specific agricultural group, a similar effect was observed with all infectious diseases (OR 1.71, CI 1.38&#x2013;2.13). When stratifying the non-specific agricultural group by disease class, significant effects were observed for parasitic (OR 1.74, CI 1.41&#x2013;2.13), vector-borne (OR 1.85, CI 1.18&#x2013;2.90) and zoonotic diseases (OR 1.63, CI 1.19&#x2013;2.24). A marginal non-significant effect was found for bacterial diseases (OR 1.79, CI 0.97&#x2013;3.31, <italic>I</italic><sup>2&#x2009;=&#x2009;</sup>89.4%) (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref> and Supplementary Table&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Agricultural exposure-based subgroup analysis. Subgroups were created a priori based on exposures that had two or more mutually exclusive estimates. Agriculture (non-specific) is defined as a category where a person indicates they work in agriculture regardless of the type of agriculture. Square points show the pooled subgroup estimates and error bars are defined as the 95% confidence interval</p></caption><graphic xlink:href="41467_2019_12333_Fig5_HTML" id="d29e567"/></fig><fig id="Fig6"><label>Fig. 6</label><caption><p>Livestock exposure-based subgroup analysis. Livestock farming is defined as a category where a person indicates they are exposed to livestock generally regardless of the specific type of livestock (e.g., chickens). Porcine, Bovine or Poultry exposure is defined as a person being exposed to each of these respective animal types. Square points show the pooled subgroup estimates and error bars are defined as the 95% confidence interval</p></caption><graphic xlink:href="41467_2019_12333_Fig6_HTML" id="d29e576"/></fig><fig id="Fig7"><label>Fig. 7</label><caption><p>Disease-based subgroup analysis. Subgroups were created a priori based on diseases that had two or more mutually exclusive estimates. <italic>Orientia tsutsugamushi</italic> is also known as Scrub typhus. <italic>Rickettsia typhi</italic> is otherwise known as murine typhus. <italic>Opisthorchis viverrini</italic> is also known as Opisthorchiasis. Square points show the pooled subgroup estimates and error bars are defined as the 95% confidence interval</p></caption><graphic xlink:href="41467_2019_12333_Fig7_HTML" id="d29e594"/></fig></p>
        <p id="Par16">Among the specific agricultural subgroups, the effect was higher in populations working or living in or near oil palm and being infected with vector-borne and&#xA0;zoonotic diseases (leptospirosis and <italic>P. knowlesi)</italic> compared to those unexposed (OR 3.25, CI 2.29&#x2013;4.61). Similarly, exposure to rubber plantations increased the risk of being infected with all types of pathogens (OR 2.27, CI 1.82&#x2013;2.82). This effect was also consistent when stratified by disease class where significant associations were found for bacterial (OR 2.27, CI 1.79&#x2013;2.89), parasitic (OR 2.24, CI 1.35&#x2013;3.74), vector-borne (OR 2.27, CI 1.82&#x2013;2.82) and zoonotic (OR 2.31, CI 1.83&#x2013;2.94) disease class subgroups (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref> and Supplementary Table&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>).</p>
        <p id="Par17">Significant associations were observed for general livestock farming (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref> and Supplementary Table&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>) and all diseases (OR 2.54, CI 1.37&#x2013;4.72), zoonotic (OR 2.46, CI 1.35&#x2013;4.48), vector-borne (OR 2.52, CI 1.48&#x2013;4.28) and bacterial (OR 4.47, CI 1.30&#x2013;15.39) diseases. A marginal non-significant-positive association was also established between livestock farming and viral diseases (OR 1.55, CI 0.83&#x2013;2.81). Further subgrouping by livestock type showed consistent marginal non-significant-positive effects. Specifically, marginal associations were observed between porcine animals and all diseases (OR 3.57, CI 0.84&#x2013;15.23), vector-borne (OR 3.09, CI 0.58&#x2013;16.46), zoonotic (OR 3.57, CI 0.84&#x2013;15.23) and viral (OR 4.31, CI 0.49&#x2013;37.81) diseases. Effect sizes found for bovine animals were consistent for all, vector-borne or zoonotic diseases (OR 2.09, CI 0.80&#x2013;5.49) and bacterial diseases (OR 2.40, CI 0.57&#x2013;10.12). No associations were found for exposure to poultry and all, vector-borne or zoonotic diseases (OR 0.91, CI 0.24&#x2013;3.45). There was no evidence of publication bias for any other exposure-based subgroups (Supplementary Table&#xA0;<xref rid="MOESM1" ref-type="media">2</xref>).</p>
        <p id="Par18">Exposure to rice paddy farming (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>) resulted in a non-significant association for all diseases (OR 1.34, CI 0.81&#x2013;2.23), bacterial (OR 1.40, CI 0.71&#x2013;2.77), zoonotic or vector-borne (OR 1.17, CI 0.62&#x2013;2.21) disease class subgroups. However, trim and fill tests (Supplementary Table&#xA0;<xref rid="MOESM1" ref-type="media">2</xref>) indicated the presence of publication bias in which positive associations between agricultural exposure and general infection were under-reported among studies on rice paddy farming. When accounted for, the effect of agricultural exposure on infection risk within the rice paddy farming subgroup became significant (OR 1.81, CI 1.04&#x2013;3.17, <italic>p</italic>&#x2009;=&#x2009;0.037 (<italic>Z-</italic>test), <italic>E</italic>&#x2009;=&#x2009;1.47), suggesting that the overall effect is likely conservative.</p>
        <p id="Par19">A final subgroup analysis based on specific diseases or disease complexes again showed consistent associations between infection and agricultural exposure (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref> and Supplementary Table&#xA0;<xref rid="MOESM1" ref-type="media">3</xref>), notably for spotted fever group rickettsioses (OR 3.91, CI 2.61&#x2013;5.85), hookworm (OR 2.42, CI 1.56&#x2013;3.75), scrub typhus (OR 2.37, CI 1.41&#x2013;3.96), malaria (OR 2.00, CI 1.46&#x2013;2.73), <italic>S. japonicum</italic> (OR 1.71, CI 1.18&#x2013;2.48) and <italic>T. trichuria</italic> (OR 1.40, CI 1.27&#x2013;1.53). In contrast, no significant association was observed for the <italic>A. lumbrocoides, O. viverrini, E. histolytica, G. intestinalis</italic>, Leptospirosis and <italic>R. typhi</italic> subgroups. Again, there was little evidence of publication bias or unmeasured confounding for significant effect sizes, although heterogeneity remained present in many groups (see Supplementary Tables&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">2</xref> and <xref rid="MOESM1" ref-type="media">3</xref> for all estimates).</p>
      </sec>
    </sec>
    <sec id="Sec5" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par20">Agricultural land-use or land-use change has been repeatedly linked to infectious disease risks in humans<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR48">48</xref>&#x2013;<xref ref-type="bibr" rid="CR53">53</xref></sup>; however, no study has systematically assessed or quantified this association. Based on currently available evidence from 37 eligible studies drawn from a corpus of over 15,000 peer-reviewed publications, our results strongly suggest that exposure to agricultural land-use either occupationally or residentially is consistently associated with increased infectious disease risk (average 74% increase), an effect evident across a wide range of agricultural types and disease groups. After pooling adjusted risk estimates from 17 eligible studies, a similar significant association was still evident, suggesting that there was little within study confounding.</p>
      <p id="Par21">Effects were most pronounced for oil palm monoculture (&gt;3 times the risk) and rubber (&gt;2 times the risk) forest monocultures and a strong association was also found for livestock farming. Associations for specific diseases or disease complexes were present for spotted fever group rickettsioses, hookworm, scrub typhus, malaria, <italic>S. japonicum</italic> and <italic>T. trichuria</italic>, but absent for other groups (<italic>A. lumbrocoides</italic>, <italic>G. intestinalis, E. histolytica</italic>, leptospirosis, opisthorchiasis and <italic>R. typhi</italic>). No evidence of publication bias was detected in the regional meta-analysis, but evidence of bias was present in the rice paddy farming subgroup analysis, whereby studies documenting positive associations between agriculture and all types of infection were under-represented, suggesting the overall effect is conservative. Considerable heterogeneity among studies and subgroups alongside negative tests for potential confounding from both measured and unmeasured effect modifiers further suggest that the results are robust to a range of possible sources of bias.</p>
      <p id="Par22">Subgroup analysis, in which data were grouped by common exposures and then stratified by aetiological agent (parasitic, viral, bacterial), transmission mode (vector-borne, zoonotic) or specific disease types or disease complexes, nevertheless highlight the potential complexity and variability of agriculture-infectious disease associations. The particularly strong effects that were observed for the two-forest monoculture-based agricultural types (oil palm and rubber) are key findings. All these crops have been planted extensively in recent decades and been major contributors to land-use changes in this region. For example, between 2005 and 2010, almost 250,000 hectares of natural vegetation with tree cover was converted to rubber plantations in SE Asia<sup><xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>, and the loss of primary forests for the cultivation of oil palm in Indonesia (especially on Sumatra and Borneo islands) quadrupled between 2000 and 2012 to 800,000 hectares a year<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. In 2010, with an estimated 122 million people working in agriculture in SE Asia, ~115 million hectares (approx. 28% of the total area) were harvested for rice, maize, oil palm, natural rubber and coconut<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Our results thus have far reaching implications for a large fraction of SE Asia currently under cultivation or planned for agricultural conversion; that agricultural land-uses and even differing agricultural types appear to exacerbate infectious disease risks more than others raises the possibility that land-use decisions could be tailored to minimise human health impacts.</p>
      <p id="Par23">Mechanisms by which crop monocultures impact the risk of infectious diseases are difficult to untangle and likely idiosyncratic. Deforestation or different agricultural land-uses may favour some disease hosts or vectors (influencing e.g., abundance, distributions or transmission dynamics), while the loss of biodiversity has also been linked to increases in disease risk in some cases<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. For example, a decrease in wild mammal species richness in fragmented habitats was associated with a higher seroprevalence of Chagas disease in small mammal reservoir hosts<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>. In other cases, different agricultural land-use types could be frequented by people, modifying contact rates with animal hosts or vectors, and combinations of these effects are also probable. Fornace et al.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, for example, show that a higher incidence of <italic>P. knowlesi</italic> is associated with larger amounts of forest loss surrounding villages, which may have caused changes in macaque or mosquito habitats in addition to increased levels of human activity, thereby increasing the risk of infection in humans.</p>
      <p id="Par24">Landscape factors such as distribution, density, behaviour and population dynamics of vectors and their hosts are partially controlled by landscape features such as vegetation cover, surface moisture, topography or soil type, which in turn may also influence the level of transmission of an infection<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Oil palm, rubber plantation and rice paddy monocultures have reduced species richness compared with primary and secondary forests<sup><xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>, and these monocultures are structurally less complex than natural forests typically exhibiting a more uniform age structure, lower or no canopy, sparse undergrowth, less stable and more extreme microclimates, and greater levels of human disturbance and presence<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref></sup>. Evidence suggests that such changes related to physical characteristics of the landscape or biodiversity loss itself could favour disease carrying hosts or vectors or increase the efficacy of disease transmission to remaining hosts (in this case people). For example, Burkett-Cadena and Vittor<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> suggest that an increased mosquito vector abundance was positively associated with deforestation. Of the mosquito species that were favoured by deforestation, 56.5% were confirmed vectors of human pathogens, compared to 27.5% of species that were negatively impacted by deforestation. Faust et al.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> also suggest that the greatest risk of spillover events occur at intermediate levels of habitat loss, whereas the largest, but rarest, epidemics occur at extremes of land conversion. Our results are thus consistent with these previous empirical<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup> and modelling studies<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR49">49</xref>&#x2013;<xref ref-type="bibr" rid="CR51">51</xref></sup>, and further support suggestions that deforestation resulting in crop monocultures is particularly problematic for elevating infection risks in susceptible nearby populations.</p>
      <p id="Par25">Whereas many previous studies have focussed on land-use change and deforestation explicitly, our analysis is largely blind to prior land-cover history. We nevertheless find variation in disease risk among specific agricultural land-use types, suggesting that an effect on disease risk likely goes beyond simply a change in land cover (e.g., from forest to crop monoculture) to include the final characteristics of modified agricultural landscapes. To further untangle mechanisms here would require a more detailed data set on land-cover history (e.g., class transitions), scale and context.</p>
      <p id="Par26">Previous research on the association between livestock farming and infectious disease risk has been inconsistent<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR66">66</xref>&#x2013;<xref ref-type="bibr" rid="CR72">72</xref></sup>, whereas here we find consistent associations between infectious disease risks and exposure to livestock farming. Our subgroup analysis for separate livestock categories (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>) suggests that infection risk may vary according to exposure to the type of animals farmed, with pigs and cattle exposure being positively associated with infection while poultry exposure having no association. Our results further show consistent positive associations between livestock farming and differing disease classes, whereby exposure to livestock can result in two to four times the risk of being infected with vector-borne, bacterial or zoonotic diseases. We also find a marginal association with livestock farming and viral diseases, albeit with small sample sizes likely limiting power to confirm the positive effect. Livestock disease transmission can occur through multiple routes, including airborne, direct faecal-oral, animal bites and scratches, contaminated animal products and consumption of uncooked meat<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>. Alternatively, the impact of livestock may be to act as amplifier hosts<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup>, while livestock housing studies show that keeping livestock, such as cattle in the house as opposed to shelters outside the house contributes to increased disease risk rather than zoo-prophylaxis<sup><xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. In addition, global changes in climate, agricultural intensification and expansion for livestock, trade, travel and closer interactions with livestock have facilitated infectious disease transmission<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. Further empirical data from appropriately powered epidemiological studies are required to confirm our results and better identify mechanisms.</p>
      <p id="Par27">Effect variability was also observed among specific disease or disease complex subgroups. Significant associations ranging between 1.4 and 2.9 times the risk of infection when exposed to agricultural land-use were identified for hookworm, malaria, scrub typhus, <italic>S. japonicum</italic>, spotted fever group rickettsioses and <italic>Trichuris trichiura</italic>. In contrast, no effect was seen for <italic>A. lumbrocoides, E. histolytica, G. intestinalis</italic>, <italic>O. viverrini</italic>, Leptospirosis and <italic>R. typhi</italic>. These results again illustrate the potential complexity of agriculture-disease associations, whereby agricultural land-use could be impacting the transmission cycles of these disease groups in different ways or otherwise unmeasured effect modifiers could be at play.</p>
      <p id="Par28">Specific disease traits or epidemiological characteristics likely explain these differences, at least in part. For example, previous research suggests that arthropod vectors, such as mosquitoes and ticks, and helminths may be more vulnerable to environmental changes, such as agricultural land-uses than other taxa<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. Since we find significant associations only for parasitic or vector-borne diseases (and no association for directly transmitted zoonotic or faecal-oral route diseases) our results broadly support this suggestion. Mechanistically, this may be linked to the modification of environmental niches, changes in the community composition, or alterations in the behaviour or movement of vector species<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR79">79</xref></sup>. For example, malaria in the Mekong region has been associated with dense forest cover and also with cultivated areas<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. Forest-fringe and deforested regions can also create suitable habitats for malaria vectors (e.g., <italic>Anopheles minimus</italic>)<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>. Therefore, the wide mosquito vector diversity and the potential for mosquito vectors to adapt in deep-forests and forest-fringes, in addition to the movement of susceptible humans to and from the forest, provide ideal conditions for sustained and novel transmission<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>.</p>
      <p id="Par29">Despite this trend, some diseases for which no effect was observed were helminths, and in this case variation in effect may be related to subtler transmission characteristics or other unmeasured confounders. <italic>A. lumbrocoides</italic> or <italic>O. viverrini</italic>, for example, are transmitted via the faecal-oral route, whereas <italic>T. trichuria, S. japonicum</italic> and hookworm are transmitted through skin penetration. Although both cases and controls will be infected via the same transmission mechanism, people exposed to agriculture may be more susceptible to infection with faecal-oral route transmitted diseases due to the use of night soil (human faeces) as fertiliser to improve crop yield. Using night soil as fertiliser is prevalent in SE Asia, although there are no estimates on how widespread it may be<sup><xref ref-type="bibr" rid="CR83">83</xref>&#x2013;<xref ref-type="bibr" rid="CR85">85</xref></sup>, making it difficult to include explicitly as a potential confounding factor. Similarly, variation in effects between diseases could be a result of differential responses to public health interventions. For example, the efficacy of praziquantel mass drug administration is higher for <italic>A. lumbrocoides</italic> compared to <italic>T. trichuria</italic> or hookworm<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>, but again incorporating treatment history as a potential effect modifier was not possible here.</p>
      <p id="Par30">Results show significant associations between exposure to agriculture and spotted fever group rickettsioses or scrub typhus, but not <italic>R. typhi</italic>. This difference could again be linked to transmission characteristics. Although all are vector-borne, both spotted fever rickettsioses and scrub typhus are tick-borne typhus-based diseases, while <italic>R. typhi</italic> is flea borne. This is in line with current research that suggests ticks are highly susceptible to environmental change<sup><xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. For example, Lyme disease (a tick-borne disease) has increased with forest fragmentation in North America<sup><xref ref-type="bibr" rid="CR89">89</xref>&#x2013;<xref ref-type="bibr" rid="CR91">91</xref></sup>. Ostfeld et al.<sup><xref ref-type="bibr" rid="CR92">92</xref></sup> also find that tick-borne infection prevalence was lowest when forest cover within a 1&#x2009;km radius was high. We find very little research to suggest environmental change as having large impacts on flea borne diseases<sup><xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. Previous research does suggest that <italic>R. typhi</italic> is largely an urban disease where overcrowding, poor public health and sanitation measures are considered key risk factors for transmission<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>. Specifically, <italic>R. typhi</italic> typically thrives in markets, grain stores, breweries and garbage depots where rats serve as the main reservoir, which may explain the lack of association with agriculture reported here<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>.</p>
      <p id="Par31">Our results also contrast with previous studies in the case of agriculture and leptospirosis. Whereas we found no overall effect for leptospirosis, previous studies have yielded mixed results<sup><xref ref-type="bibr" rid="CR94">94</xref>&#x2013;<xref ref-type="bibr" rid="CR96">96</xref></sup>. Research conducted in Thailand suggests that the sources of human and rodent infections are different, where humans are infected in villages in non-forested areas located near rivers while rats are infected in forest patches situated in the hilly areas<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. In Asia, humans are known to be infected through prolonged contact with water that may be contaminated by infected animal hosts<sup><xref ref-type="bibr" rid="CR97">97</xref>,<xref ref-type="bibr" rid="CR98">98</xref></sup>. Such environmental transmission is directly linked to frequent occupational exposure to agricultural land-use and establishing causal pathways between the environment, animal hosts and human risk is therefore required for such complex eco-epidemiologies.</p>
      <p id="Par32">Although we find a consistent association between agricultural land-use and infectious disease risk in humans, there are several inherent challenges in resolving agriculture-disease associations and some limitations in this study that could be improved upon or resolved in future studies.</p>
      <p id="Par33">First, despite the diverse range of generally robust results reported in this study, our systematic assessment of study quality does highlight an apparent lack of robust and high-quality studies that assess the impact of differing agriculture types, the degree of exposure to agriculture (e.g., more or less) and land-use change on infectious disease risks in SE Asia. Considering an initial 15,476 articles were generated from a sensitive and specific search strategy, just 34 (0.2%) met the inclusion and exclusion criteria and were included in the regional meta-analysis. All retained articles focus on agriculture as the main land-use types, as opposed to other conventional land-use practices, such as road building, dam building, mining and urbanisation. Only a small number of studies focus on the final human health outcome, while in contrast many studies focus on infectious diseases in plants or animals<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR99">99</xref>&#x2013;<xref ref-type="bibr" rid="CR101">101</xref></sup>. Similar research aiming to evaluate the impacts of agricultural land-use on biodiversity appears far more prevalent and incorporates a wider range of land-use types<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR102">102</xref>,<xref ref-type="bibr" rid="CR103">103</xref></sup>. Caution is therefore advised in interpreting our results so as to avoid generalisations not supported by the data.</p>
      <p id="Par34">In addition, studies in the meta-analysis were all either case control or cross-sectional studies, which, in the hierarchy of evidence within the medical sciences, are considered more prone to bias and confounding than some other study designs (i.e., cohort studies or randomised controlled trials)<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. Nevertheless, most of the studies were evaluated to have probably low risk of bias or be of fair quality, indicating that there is only a small chance that a fatal flaw would invalidate an individual study&#x2019;s findings. Despite this, we identify a general paucity of the highest quality studies on the human health implications of land-use decision making and policy, and its impacts on infectious diseases. Further studies that capture bias, confounding and effect modification would be particularly valuable.</p>
      <p id="Par35">Second, we were not able to determine whether the associations are significant spatially and temporally or if the associations are transient. Understanding whether the association between land-use and infectious disease is consistent both spatially and temporally is an important avenue for future research. Specifically, understanding the causal relationships, leading from distal environmental changes to alterations in more proximal environmental characteristics and disease transmission cycles, which eventually lead to a shift in the risk of infectious diseases at the landscape level<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> should be prioritised for future research.</p>
      <p id="Par36">Third, although we made extensive efforts to control (through our inclusion/exclusion criteria and the subgroup analysis) or at least detect (through tests of heterogeneity, the meta-analysis of adjusted odds ratios and <italic>E</italic>-score tests) the potential effect of confounders and effect modifiers, there are likely to be environmental, social, demographic or even economic factors that could impact the association between land-use and infectious disease risks. Participatory epidemiology offers the opportunity to conduct bottom up agro-system analytical research on the patterns of diseases in animal and human populations<sup><xref ref-type="bibr" rid="CR105">105</xref>&#x2013;<xref ref-type="bibr" rid="CR107">107</xref></sup>. Participatory epidemiological research has previously provided insights into how social factors (which can be potential confounders or effect modifiers) can impact ecological processes. For example, the involvement of women in the care and preparation of poultry carcasses in Egypt could contribute to higher incidence of highly pathogenic avian influenza in women<sup><xref ref-type="bibr" rid="CR106">106</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup>. Similarly, understanding how local indigenous herder knowledge on the clinical signs of classical acute and milder rinderpest has previously aided in the control and eradication of rinderpest<sup><xref ref-type="bibr" rid="CR106">106</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup>. Hence, participatory mixed methods research is an ideal platform to assess effect modification and confounding and their potential impact on disease-agriculture relationships.</p>
      <p id="Par37">Finally, substantial heterogeneity was also observed in our regional meta-analyses, where <italic>I</italic><sup>2</sup> values were &gt;80%. The substantial heterogeneity may be due to clinical heterogeneity or statistical heterogeneity. Clinical heterogeneity occurs where the exposure is modified by factors that vary across studies, the type of exposure (e.g., different agricultural types&#x2014;rice vs. rubber) or study participant characteristics<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>. Differences between studies in the definition or the measurement of exposure or outcome, may all lead to a difference in effects. In contrast, statistical heterogeneity exists when the true effects being evaluated differ between studies and may be detectable if the variation between the results of the studies is above that expected by chance<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. Further subgroup and sensitivity analysis showed that heterogeneity decreased to a moderate level (<italic>I</italic><sup>2</sup>&#x2009;&lt;&#x2009;60%) only for certain subgroups<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR112">112</xref></sup>. This suggests that some of the observed heterogeneity is attributable to epidemiological and environmental differences within this subgroup<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR113">113</xref></sup>. There was little evidence of significant publication bias in our analyses (except for rice paddy farming), and any publication bias that was present had very little impact on the pooled association.</p>
      <p id="Par38">This meta-analysis provides broad evidence that occupational or residential exposure to differing types of agriculture can consistently exacerbate infectious disease risks in humans in SE Asia. These trends suggest that further expansion or intensification of land-use for agricultural purposes may result in the novel emergence of pathogens as observed elsewhere (e.g., refs. <sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR114">114</xref>,<xref ref-type="bibr" rid="CR115">115</xref></sup>) or increased transmission of zoonotic, parasitic or vector-borne diseases (e.g., refs. <sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>). However, the results presented in this study also provide an opportunity for land-use decision makers, governments, companies and agriculturalists to recognise the impact that agricultural land-use or land-use change may have on susceptible populations and proactively identify measures to mitigate these risks.</p>
      <p id="Par39">Given a range of other negative externalities of agriculture identified in other fields (e.g., carbon emissions, air pollution, biodiversity loss), the potential for better land-use decisions to collectively minimise infectious disease impacts alongside these other impacts is large. Enhancing the sustainability of agriculture has already been identified as a nexus issue that is central to meeting a diverse range of development and environmental targets, such as the SDGs, the Aichi biodiversity targets, and the Paris agreement<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Key measures are already being proposed to sustainably meet this multiplicity of demands through policy changes, such as reducing food wastage throughout the food supply chain<sup><xref ref-type="bibr" rid="CR116">116</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup>, advocation of reduced emissions and more sustainable diets<sup><xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup>, efforts in soil management techniques<sup><xref ref-type="bibr" rid="CR120">120</xref></sup>, responsible consumption of animal products<sup><xref ref-type="bibr" rid="CR120">120</xref></sup> and biodiversity-friendly farming practices<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. Our study provides critical additional evidence to propel human health impacts from infectious diseases into this mix to further advance health targets (e.g., SDG3, Target 3.3)<sup><xref ref-type="bibr" rid="CR122">122</xref></sup> as a central component of improving the sustainability of agricultural development more broadly.</p>
    </sec>
    <sec id="Sec6">
      <title>Methods</title>
      <sec id="Sec7">
        <title>Search strategy and selection process</title>
        <p id="Par40">Following PRISMA protocol and reporting standards for systematic reviews, we independently and systematically screened articles in April 2017 using five academic literature databases: Medline, PubMed, Global Health, Web of Science and EMBASE alongside Google Scholar.</p>
        <p id="Par41">Search strings were created through a PECOS statement using three categories (exposure, location and outcome) with Boolean operators AND between categories and OR within categories. Where applicable, MeSH terms for communicable disease, SE Asia, land-use and agriculture were also used. Differing land-use types were incorporated into the search strategy to improve the sensitivity of the search. To improve the specificity of the search strategy, the location category was only applied for title and abstracts, to capture all publications that had a study context within SE Asia. No language restrictions were placed within the search strategy. An example of the search strategy can be found in the Supplementary Note&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>.</p>
        <p id="Par42">Articles were initially assessed for relevance first by title, as well as keywords if these were available, then by abstract and finally by full text. We simultaneously assessed the suitability of the studies retained after screening for full text analysis for their potential inclusion in meta-analyses, rejecting studies for which risk or odds estimates could not be calculated. Disagreements were resolved by consensus, and where no consensus was achieved a third investigator was consulted. One reviewer (H.S.) then extracted outcome and exposure data as well as data on population and study characteristics into a bespoke data extraction framework, which was then validated by a second reviewer (P.H.)<sup><xref ref-type="bibr" rid="CR112">112</xref></sup>.</p>
      </sec>
      <sec id="Sec8">
        <title>Eligibility</title>
        <p id="Par43">Following PRISMA guidelines and the PICOS framework, we considered the following factors to determine eligibility criteria: &#x2018;study question&#x2019;, &#x2018;populations&#x2019;, &#x2018;exposure&#x2019;, &#x2018;comparators&#x2019; and &#x2018;outcome&#x2019;. A description of each follows.</p>
        <p id="Par44">Study Question&#x2014;Is there an association between occupational or residential exposure to agricultural land-uses and being infected with a pathogen for adults aged 18 and above in SE Asia?</p>
        <p id="Par45">Study Design&#x2014;Empirical observational studies (longitudinal cohorts, case control or cross-sectional) studies conducted in the Association of Southeast Asian Nations (ASEAN) region and reported in English were considered eligible. We anticipated that the extent and effects of language bias may have diminished recently because of the shift towards publication of studies in English<sup><xref ref-type="bibr" rid="CR123">123</xref></sup><xref ref-type="bibr" rid="CR123">;</xref> however, we reserved the option to have non-English articles translated to bolster sample sizes if a reasonable number of non-English studies were found.</p>
        <p id="Par46">Populations&#x2014;This study drew participants from the general adult population aged 18 and above in SE Asia. Studies that recruited participants of all ages (including children) were also included. Studies that focused exclusively on the child population were excluded.</p>
        <p id="Par47">Exposure&#x2014;The primary exposure of interest was defined as occupational or residential exposure to agriculture or agricultural land-use. This was defined as whether study participants would be working or living in or near agricultural land. Specifically, agricultural exposure was defined as any person who partakes in the cultivation of land and breeding of animals and plants to provide food, fibre, medicinal plants and other products either for domestic, residential, occupational or economic purposes<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>.</p>
        <p id="Par48">Comparators&#x2014;Studies were included if they compared outcomes in the exposed group with those in a group of unexposed people (people who are not occupationally or residentially exposed to agriculture or agricultural land-use).</p>
        <p id="Par49">Outcome&#x2014;Studies were included if one of the primary outcomes include prevalence, seroprevalence or incidence for all infectious diseases that have a biologically plausible link to agriculture or agricultural land-use.</p>
        <p id="Par50">Studies that investigated non-communicable disease or infectious diseases of plants, invertebrates or fish were excluded. We also excluded studies that were not based on SE Asia, did not include some form of land-use as an exposure or study focus, were theoretical research papers, reviews, commentaries or letters, or were not published in English (following determining that few non-English studies meeting all other criteria were available, see above). Studies that presented odds ratios based on the co-infection of &gt;1 disease were excluded as co-infection could increase susceptibility to other infectious diseases<sup><xref ref-type="bibr" rid="CR124">124</xref></sup>. Studies that assessed the impact of using human faeces (night soil) as fertiliser in agriculture were also excluded<sup><xref ref-type="bibr" rid="CR83">83</xref>&#x2013;<xref ref-type="bibr" rid="CR85">85</xref></sup>. This is because using human faeces as fertiliser was not considered a land-use but rather a confounding behavioural activity. Studies that assessed risk factors of disease in children were also excluded<sup><xref ref-type="bibr" rid="CR125">125</xref>,<xref ref-type="bibr" rid="CR126">126</xref></sup> as children may be exposed to agricultural work but may also be more susceptible to certain diseases. An explicit bulleted inclusion and exclusion criteria can be found in the Supplementary Note&#xA0;<xref rid="MOESM1" ref-type="media">2</xref>.</p>
      </sec>
      <sec id="Sec9">
        <title>Study quality</title>
        <p id="Par51">A methodological study quality assessment was conducted using two quality appraisal tools sourced from the OHAT and the NHLBI Quality Assessment website.</p>
        <p id="Par52">The first tool was the OHAT Risk of Bias Rating Tool for Human and Animal Studies, which evaluates the assessment of whether the design and conduct of the study compromised the credibility of the link between exposure and outcome. The OHAT for human studies contains 11 risk-of-bias questions that cover six different domains, including selection, confounding, performance, attrition/exclusion, detection, and selective reporting bias. Six of the 11 questions are applicable for cross-sectional and case control studies and are answered using one of four predefined answer choices (1) definitely low risk of bias; (2) probably low risk of bias; (3) probably high risk of bias; and (4) definitely high risk of bias. Studies were excluded from this review if they had an average rating of definitely high risk of bias and/or if there was substantial evidence that the studies showed threats to internal validity.</p>
        <p id="Par53">The second set of tools were for Observational Cohort and Cross-Sectional Studies (QAT&#x2014;OCCSS), and for case control studies (QAT&#x2014;CCS). Both tools had 14 and 9 items, respectively, that classified study quality using specific epidemiological parameters, such as transparency of research question, sources of potential bias (e.g., selection or measurement), study power, confounding and other items that inferred internal validity of each study<sup><xref ref-type="bibr" rid="CR127">127</xref>,<xref ref-type="bibr" rid="CR128">128</xref></sup>. A greater number of Yes responses indicated a higher study quality for both study quality tools. Studies were classed as good if they presented information on all key criteria within the tools such as: research question, study population, sample size justification, exposure measurement and outcome measurement. Studies were classed as fair if they presented some information on the key criteria. Poor studies were classed as studies that could not satisfy the majority of key criteria.</p>
      </sec>
      <sec id="Sec10">
        <title>Data synthesis and statistical analysis</title>
        <p id="Par54">Data were summarised as the number of individuals with and without infection stratified by whether they were exposed to agricultural land-use or not. Associations were quantified using the odds ratio (OR) with a 95% confidence interval. This was extracted where possible from the studies or self-calculated using relevant data where possible. Where ORs could not be extracted or calculated due to poor or non-reported data, studies were excluded from the meta-analysis<sup><xref ref-type="bibr" rid="CR112">112</xref></sup>.</p>
        <p id="Par55">A regional meta-analysis was conducted with a random effects model<sup><xref ref-type="bibr" rid="CR110">110</xref>,<xref ref-type="bibr" rid="CR129">129</xref></sup> to calculate a pooled estimate that quantifies the overall impact of how any occupational or residential exposure to agricultural land-use impacts the odds of infectious disease prevalence. For this, we selected mutually exclusive studies and odds estimates to be incorporated into the regional meta-analysis. This was to avoid any double counting of estimates, which could otherwise bias pooled estimates. Only one estimate was used per study and other estimates from the same study population were excluded. This was achieved by systematically selecting risk/odds estimates based on agriculture as a general occupational exposure. However, in some cases, studies provided multiple agricultural exposures or multiple disease outcomes in the same study (e.g., oil palm, rice, rubber as an exposure type or hookworm, <italic>T. trichuria</italic> and <italic>A. lumbrocoides</italic> infection as the outcome). In these types of studies, we selected the exposure and outcome that had the largest number of cases to maximise study power. In some instances, there were multiple publications by the same author analysing the same study population<sup><xref ref-type="bibr" rid="CR130">130</xref>&#x2013;<xref ref-type="bibr" rid="CR132">132</xref></sup>. In these cases, only the most recent publication was selected for incorporation into the overall analysis.</p>
        <p id="Par56">Random effects meta-analyses assume that a distribution of effects exists across all studies included in the analyses, resulting in heterogeneity among study results. The use of a random effects model was considered appropriate here because we assume that the associations between occupational or residential exposure to agricultural land-use or land-use change and infectious disease risks are likely to be inconsistent and idiosyncratic, which might otherwise bias the results. Therefore, we considered a random effects meta-analysis to be a more conservative approach than fixed effects analysis<sup><xref ref-type="bibr" rid="CR110">110</xref>,<xref ref-type="bibr" rid="CR129">129</xref></sup>.</p>
        <p id="Par57">All analyses were conducted in R version 3.2.5<sup><xref ref-type="bibr" rid="CR133">133</xref></sup> with the metafor package<sup><xref ref-type="bibr" rid="CR134">134</xref></sup>.</p>
      </sec>
      <sec id="Sec11">
        <title>Heterogeneity and subgroup analysis</title>
        <p id="Par58">We first tested heterogeneity of effect sizes among studies included in our overall analysis using the <italic>I</italic><sup>2</sup> statistic and the Cochranes <italic>Q-</italic>test. A value of &gt;75% for the <italic>I</italic><sup>2</sup> statistic is generally considered to suggest substantial heterogeneity<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR113">113</xref></sup>.</p>
        <p id="Par59">We performed a subgroup analysis to determine how robust the regional meta-analysis result would be to certain study characteristics using the estimates from the regional meta-analysis. Here we created a priori subgroups on study type, sampling strategy, study setting, outcome measurement, study quality, study country and the characteristics of the study population.</p>
        <p id="Par60">Subgroup analyses were conducted on common exposures stratified by aetiological agent (parasitic, viral, bacterial) and transmission mode (vector-borne, zoonotic) or specific disease or disease complex subgroups that had more than two mutually exclusive estimates available. In order to preserve sample sizes and remain epidemiologically realistic, aetiological agent and transmission mode subgroups were not constrained to be mutually exclusive (e.g., a disease can be both vector-borne and zoonotic, such as zoonotic malaria).</p>
        <p id="Par61">Common exposures that had more than two estimates included non-specific agriculture (defined as a category where a person indicates they work in agriculture regardless of the type of agriculture), livestock farming, oil palm plantation work, rice paddy farming and rubber plantation work. Livestock farming was further stratified into common livestock groups, including porcine, bovine and poultry related exposure. Common diseases that had more than two risk estimates included <italic>Ascaris lumbrocoides, Entamoeba histolytica, Giardia intestinalis</italic>, hookworm, leptospirosis, malaria, <italic>Opisthorchis viverrini</italic>, scrub typhus (<italic>Orientia tsutsugamushi), Rickettsia typhi, Schistosoma japonicum</italic>, spotted fever group and <italic>Trichuris trichiura</italic>.</p>
      </sec>
      <sec id="Sec12">
        <title>Confounding</title>
        <p id="Par62">We were unable to adjust our pooled regional meta-analysis estimate for known confounders and effect modifiers due to lack of individual participant level data. However, we conducted a meta-analysis of adjusted odds ratios extracted from each study to assess the potential impact of within study confounding.</p>
        <p id="Par63">In addition, considering that the association between land-use and infectious disease may be impacted by many variables that are unmeasured or unreported in published articles (e.g., temperature, rainfall, climate, soil type, topography, socio-economic status), we conducted a sensitivity analysis using an <italic>E</italic>-value to test for between-study unmeasured confounding. The <italic>E</italic>-value represents the strength of association an unmeasured confounder would need to have with both the treatment and outcome to fully explain away a specific risk factor-outcome association<sup><xref ref-type="bibr" rid="CR135">135</xref></sup>. The <italic>E</italic>-value is calculated using the following equation: <italic>E</italic>-value&#x2009;=&#x2009;OR&#x2009;+&#x2009;sqrt {OR&#x2009;&#xD7;&#x2009;(OR&#x2009;&#x2212;&#x2009;1)}<sup><xref ref-type="bibr" rid="CR135">135</xref></sup>.</p>
        <p id="Par64">When calculating the <italic>E</italic>-value, unmeasured confounders are not listed and tested explicitly. Additionally, the <italic>E</italic>-value, does not assess measurement or selection bias. The <italic>E</italic>-value results also do not guarantee that if a confounder with parameters of a particular strength exists, then it necessarily explains away the effect. Rather, it is, only possible to construct scenarios in which it could. Readers and other researchers may then assess whether any confounding associations of that magnitude are biologically plausible<sup><xref ref-type="bibr" rid="CR135">135</xref></sup>.</p>
      </sec>
      <sec id="Sec13">
        <title>Publication bias</title>
        <p id="Par65">We assessed publication bias in three ways. First, we plotted individual study effect sizes against the standard error of each study as a measure of the study size in funnel plots to visually assess asymmetry<sup><xref ref-type="bibr" rid="CR136">136</xref></sup>. Second, we tested this asymmetry using Egger&#x2019;s linear regression test, in which significant asymmetry would suggest bias or heterogeneity<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>. Finally, we used a trim and fill method to further assess if there was a likelihood of missing studies that might exist and whether this would impact the pooled estimate. This method imputes hypothetical negative unpublished studies to mirror the positive studies, and recalculates a pooled estimate to assess the impact these hypothetical studies have on the pooled effect size<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR139">139</xref></sup>.</p>
      </sec>
      <sec id="Sec14">
        <title>Reporting summary</title>
        <p id="Par66">Further information on research design is available in the&#xA0;<xref rid="MOESM3" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec15">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2019_12333_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2019_12333_MOESM2_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2019_12333_MOESM3_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41467_2019_12333_MOESM4_ESM.pdf"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41467_2019_12333_MOESM5_ESM.csv"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Peer review information</bold> Nature Communications thanks Richard Kock and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.</p>
      </fn>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p><bold>Supplementary Information</bold> accompanies this paper at 10.1038/s41467-019-12333-z.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Julie Wendling for research support. We thank Julia Dunn (Imperial College London) for her insights into the epidemiology and control of helminths. We also thank the many experts that provided constructive feedback on earlier drafts of the manuscript, including Professor Paolo Vineis, Dr Roman Carrasco, and members of the EXPOsOMICS and Malaria Modelling teams at Imperial College London. We also acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development (MR/R015600/1). H.S. is a Grantham Institute and Commonwealth Scientific and Industrial Research Organisation (CSIRO) funded Ph.D student with the Science and Solutions for a Changing Planet Doctoral Training Partnership at the Grantham Institute, Imperial College London. P.H. is a Natural Environment Research Council (NERC) funded Ph.D student with the Science and Solutions for a Changing Planet Doctoral Training Partnership at the Grantham Institute, Imperial College London.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>H.S., J.E. and K.M. designed the study. H.S. and P.H. conducted the systematic review. H.S. wrote the modelling code, conducted the analysis and generated the figures. H.S. and K.M. wrote the manuscript, and all authors contributed to edits and revisions.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>The authors declare that all published data collated during the systematic review supporting the findings of this study are available within the paper and its Supplementary Information files. The final data set is presented in Supplementary Data&#xA0;<xref rid="MOESM5" ref-type="media">1</xref> and Supplementary Note&#xA0;<xref rid="MOESM1" ref-type="media">3</xref>. This data set presents information extracted by the reviewers and highlights the estimates used for each analysis. A description of the data set is presented in Description of Additional Supplementary Files.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par67">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawler</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Projected land-use change impacts on ecosystem services in the United States</article-title>
          <source>Proc. Natl. Acad. Sci.</source>
          <year>2014</year>
          <volume>111</volume>
          <fpage>7492</fpage>
          <lpage>7497</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1405557111</pub-id>
          <pub-id pub-id-type="pmid">24799685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costanza</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Changes in the global value of ecosystem services</article-title>
          <source>Glob. Environ. Chang.</source>
          <year>2014</year>
          <volume>26</volume>
          <fpage>152</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.1016/j.gloenvcha.2014.04.002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costanza</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The value of the world&#x2019;s ecosystem services and natural capital</article-title>
          <source>Nature</source>
          <year>1998</year>
          <volume>387</volume>
          <fpage>253</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1038/387253a0</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houghton</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Revised estimates of the annual net flux of carbon to the atmosphere from changes in land use and land management 1850-2000</article-title>
          <source>Tellus, Ser. B Chem. Phys. Meteorol.</source>
          <year>2003</year>
          <volume>55</volume>
          <fpage>378</fpage>
          <lpage>390</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vermeulen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ingram</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Climate change and food systems</article-title>
          <source>Annu. Rev. Environ. Resour.</source>
          <year>2012</year>
          <volume>37</volume>
          <fpage>195</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-environ-020411-130608</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilcove</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Giam</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>LP</given-names>
            </name>
          </person-group>
          <article-title>Navjot&#x2019;s nightmare revisited: logging, agriculture, and biodiversity in Southeast Asia</article-title>
          <source>TRENDS Ecol. Evol.</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>531</fpage>
          <lpage>540</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tree.2013.04.005</pub-id>
          <pub-id pub-id-type="pmid">23764258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sodhi</surname>
              <given-names>NS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deforestation and avian extinction on tropical landbridge islands</article-title>
          <source>Conserv. Biol.</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>1290</fpage>
          <lpage>1298</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1523-1739.2010.01495.x</pub-id>
          <pub-id pub-id-type="pmid">20345403</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sodhi</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Brook</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>PKLL</given-names>
            </name>
          </person-group>
          <article-title>Southeast Asian biodiversity: an impending disaster</article-title>
          <source>Trends Ecol. Evol.</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>654</fpage>
          <lpage>660</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tree.2004.09.006</pub-id>
          <pub-id pub-id-type="pmid">16701328</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wanger</surname>
              <given-names>TC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of land-use change on community composition of tropical amphibians and reptiles in Sulawesi, Indonesia</article-title>
          <source>Conserv. Biol.</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>795</fpage>
          <lpage>802</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1523-1739.2009.01434.x</pub-id>
          <pub-id pub-id-type="pmid">20151989</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newbold</surname>
              <given-names>Tim</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>Lawrence N.</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>Helen R. P.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>Samantha L. L.</given-names>
            </name>
            <name>
              <surname>Contu</surname>
              <given-names>Sara</given-names>
            </name>
            <name>
              <surname>Lysenko</surname>
              <given-names>Igor</given-names>
            </name>
            <name>
              <surname>Blandon</surname>
              <given-names>Abigayil</given-names>
            </name>
            <name>
              <surname>Butchart</surname>
              <given-names>Stuart H. M.</given-names>
            </name>
            <name>
              <surname>Booth</surname>
              <given-names>Hollie L.</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>Julie</given-names>
            </name>
            <name>
              <surname>De Palma</surname>
              <given-names>Adriana</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>Michelle L. K.</given-names>
            </name>
            <name>
              <surname>Kirkpatrick</surname>
              <given-names>Lucinda</given-names>
            </name>
            <name>
              <surname>Pynegar</surname>
              <given-names>Edwin</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>Alexandra</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>Jake</given-names>
            </name>
            <name>
              <surname>Mace</surname>
              <given-names>Georgina M.</given-names>
            </name>
            <name>
              <surname>Scharlemann</surname>
              <given-names>J&#xF6;rn P. W.</given-names>
            </name>
            <name>
              <surname>Purvis</surname>
              <given-names>Andy</given-names>
            </name>
          </person-group>
          <article-title>A global model of the response of tropical and sub-tropical forest biodiversity to anthropogenic pressures</article-title>
          <source>Proceedings of the Royal Society B: Biological Sciences</source>
          <year>2014</year>
          <volume>281</volume>
          <issue>1792</issue>
          <fpage>20141371</fpage>
          <pub-id pub-id-type="doi">10.1098/rspb.2014.1371</pub-id>
          <pub-id pub-id-type="pmid">25143038</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gibson</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary forests are irreplaceable for sustaining tropical biodiversity</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>478</volume>
          <fpage>378</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="doi">10.1038/nature10425</pub-id>
          <pub-id pub-id-type="pmid">21918513</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">Houghton, J. T. et al. <italic>Climate Change 2001: The Scientific Basis</italic>. (Cambridge University Press, 2001).</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pielke</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Betts</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Land use and climate change</article-title>
          <source>Sci. (80-.).</source>
          <year>2005</year>
          <volume>310</volume>
          <fpage>1625</fpage>
          <lpage>1626</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1120529</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feddema</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>The importance of land-cover change in simulating future climates</article-title>
          <source>Sci. (80-.).</source>
          <year>2005</year>
          <volume>310</volume>
          <fpage>1674</fpage>
          <lpage>1678</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1118160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Scanlon, B. R., Jolly, I., Sophocleous, M. &amp; Zhang, L. Global impacts of conversions from natural to agricultural ecosystems on water resources: quantity versus quality. <italic>Water Resour. Res</italic>. <bold>43</bold>, W03437 (2007).</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Leavitt</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Quinlan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dixit</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Smol</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Effects of agriculture, urbanization, and climate on water quality in the northern Great Plains</article-title>
          <source>Limnol. Oceanogr.</source>
          <year>1999</year>
          <volume>44</volume>
          <fpage>739</fpage>
          <lpage>756</lpage>
          <pub-id pub-id-type="doi">10.4319/lo.1999.44.3_part_2.0739</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aneja</surname>
              <given-names>VP</given-names>
            </name>
            <name>
              <surname>Carolina</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Carolina</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schlesinger</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Erisman</surname>
              <given-names>JANW</given-names>
            </name>
          </person-group>
          <article-title>ons</article-title>
          <source>Environ. Sci. Technol.</source>
          <year>2009</year>
          <volume>43</volume>
          <fpage>4234</fpage>
          <pub-id pub-id-type="doi">10.1021/es8024403</pub-id>
          <pub-id pub-id-type="pmid">19603628</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moss</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Water pollution by agriculture</article-title>
          <source>Philos. Trans. R. Soc. B Biol. Sci.</source>
          <year>2008</year>
          <volume>363</volume>
          <fpage>659</fpage>
          <lpage>666</lpage>
          <pub-id pub-id-type="doi">10.1098/rstb.2007.2176</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rockstr&#xF6;m</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sustainable intensification of agriculture for human prosperity and global sustainability</article-title>
          <source>Ambio</source>
          <year>2017</year>
          <volume>46</volume>
          <fpage>4</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1007/s13280-016-0793-6</pub-id>
          <pub-id pub-id-type="pmid">27405653</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="other">IPCC. <italic>Land Use, Land-Use Change, and Forestry</italic>. <italic>Intergovernmental Panel on Climate Change</italic> (IPCC, 2000).</mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newbold</surname>
              <given-names>Tim</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>Lawrence N.</given-names>
            </name>
            <name>
              <surname>Arnell</surname>
              <given-names>Andrew P.</given-names>
            </name>
            <name>
              <surname>Contu</surname>
              <given-names>Sara</given-names>
            </name>
            <name>
              <surname>De Palma</surname>
              <given-names>Adriana</given-names>
            </name>
            <name>
              <surname>Ferrier</surname>
              <given-names>Simon</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>Samantha L. L.</given-names>
            </name>
            <name>
              <surname>Hoskins</surname>
              <given-names>Andrew J.</given-names>
            </name>
            <name>
              <surname>Lysenko</surname>
              <given-names>Igor</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>Helen R. P.</given-names>
            </name>
            <name>
              <surname>Burton</surname>
              <given-names>Victoria J.</given-names>
            </name>
            <name>
              <surname>Chng</surname>
              <given-names>Charlotte W. T.</given-names>
            </name>
            <name>
              <surname>Emerson</surname>
              <given-names>Susan</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Di</given-names>
            </name>
            <name>
              <surname>Pask-Hale</surname>
              <given-names>Gwilym</given-names>
            </name>
            <name>
              <surname>Hutton</surname>
              <given-names>Jon</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>Martin</given-names>
            </name>
            <name>
              <surname>Sanchez-Ortiz</surname>
              <given-names>Katia</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>Benno I.</given-names>
            </name>
            <name>
              <surname>Whitmee</surname>
              <given-names>Sarah</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Hanbin</given-names>
            </name>
            <name>
              <surname>Scharlemann</surname>
              <given-names>J&#xF6;rn P. W.</given-names>
            </name>
            <name>
              <surname>Purvis</surname>
              <given-names>Andy</given-names>
            </name>
          </person-group>
          <article-title>Has land use pushed terrestrial biodiversity beyond the planetary boundary? A global assessment</article-title>
          <source>Science</source>
          <year>2016</year>
          <volume>353</volume>
          <issue>6296</issue>
          <fpage>288</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1126/science.aaf2201</pub-id>
          <pub-id pub-id-type="pmid">27418509</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newbold</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global effects of land use on local terrestrial biodiversity</article-title>
          <source>Nature</source>
          <year>2015</year>
          <volume>520</volume>
          <fpage>45</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1038/nature14324</pub-id>
          <pub-id pub-id-type="pmid">25832402</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muchuweti</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heavy metal content of vegetables irrigated with mixtures of wastewater and sewage sludge in Zimbabwe: Implications for human health</article-title>
          <source>Agric. Ecosyst. Environ.</source>
          <year>2006</year>
          <volume>112</volume>
          <fpage>41</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1016/j.agee.2005.04.028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wesseling</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McConnell</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Partanen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hogstedt</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Agricultural pesticide use in developing countries: health effects and research needs</article-title>
          <source>Int. J. Heal. Serv.</source>
          <year>1997</year>
          <volume>27</volume>
          <fpage>273</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.2190/E259-N3AH-TA1Y-H591</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patz</surname>
              <given-names>Jonathan A.</given-names>
            </name>
            <name>
              <surname>Daszak</surname>
              <given-names>Peter</given-names>
            </name>
            <name>
              <surname>Tabor</surname>
              <given-names>Gary M.</given-names>
            </name>
            <name>
              <surname>Aguirre</surname>
              <given-names>A. Alonso</given-names>
            </name>
            <name>
              <surname>Pearl</surname>
              <given-names>Mary</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>Jon</given-names>
            </name>
            <name>
              <surname>Wolfe</surname>
              <given-names>Nathan D.</given-names>
            </name>
            <name>
              <surname>Kilpatrick</surname>
              <given-names>A. Marm</given-names>
            </name>
            <name>
              <surname>Foufopoulos</surname>
              <given-names>Johannes</given-names>
            </name>
            <name>
              <surname>Molyneux</surname>
              <given-names>David</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>David J.</given-names>
            </name>
          </person-group>
          <article-title>Unhealthy Landscapes: Policy Recommendations on Land Use Change and Infectious Disease Emergence</article-title>
          <source>Environmental Health Perspectives</source>
          <year>2004</year>
          <volume>112</volume>
          <issue>10</issue>
          <fpage>1092</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="doi">10.1289/ehp.6877</pub-id>
          <pub-id pub-id-type="pmid">15238283</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patz</surname>
              <given-names>Jonathan A.</given-names>
            </name>
            <name>
              <surname>Graczyk</surname>
              <given-names>Thaddeus K.</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>Nina</given-names>
            </name>
            <name>
              <surname>Vittor</surname>
              <given-names>Amy Y.</given-names>
            </name>
          </person-group>
          <article-title>Effects of environmental change on emerging parasitic diseases</article-title>
          <source>International Journal for Parasitology</source>
          <year>2000</year>
          <volume>30</volume>
          <issue>12-13</issue>
          <fpage>1395</fpage>
          <lpage>1405</lpage>
          <pub-id pub-id-type="doi">10.1016/S0020-7519(00)00141-7</pub-id>
          <pub-id pub-id-type="pmid">11113264</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottdenker</surname>
              <given-names>Nicole L.</given-names>
            </name>
            <name>
              <surname>Streicker</surname>
              <given-names>Daniel G.</given-names>
            </name>
            <name>
              <surname>Faust</surname>
              <given-names>Christina L.</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>C. R.</given-names>
            </name>
          </person-group>
          <article-title>Anthropogenic Land Use Change and Infectious Diseases: A Review of the Evidence</article-title>
          <source>EcoHealth</source>
          <year>2014</year>
          <volume>11</volume>
          <issue>4</issue>
          <fpage>619</fpage>
          <lpage>632</lpage>
          <pub-id pub-id-type="doi">10.1007/s10393-014-0941-z</pub-id>
          <pub-id pub-id-type="pmid">24854248</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambin</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vanwambeke</surname>
              <given-names>SO</given-names>
            </name>
            <name>
              <surname>Linard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Soti</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Pathogenic landscapes: Interactions between land, people, disease vectors, and their animal hosts</article-title>
          <source>Int. J. Health Geogr.</source>
          <year>2010</year>
          <volume>9</volume>
          <fpage>54</fpage>
          <pub-id pub-id-type="doi">10.1186/1476-072X-9-54</pub-id>
          <pub-id pub-id-type="pmid">20979609</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="other">McFarlane, R. A., Sleigh, A. C. &amp; McMichael, A. J. Land-use change and emerging infectious disease on an island continent. <italic>Int. J. Environ. Res. Public Health</italic> (2013). 10.3390/ijerph1007269</mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>Kris A</given-names>
            </name>
            <name>
              <surname>Daszak</surname>
              <given-names>Peter</given-names>
            </name>
          </person-group>
          <article-title>Human ecology in pathogenic landscapes: two hypotheses on how land use change drives viral emergence</article-title>
          <source>Current Opinion in Virology</source>
          <year>2013</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>79</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1016/j.coviro.2013.01.006</pub-id>
          <pub-id pub-id-type="pmid">23415415</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faust</surname>
              <given-names>CL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pathogen spillover during land conversion</article-title>
          <source>Ecol. Lett.</source>
          <year>2018</year>
          <volume>21</volume>
          <fpage>471</fpage>
          <lpage>483</lpage>
          <pub-id pub-id-type="doi">10.1111/ele.12904</pub-id>
          <pub-id pub-id-type="pmid">29466832</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>BA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Zoonosis emergence linked to agricultural intensification and environmental change</article-title>
          <source>Proc. Natl Acad. Sci.</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>8399</fpage>
          <lpage>8404</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1208059110</pub-id>
          <pub-id pub-id-type="pmid">23671097</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kock</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Vertebrate reservoirs and secondary epidemiological cycles of vector-borne diseases</article-title>
          <source>Rev. Sci. Tech.</source>
          <year>2015</year>
          <volume>34</volume>
          <fpage>151</fpage>
          <lpage>163</lpage>
          <pub-id pub-id-type="doi">10.20506/rst.34.1.2351</pub-id>
          <pub-id pub-id-type="pmid">26470455</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erlanger</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Keiser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Utzinger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wiedenmayer</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Past, present, and future of Japanese encephalitis</article-title>
          <source>Emerg. Infect. Dis.</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.3201/eid1501.080311</pub-id>
          <pub-id pub-id-type="pmid">19116041</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Misra</surname>
              <given-names>UK</given-names>
            </name>
            <name>
              <surname>Kalita</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Overview: Japanese encephalitis</article-title>
          <source>Prog. Neurobiol.</source>
          <year>2010</year>
          <volume>91</volume>
          <fpage>108</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pneurobio.2010.01.008</pub-id>
          <pub-id pub-id-type="pmid">20132860</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keiser</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of irrigated rice agriculture on Japanese encephalitis, including challenges and opportunities for integrated vector management</article-title>
          <source>Acta Trop.</source>
          <year>2005</year>
          <volume>95</volume>
          <fpage>40</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1016/j.actatropica.2005.04.012</pub-id>
          <pub-id pub-id-type="pmid">15878762</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fornace</surname>
              <given-names>Kimberly M.</given-names>
            </name>
            <name>
              <surname>Abidin</surname>
              <given-names>Tommy Rowel</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>Neal</given-names>
            </name>
            <name>
              <surname>Brock</surname>
              <given-names>Paddy</given-names>
            </name>
            <name>
              <surname>Grigg</surname>
              <given-names>Matthew J.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>Amanda</given-names>
            </name>
            <name>
              <surname>William</surname>
              <given-names>Timothy</given-names>
            </name>
            <name>
              <surname>Menon</surname>
              <given-names>Jayaram</given-names>
            </name>
            <name>
              <surname>Drakeley</surname>
              <given-names>Chris J.</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>Jonathan</given-names>
            </name>
          </person-group>
          <article-title>Association between Landscape Factors and Spatial Patterns ofPlasmodium knowlesiInfections in Sabah, Malaysia</article-title>
          <source>Emerging Infectious Diseases</source>
          <year>2016</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>201</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="doi">10.3201/eid2202.150656</pub-id>
          <pub-id pub-id-type="pmid">26812373</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Mapping the risk of Nipah virus spillover into human populations in South and Southeast Asia</article-title>
          <source>Trans. R. Soc. Trop. Med. Hyg.</source>
          <year>2015</year>
          <volume>109</volume>
          <fpage>563</fpage>
          <lpage>571</lpage>
          <pub-id pub-id-type="doi">10.1093/trstmh/trv055</pub-id>
          <pub-id pub-id-type="pmid">26179654</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DELLA ROSSA</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>TANTRAKARNAPA</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>SUTDAN</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>KASETSINSOMBAT</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>COSSON</surname>
              <given-names>J.-F.</given-names>
            </name>
            <name>
              <surname>SUPPUTAMONGKOL</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>CHAISIRI</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>TRAN</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>SUPPUTAMONGKOL</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>BINOT</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>LAJAUNIE</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>MORAND</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Environmental factors and public health policy associated with human and rodent infection by leptospirosis: a land cover-based study in Nan province, Thailand</article-title>
          <source>Epidemiology and Infection</source>
          <year>2015</year>
          <volume>144</volume>
          <issue>7</issue>
          <fpage>1550</fpage>
          <lpage>1562</lpage>
          <pub-id pub-id-type="doi">10.1017/S0950268815002903</pub-id>
          <pub-id pub-id-type="pmid">26607833</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baeza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Santos-Vega</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dobson</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Pascual</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The rise and fall of malaria under land-use change in frontier regions</article-title>
          <source>Nat. Ecol. Evol.</source>
          <year>2017</year>
          <volume>1</volume>
          <fpage>0108</fpage>
          <pub-id pub-id-type="doi">10.1038/s41559-017-0108</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <mixed-citation publication-type="other">Guo, F., Bonebrake, T. C. &amp; Gibson, L. Land-use change alters host and vector communities and may elevate disease risk. <italic>Ecohealth</italic> 1&#x2013;12 (2018). 10.1007/s10393-018-1336-3</mixed-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rohr</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Emerging human infectious diseases and the links to global food production</article-title>
          <source>Nat. Sustain.</source>
          <year>2019</year>
          <volume>2</volume>
          <fpage>445</fpage>
          <lpage>456</lpage>
          <pub-id pub-id-type="doi">10.1038/s41893-019-0293-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Civitello</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biodiversity inhibits parasites: Broad evidence for the dilution effect</article-title>
          <source>Proc. Natl Acad. Sci. U.S.A.</source>
          <year>2015</year>
          <volume>112</volume>
          <fpage>8667</fpage>
          <lpage>8671</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1506279112</pub-id>
          <pub-id pub-id-type="pmid">26069208</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salkeld</surname>
              <given-names>Daniel J</given-names>
            </name>
            <name>
              <surname>Padgett</surname>
              <given-names>Kerry A</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>James Holland</given-names>
            </name>
          </person-group>
          <article-title>A meta-analysis suggesting that the relationship between biodiversity and risk of zoonotic pathogen transmission is idiosyncratic</article-title>
          <source>Ecology Letters</source>
          <year>2013</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>679</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="doi">10.1111/ele.12101</pub-id>
          <pub-id pub-id-type="pmid">23489376</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coker</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Rudge</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Liverani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hanvoravongchai</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Emerging infectious diseases in southeast Asia: regional challenges to control</article-title>
          <source>Lancet (Lond., Engl.)</source>
          <year>2011</year>
          <volume>377</volume>
          <fpage>599</fpage>
          <lpage>609</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(10)62004-1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="other">World Health Organization (WHO). <italic>WHO | Communicable Diseases in the South-East Asia Region of the World Health Organization: Towards A More Effective Response</italic>. (WHO, 2011).</mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coleman</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Top 100 research questions for biodiversity conservation in Southeast Asia</article-title>
          <source>Biol. Conserv.</source>
          <year>2019</year>
          <volume>234</volume>
          <fpage>211</fpage>
          <lpage>220</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biocon.2019.03.028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keesing</surname>
              <given-names>Felicia</given-names>
            </name>
            <name>
              <surname>Belden</surname>
              <given-names>Lisa K.</given-names>
            </name>
            <name>
              <surname>Daszak</surname>
              <given-names>Peter</given-names>
            </name>
            <name>
              <surname>Dobson</surname>
              <given-names>Andrew</given-names>
            </name>
            <name>
              <surname>Harvell</surname>
              <given-names>C. Drew</given-names>
            </name>
            <name>
              <surname>Holt</surname>
              <given-names>Robert D.</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>Peter</given-names>
            </name>
            <name>
              <surname>Jolles</surname>
              <given-names>Anna</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>Kate E.</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>Charles E.</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>Samuel S.</given-names>
            </name>
            <name>
              <surname>Bogich</surname>
              <given-names>Tiffany</given-names>
            </name>
            <name>
              <surname>Ostfeld</surname>
              <given-names>Richard S.</given-names>
            </name>
          </person-group>
          <article-title>Impacts of biodiversity on the emergence and transmission of infectious diseases</article-title>
          <source>Nature</source>
          <year>2010</year>
          <volume>468</volume>
          <issue>7324</issue>
          <fpage>647</fpage>
          <lpage>652</lpage>
          <pub-id pub-id-type="doi">10.1038/nature09575</pub-id>
          <pub-id pub-id-type="pmid">21124449</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="other">Herrera, D. et al. Upstream watershed condition predicts rural children&#x2019;s health across 35 developing countries. <italic>Nat. Commun</italic>. <bold>8</bold>, 811 (2017).</mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olivero</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recent loss of closed forests is associated with Ebola virus disease outbreaks</article-title>
          <source>Sci. Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>14291</fpage>
          <pub-id pub-id-type="doi">10.1038/s41598-017-14727-9</pub-id>
          <pub-id pub-id-type="pmid">29085050</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pienkowski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dickens</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Carrasco</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Empirical evidence of the public health benefits of tropical forest conservation in Cambodia: a generalised linear mixed-effects model analysis</article-title>
          <source>Lancet Planet. Heal.</source>
          <year>2017</year>
          <volume>1</volume>
          <fpage>e180</fpage>
          <lpage>e187</lpage>
          <pub-id pub-id-type="doi">10.1016/S2542-5196(17)30081-5</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Myers</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Patz</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Emerging threats to human health from global environmental change</article-title>
          <source>Annu. Rev. Environ. Resour.</source>
          <year>2009</year>
          <volume>34</volume>
          <fpage>223</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.environ.033108.102650</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eisenberg</surname>
              <given-names>Joseph N.S.</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>Manish A.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>Karen</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>Sarah J.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>Song</given-names>
            </name>
            <name>
              <surname>Naumoff</surname>
              <given-names>Kyra</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>James C.</given-names>
            </name>
          </person-group>
          <article-title>Environmental Determinants of Infectious Disease: A Framework for Tracking Causal Links and Guiding Public Health Research</article-title>
          <source>Environmental Health Perspectives</source>
          <year>2007</year>
          <volume>115</volume>
          <issue>8</issue>
          <fpage>1216</fpage>
          <lpage>1223</lpage>
          <pub-id pub-id-type="doi">10.1289/ehp.9806</pub-id>
          <pub-id pub-id-type="pmid">17687450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahrends</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Current trends of rubber plantation expansion may threaten biodiversity and livelihoods</article-title>
          <source>Glob. Environ. Chang. POLICY Dimens.</source>
          <year>2015</year>
          <volume>34</volume>
          <fpage>48</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1016/j.gloenvcha.2015.06.002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bartholom&#xE9;</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Belward</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>GLC2000: a new approach to global land cover mapping from earth observation data</article-title>
          <source>Int. J. Remote Sens.</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>1959</fpage>
          <lpage>1977</lpage>
          <pub-id pub-id-type="doi">10.1080/01431160412331291297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Margono</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Potapov</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Turubanova</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stolle</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Primary forest cover loss in indonesia over 2000-2012</article-title>
          <source>Nat. Clim. Chang.</source>
          <year>2014</year>
          <volume>4</volume>
          <fpage>730</fpage>
          <lpage>735</lpage>
          <pub-id pub-id-type="doi">10.1038/nclimate2277</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <mixed-citation publication-type="other">Redfern, S. K., Azzu, N. &amp; Binamira, J. S. Rice in Southeast Asia: facing risks and vulnerabilities to respond to climate change. In&#xA0;<italic>Building Resilience for Adaptation to Climate Change in the Agricultural Sector</italic>&#xA0;(ed. Meybeck, A.) 295&#x2013;314 (UN Food and Agriculture Organization, Rome, 2012).</mixed-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <mixed-citation publication-type="other">The World Bank Group. <italic>Employment in Agriculture (% of Total Employment) (Modeled ILO Estimate) | Data</italic>. (2018). Available at: <ext-link ext-link-type="uri" xlink:href="https://data.worldbank.org/indicator/sl.agr.empl.zs?end=2014&amp;start=1991&amp;year_high_desc=true">https://data.worldbank.org/indicator/sl.agr.empl.zs?end=2014&amp;start=1991&amp;year_high_desc=true</ext-link>. (Accessed: 23rd July 2018)</mixed-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaz</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>D&#x2019;Andrea</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Effects of habitat fragmentation on wild mammal infection by Trypanosoma cruzi</article-title>
          <source>Parasitology</source>
          <year>2007</year>
          <volume>134</volume>
          <fpage>1785</fpage>
          <lpage>1793</lpage>
          <pub-id pub-id-type="doi">10.1017/S003118200700323X</pub-id>
          <pub-id pub-id-type="pmid">17651530</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Savilaakso</surname>
              <given-names>Sini</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>Claude</given-names>
            </name>
            <name>
              <surname>Garcia-Ulloa</surname>
              <given-names>John</given-names>
            </name>
            <name>
              <surname>Ghazoul</surname>
              <given-names>Jaboury</given-names>
            </name>
            <name>
              <surname>Groom</surname>
              <given-names>Martha</given-names>
            </name>
            <name>
              <surname>Guariguata</surname>
              <given-names>Manuel R</given-names>
            </name>
            <name>
              <surname>Laumonier</surname>
              <given-names>Yves</given-names>
            </name>
            <name>
              <surname>Nasi</surname>
              <given-names>Robert</given-names>
            </name>
            <name>
              <surname>Petrokofsky</surname>
              <given-names>Gillian</given-names>
            </name>
            <name>
              <surname>Snaddon</surname>
              <given-names>Jake</given-names>
            </name>
            <name>
              <surname>Zrust</surname>
              <given-names>Michal</given-names>
            </name>
          </person-group>
          <article-title>Systematic review of effects on biodiversity from oil palm production</article-title>
          <source>Environmental Evidence</source>
          <year>2014</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>4</fpage>
          <pub-id pub-id-type="doi">10.1186/2047-2382-3-4</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <mixed-citation publication-type="other">Martin, K. &amp; He, P. Effects of rubber cultivation on biodiversity in the Mekong Region. <italic>CAB Rev</italic>. <bold>10</bold>, 1&#x2013;7 (2015).</mixed-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fitzherbert</surname>
              <given-names>EB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>How will oil palm expansion affect biodiversity?</article-title>
          <source>Trends Ecol. Evol.</source>
          <year>2008</year>
          <volume>23</volume>
          <fpage>538</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tree.2008.06.012</pub-id>
          <pub-id pub-id-type="pmid">18775582</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burkett-Cadena</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Vittor</surname>
              <given-names>AY</given-names>
            </name>
          </person-group>
          <article-title>Deforestation and vector-borne disease: Forest conversion favors important mosquito vectors of human pathogens</article-title>
          <source>Basic Appl. Ecol.</source>
          <year>2018</year>
          <volume>26</volume>
          <fpage>101</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="doi">10.1016/j.baae.2017.09.012</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sparagano</surname>
              <given-names>OAE</given-names>
            </name>
          </person-group>
          <article-title>Impact of ticks and tick-borne diseases on agriculture and human populations in Europe</article-title>
          <source>J. Agric. Sci.</source>
          <year>2005</year>
          <volume>143</volume>
          <fpage>463</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="doi">10.1017/S0021859605005526</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janko</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The links between agriculture, Anopheles mosquitoes, and malaria risk in children younger than 5 years in the Democratic Republic of the Congo: a population-based, cross-sectional, spatial study</article-title>
          <source>Lancet Planet. Heal.</source>
          <year>2018</year>
          <volume>2</volume>
          <fpage>e74</fpage>
          <lpage>e82</lpage>
          <pub-id pub-id-type="doi">10.1016/S2542-5196(18)30009-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forrer</surname>
              <given-names>Armelle</given-names>
            </name>
            <name>
              <surname>Sayasone</surname>
              <given-names>Somphou</given-names>
            </name>
            <name>
              <surname>Vounatsou</surname>
              <given-names>Penelope</given-names>
            </name>
            <name>
              <surname>Vonghachack</surname>
              <given-names>Youthanavanh</given-names>
            </name>
            <name>
              <surname>Bouakhasith</surname>
              <given-names>Dalouny</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>Steffen</given-names>
            </name>
            <name>
              <surname>Glaser</surname>
              <given-names>R&#xFC;diger</given-names>
            </name>
            <name>
              <surname>Utzinger</surname>
              <given-names>J&#xFC;rg</given-names>
            </name>
            <name>
              <surname>Akkhavong</surname>
              <given-names>Kongsap</given-names>
            </name>
            <name>
              <surname>Odermatt</surname>
              <given-names>Peter</given-names>
            </name>
          </person-group>
          <article-title>Spatial Distribution of, and Risk Factors for, Opisthorchis viverrini Infection in Southern Lao PDR</article-title>
          <source>PLoS Neglected Tropical Diseases</source>
          <year>2012</year>
          <volume>6</volume>
          <issue>2</issue>
          <fpage>e1481</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pntd.0001481</pub-id>
          <pub-id pub-id-type="pmid">22348157</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindahl</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Grace</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The consequences of human actions on risks for infectious diseases: a review</article-title>
          <source>Infect. Ecol. Epidemiol.</source>
          <year>2015</year>
          <volume>5</volume>
          <fpage>11</fpage>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnold</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Infectious diseases associated with livestock production</article-title>
          <source>Sci. Sel.</source>
          <year>2013</year>
          <volume>121</volume>
          <fpage>8837</fpage>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomley</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Shirley</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Livestock infectious diseases and zoonoses</article-title>
          <source>Philos. Trans. R. Soc. B Biol. Sci.</source>
          <year>2009</year>
          <volume>364</volume>
          <fpage>2637</fpage>
          <lpage>2642</lpage>
          <pub-id pub-id-type="doi">10.1098/rstb.2009.0133</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klous</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Huss</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Heederik</surname>
              <given-names>DJJ</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Human-livestock contacts and their relationship to transmission of zoonotic pathogens, a systematic review of literature</article-title>
          <source>One Heal.</source>
          <year>2016</year>
          <volume>2</volume>
          <fpage>65</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.1016/j.onehlt.2016.03.001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>F&#xE8;vre</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An integrated study of human and animal infectious disease in the Lake Victoria crescent small-holder crop-livestock production system, Kenya</article-title>
          <source>BMC Infect. Dis.</source>
          <year>2017</year>
          <volume>17</volume>
          <fpage>1</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1186/s12879-017-2559-6</pub-id>
          <pub-id pub-id-type="pmid">28049444</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hoek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Jong</surname>
              <given-names>MCM</given-names>
            </name>
          </person-group>
          <article-title>Assessing and controlling health risks from animal husbandry</article-title>
          <source>NJAS&#x2014;Wagening. J. Life Sci.</source>
          <year>2013</year>
          <volume>66</volume>
          <fpage>7</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1016/j.njas.2013.05.003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Suer</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Review: the important bacterial zoonoses in &#x2018;one health&#x2019; concept</article-title>
          <source>Front. Public Heal.</source>
          <year>2014</year>
          <volume>2</volume>
          <fpage>1</fpage>
          <lpage>8</lpage>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pulliam</surname>
              <given-names>JRC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis</article-title>
          <source>J. R. Soc. Interface</source>
          <year>2012</year>
          <volume>9</volume>
          <fpage>89</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="doi">10.1098/rsif.2011.0223</pub-id>
          <pub-id pub-id-type="pmid">21632614</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ricklin</surname>
              <given-names>ME</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vector-free transmission and persistence of Japanese encephalitis virus in pigs</article-title>
          <source>Nat. Commun.</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1038/ncomms10832</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pesavento</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Common and emerging infectious diseases in the animal shelter</article-title>
          <source>Vet. Pathol.</source>
          <year>2014</year>
          <volume>51</volume>
          <fpage>478</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="doi">10.1177/0300985813511129</pub-id>
          <pub-id pub-id-type="pmid">24265288</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hasyim</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Does livestock protect from malaria or facilitate malaria prevalence? A cross-sectional study in endemic rural areas of Indonesia</article-title>
          <source>Malar. J.</source>
          <year>2018</year>
          <volume>17</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1186/s12936-017-2149-5</pub-id>
          <pub-id pub-id-type="pmid">29291736</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loh</surname>
              <given-names>EH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeting transmission pathways for emerging zoonotic disease surveillance and control</article-title>
          <source>Vector-Borne Zoonotic Dis.</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>432</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.1089/vbz.2013.1563</pub-id>
          <pub-id pub-id-type="pmid">26186515</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>Kris A.</given-names>
            </name>
            <name>
              <surname>Olivero</surname>
              <given-names>Jes&#xFA;s</given-names>
            </name>
            <name>
              <surname>Roche</surname>
              <given-names>Benjamin</given-names>
            </name>
            <name>
              <surname>Tiedt</surname>
              <given-names>Sonia</given-names>
            </name>
            <name>
              <surname>Gu&#xE9;gan</surname>
              <given-names>Jean-Francois</given-names>
            </name>
          </person-group>
          <article-title>Pathogeography: leveraging the biogeography of human infectious diseases for global health management</article-title>
          <source>Ecography</source>
          <year>2018</year>
          <volume>41</volume>
          <issue>9</issue>
          <fpage>1411</fpage>
          <lpage>1427</lpage>
          <pub-id pub-id-type="doi">10.1111/ecog.03625</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <mixed-citation publication-type="other">Singhasivanon, P. Malaria in tree crop plantations in south eastern and western provinces in Thailand. <italic>Southeast Asian J. Trop. Med. Public Heal</italic>. <bold>30</bold>, 399&#x2013;404. (1999).</mixed-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guerra</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Snow</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Hay</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>A global assessment of closed forests, deforestation and malaria risk</article-title>
          <source>Ann. Trop. Med. Parasitol.</source>
          <year>2006</year>
          <volume>100</volume>
          <fpage>189</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="doi">10.1179/136485906X91512</pub-id>
          <pub-id pub-id-type="pmid">16630376</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <mixed-citation publication-type="other">Lane, R. P. &amp; Crosskey, R. W. <italic>Medical Insects and Arachnids</italic>. (Springer Netherlands, 1993).</mixed-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trang</surname>
              <given-names>DT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Skin disease among farmers using wastewater in rice cultivation in Nam Dinh, Vietnam</article-title>
          <source>Trop. Med. Int. Heal.</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>51</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-3156.2007.01941.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trang</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Hien</surname>
              <given-names>BTT</given-names>
            </name>
            <name>
              <surname>M&#xF8;lbak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cam</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Dalsgaard</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology and aetiology of diarrhoeal diseases in adults engaged in wastewater-fed agriculture and aquaculture in Hanoi, Vietnam</article-title>
          <source>Trop. Med. Int. Heal.</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>23</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-3156.2007.01938.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trang</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>M&#xF8;lbak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cam</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Dalsgaard</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Helminth infections among people using wastewater and human excreta in peri-urban agriculture and aquaculture in Hanoi, Vietnam</article-title>
          <source>Trop. Med. Int. Heal.</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>82</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-3156.2007.01945.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <mixed-citation publication-type="other">Keiser, J. &amp; Utzinger, J. Efficacy of Current drugs against soil-transmitted helminth infections. <italic>JAMA</italic><bold>299</bold>, 1937&#x2013;1948 (2008).</mixed-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dantas-Torres</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Climate change, biodiversity, ticks and tick-borne diseases: The butterfly effect</article-title>
          <source>Int. J. Parasitol. Parasites Wildl.</source>
          <year>2015</year>
          <volume>4</volume>
          <fpage>452</fpage>
          <lpage>461</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijppaw.2015.07.001</pub-id>
          <pub-id pub-id-type="pmid">26835253</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beugnet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chalvet-Monfray</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Impact of climate change in the epidemiology of vector-borne diseases in domestic carnivores</article-title>
          <source>Comp. Immunol. Microbiol. Infect. Dis.</source>
          <year>2013</year>
          <volume>36</volume>
          <fpage>559</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cimid.2013.07.003</pub-id>
          <pub-id pub-id-type="pmid">23953958</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Killilea</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Swei</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Briggs</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Ostfeld</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Spatial dynamics of lyme disease: a review</article-title>
          <source>Ecohealth</source>
          <year>2008</year>
          <volume>5</volume>
          <fpage>167</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="doi">10.1007/s10393-008-0171-3</pub-id>
          <pub-id pub-id-type="pmid">18787920</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brownstein</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Skelly</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Holford</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Fish</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Forest fragmentation predicts local scale heterogeneity of Lyme disease risk</article-title>
          <source>Oecologia</source>
          <year>2005</year>
          <volume>146</volume>
          <fpage>469</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="doi">10.1007/s00442-005-0251-9</pub-id>
          <pub-id pub-id-type="pmid">16187106</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allan</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Keesing</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ostfeld</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Effect of forest fragmentation on lyme disease risk</article-title>
          <source>Conserv. Biol.</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>267</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1739.2003.01260.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostfeld</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Keesing</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Oggenfuss</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Canham</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Tick-borne disease risk in a forest food web</article-title>
          <source>Ecology</source>
          <year>2018</year>
          <volume>99</volume>
          <fpage>0</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="doi">10.1002/ecy.2386</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aung</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Spelman</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Graves</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Rickettsial infections in Southeast Asia: implications for local populace and febrile returned travelers</article-title>
          <source>Am. J. Trop. Med. Hyg.</source>
          <year>2014</year>
          <volume>91</volume>
          <fpage>451</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="doi">10.4269/ajtmh.14-0191</pub-id>
          <pub-id pub-id-type="pmid">24957537</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vijayachari</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sugunan</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Natarajaseenivasan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sehgal</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Seroprevalence of leptospirosis among high-risk population of Andaman Islands, India</article-title>
          <source>Am. J. Trop. Med. Hyg.</source>
          <year>2006</year>
          <volume>74</volume>
          <fpage>278</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="doi">10.4269/ajtmh.2006.74.278</pub-id>
          <pub-id pub-id-type="pmid">16474084</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monno</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Seroprevalence of Q fever, brucellosis and leptospirosis in farmers and agricultural workers in Bari, Southern Italy</article-title>
          <source>Ann. Agric. Environ. Med.</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>205</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="pmid">20047252</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cifuentes</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk factors for Giardia intestinalis infection in agricultural villages practicing wastewater irrigation in Mexico</article-title>
          <source>Am. J. Trop. Med. Hyg.</source>
          <year>2000</year>
          <volume>62</volume>
          <fpage>388</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="doi">10.4269/ajtmh.2000.62.388</pub-id>
          <pub-id pub-id-type="pmid">11037783</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mwachui</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Crump</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hartskeerl</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zinsstag</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hattendorf</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Environmental and behavioural determinants of leptospirosis transmission: a systematic review</article-title>
          <source>PLoS Negl. Trop. Dis.</source>
          <year>2015</year>
          <volume>9</volume>
          <fpage>1</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.pntd.0003843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Victoriano</surname>
              <given-names>AFB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Leptospirosis in the Asia Pacific region</article-title>
          <source>BMC Infect. Dis.</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>147</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2334-9-147</pub-id>
          <pub-id pub-id-type="pmid">19732423</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vanwambeke</surname>
              <given-names>SO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of land-use change on dengue and malaria in northern Thailand</article-title>
          <source>Ecohealth</source>
          <year>2007</year>
          <volume>4</volume>
          <fpage>37</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1007/s10393-007-0085-5</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yasuoka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Levins</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Impact of deforestation and agricultural development on anopheline ecology and malaria epidemiology</article-title>
          <source>Am. J. Trop. Med. Hyg.</source>
          <year>2007</year>
          <volume>76</volume>
          <fpage>450</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="doi">10.4269/ajtmh.2007.76.450</pub-id>
          <pub-id pub-id-type="pmid">17360867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilbert</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mapping H5N1 highly pathogenic avian influenza risk in Southeast Asia</article-title>
          <source>Proc. Natl. Acad. Sci.</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>4769</fpage>
          <lpage>4774</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0710581105</pub-id>
          <pub-id pub-id-type="pmid">18362346</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hughes</surname>
              <given-names>Alice C.</given-names>
            </name>
          </person-group>
          <article-title>Understanding the drivers of Southeast Asian biodiversity loss</article-title>
          <source>Ecosphere</source>
          <year>2017</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>e01624</fpage>
          <pub-id pub-id-type="doi">10.1002/ecs2.1624</pub-id>
        </element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schipper</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The status of the world&#x2019;s land and marine mammals: diversity, threat, and knowledge</article-title>
          <source>Sci. (80-.).</source>
          <year>2008</year>
          <volume>322</volume>
          <fpage>225</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1165115</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mann</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Observational research methods. Research design II</article-title>
          <source>Emerg. Med. J.</source>
          <year>2003</year>
          <volume>20</volume>
          <fpage>54</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="doi">10.1136/emj.20.1.54</pub-id>
          <pub-id pub-id-type="pmid">12533370</pub-id>
        </element-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chenais</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Increasing the local relevance of epidemiological research: situated knowledge of cattle disease among basongora pastoralists in Uganda</article-title>
          <source>Front. Vet. Sci.</source>
          <year>2018</year>
          <volume>5</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.3389/fvets.2018.00119</pub-id>
          <pub-id pub-id-type="pmid">29417054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catley</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alders</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>JLN</given-names>
            </name>
          </person-group>
          <article-title>Participatory epidemiology: approaches, methods, experiences</article-title>
          <source>Vet. J.</source>
          <year>2012</year>
          <volume>191</volume>
          <fpage>151</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tvjl.2011.03.010</pub-id>
          <pub-id pub-id-type="pmid">21856195</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allepuz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Balogh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aguanno</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heilmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beltran-Alcrudo</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Review of participatory epidemiology practices in animal health (1980-2015) and future practice directions</article-title>
          <source>PLoS ONE</source>
          <year>2017</year>
          <volume>12</volume>
          <fpage>1</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0169198</pub-id>
        </element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaoud</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>Eco-epidemiologic impacts of HPAI on avian and human health in Egypt</article-title>
          <source>Int. J. Poult. Sci.</source>
          <year>2008</year>
          <volume>7</volume>
          <fpage>72</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.3923/ijps.2008.72.76</pub-id>
        </element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mariner</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Roeder</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Use of participatory epidemiology in studies of the persistence of lineage 2 rinderpest virus in East Africa</article-title>
          <source>Vet. Rec.</source>
          <year>2003</year>
          <volume>152</volume>
          <fpage>641</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="doi">10.1136/vr.152.21.641</pub-id>
          <pub-id pub-id-type="pmid">12790233</pub-id>
        </element-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haidich</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Meta-analysis in medical research</article-title>
          <source>Hippokratia</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>29</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">21487488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higgins</surname>
              <given-names>JPT</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Quantifying heterogeneity in a meta-analysis</article-title>
          <source>Stat. Med.</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>1539</fpage>
          <lpage>1558</lpage>
          <pub-id pub-id-type="doi">10.1002/sim.1186</pub-id>
          <pub-id pub-id-type="pmid">12111919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <mixed-citation publication-type="other">Chandler, J., Higgins, J., Deeks, J., Davenport, C. &amp; Clarke, M. in <italic>Cochrane Handbook for Systematic Reviews of Interventions</italic>Vers. 5.2.0&#xA0;(eds Higgins J. P. T., Churchill R., Chandler J., Cumpston M.) Ch. 1 (The Cochrane Collaboration, Oxford, 2017).</mixed-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higgins</surname>
              <given-names>JPT</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Deeks</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Altman</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Measuring inconsistency in meta-analyses</article-title>
          <source>BMJ Br. Med. J.</source>
          <year>2003</year>
          <volume>327</volume>
          <fpage>557</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id>
          <pub-id pub-id-type="pmid">12958120</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global hotspots and correlates of emerging zoonotic diseases</article-title>
          <source>Nat. Commun.</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1038/s41467-016-0009-6</pub-id>
          <pub-id pub-id-type="pmid">28232747</pub-id>
        </element-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daszak</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interdisciplinary approaches to understanding disease emergence: the past, present, and future drivers of Nipah virus emergence</article-title>
          <source>Proc. Natl Acad. Sci. U.S.A.</source>
          <year>2013</year>
          <volume>110</volume>
          <issue>Suppl</issue>
          <fpage>3681</fpage>
          <lpage>3688</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1201243109</pub-id>
          <pub-id pub-id-type="pmid">22936052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kummu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lost food, wasted resources: Global food supply chain losses and their impacts on freshwater, cropland, and fertiliser use</article-title>
          <source>Sci. Total Environ.</source>
          <year>2012</year>
          <volume>438</volume>
          <fpage>477</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="doi">10.1016/j.scitotenv.2012.08.092</pub-id>
          <pub-id pub-id-type="pmid">23032564</pub-id>
        </element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parfitt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barthel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>MacNaughton</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Food waste within food supply chains: Quantification and potential for change to 2050</article-title>
          <source>Philos. Trans. R. Soc. B Biol. Sci.</source>
          <year>2010</year>
          <volume>365</volume>
          <fpage>3065</fpage>
          <lpage>3081</lpage>
          <pub-id pub-id-type="doi">10.1098/rstb.2010.0126</pub-id>
        </element-citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dangour</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Environmental impacts of current and future diets in India</article-title>
          <source>Lancet Planet. Heal.</source>
          <year>2018</year>
          <volume>2</volume>
          <fpage>S28</fpage>
          <pub-id pub-id-type="doi">10.1016/S2542-5196(18)30113-X</pub-id>
        </element-citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Springmann</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health and nutritional aspects of sustainable diet strategies and their association with environmental impacts: a global modelling analysis with country-level detail</article-title>
          <source>Lancet Planet. Heal.</source>
          <year>2018</year>
          <volume>2</volume>
          <fpage>e451</fpage>
          <lpage>e461</lpage>
          <pub-id pub-id-type="doi">10.1016/S2542-5196(18)30206-7</pub-id>
        </element-citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keesstra</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of soil management techniques on soil water erosion in apricot orchards</article-title>
          <source>Sci. Total Environ.</source>
          <year>2016</year>
          <volume>551&#x2013;552</volume>
          <fpage>357</fpage>
          <lpage>366</lpage>
          <pub-id pub-id-type="doi">10.1016/j.scitotenv.2016.01.182</pub-id>
          <pub-id pub-id-type="pmid">26881727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kov&#xE1;cs-Hosty&#xE1;nszki</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ecological intensification to mitigate impacts of conventional intensive land use on pollinators and pollination</article-title>
          <source>Ecol. Lett.</source>
          <year>2017</year>
          <volume>20</volume>
          <fpage>673</fpage>
          <lpage>689</lpage>
          <pub-id pub-id-type="doi">10.1111/ele.12762</pub-id>
          <pub-id pub-id-type="pmid">28346980</pub-id>
        </element-citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raviglione</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maher</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Ending infectious diseases in the era of the sustainable development goals</article-title>
          <source>Porto Biomed. J.</source>
          <year>2017</year>
          <volume>2</volume>
          <fpage>140</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pbj.2017.08.001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <mixed-citation publication-type="other"><italic>Cochrane Handbook&#x2014;Language Bias</italic>. Available at: <ext-link ext-link-type="uri" xlink:href="https://handbook-5-1.cochrane.org/chapter_10/10_2_2_4_language_bias.htm">https://handbook-5-1.cochrane.org/chapter_10/10_2_2_4_language_bias.htm</ext-link>. (Accessed: 30th May 2019)</mixed-citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lello</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The relative contribution of co-infection to focal infection risk in children</article-title>
          <source>Proc. R. Soc. B Biol. Sci.</source>
          <year>2013</year>
          <volume>280</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1098/rspb.2012.2813</pub-id>
        </element-citation>
      </ref>
      <ref id="CR125">
        <label>125.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vonghachack</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transmission of Opisthorchis viverrini, Schistosoma mekongi and soil-transmitted helminthes on the Mekong Islands, Southern Lao PDR</article-title>
          <source>Infect. Dis. Poverty</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>1</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1186/s40249-016-0216-8</pub-id>
          <pub-id pub-id-type="pmid">28160773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR126">
        <label>126.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LIU</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk factors for Japanese encephalitis: a case-control study</article-title>
          <source>Epidemiol. Infect.</source>
          <year>2010</year>
          <volume>138</volume>
          <fpage>1292</fpage>
          <lpage>1297</lpage>
          <pub-id pub-id-type="doi">10.1017/S0950268810000063</pub-id>
          <pub-id pub-id-type="pmid">20109262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR127">
        <label>127.</label>
        <mixed-citation publication-type="other"><italic>Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies&#x2014;NHLBI, NIH</italic>. (2017). Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort">https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort</ext-link>. (Accessed: 24th October 2017)</mixed-citation>
      </ref>
      <ref id="CR128">
        <label>128.</label>
        <mixed-citation publication-type="other"><italic>Quality Assessment Tool for Case Control Studies&#x2014;NHLBI, NIH</italic>. (2017). Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</ext-link>. (Accessed: 24th October 2017)</mixed-citation>
      </ref>
      <ref id="CR129">
        <label>129.</label>
        <mixed-citation publication-type="other">Borenstein, M., Hedges, L. V., Higgens, J. P. T. &amp; Rothstein, H. A basic introduction to fixed-effect and andom-effects models for meta-analysis. <italic>Res Synth Methods</italic><bold>1</bold>, 97&#x2013;111 (2010).</mixed-citation>
      </ref>
      <ref id="CR130">
        <label>130.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaewpitoon</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Community-based cross-sectional study of carcinogenic human liver fluke in elderly from surin province, thailand</article-title>
          <source>Asian Pac. J. Cancer Prev.</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>4285</fpage>
          <lpage>4288</lpage>
          <pub-id pub-id-type="doi">10.7314/APJCP.2012.13.9.4285</pub-id>
          <pub-id pub-id-type="pmid">23167329</pub-id>
        </element-citation>
      </ref>
      <ref id="CR131">
        <label>131.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaewpitoon</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Opisthorchis viverrini infection among people in the border areas of three provinces, northeast of thailand</article-title>
          <source>Asian Pac. J. Cancer Prev.</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>2973</fpage>
          <lpage>2977</lpage>
          <pub-id pub-id-type="pmid">27356720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR132">
        <label>132.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaewpitoon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Loyd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kaewpitoon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rujirakul</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Malaria risk areas in Thailand border</article-title>
          <source>J. Med. Assoc. Thai.</source>
          <year>2015</year>
          <volume>98</volume>
          <issue>Suppl 4</issue>
          <fpage>S17</fpage>
          <lpage>S21</lpage>
          <pub-id pub-id-type="pmid">26201129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR133">
        <label>133.</label>
        <mixed-citation publication-type="other">R Core Team &amp; R Development Core Team. <italic>A Language and Environment for Statistical Computing</italic>. (R Core Team &amp; R Development Core Team, 2013).</mixed-citation>
      </ref>
      <ref id="CR134">
        <label>134.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Viechtbauer</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Conducting meta-analyses in <italic>R</italic> with the metafor package</article-title>
          <source>J. Stat. Softw.</source>
          <year>2010</year>
          <volume>36</volume>
          <fpage>1</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.18637/jss.v036.i03</pub-id>
        </element-citation>
      </ref>
      <ref id="CR135">
        <label>135.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>VanderWeele</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity analysis in observational research: introducing the E-value</article-title>
          <source>Ann. Intern. Med.</source>
          <year>2017</year>
          <volume>167</volume>
          <fpage>268</fpage>
          <pub-id pub-id-type="doi">10.7326/M16-2607</pub-id>
          <pub-id pub-id-type="pmid">28693043</pub-id>
        </element-citation>
      </ref>
      <ref id="CR136">
        <label>136.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sterne</surname>
              <given-names>JAC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</article-title>
          <source>BMJ</source>
          <year>2011</year>
          <volume>343</volume>
          <fpage>d4002</fpage>
          <pub-id pub-id-type="doi">10.1136/bmj.d4002</pub-id>
          <pub-id pub-id-type="pmid">21784880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR137">
        <label>137.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davey Smith</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Minder</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>
          <source>Br. Med. J.</source>
          <year>1997</year>
          <volume>315</volume>
          <fpage>629</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id>
          <pub-id pub-id-type="pmid">9310563</pub-id>
        </element-citation>
      </ref>
      <ref id="CR138">
        <label>138.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duval</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tweedie</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A Nonparametric &#x2018;trim and fill&#x2019; method of accounting for publication bias in meta-analysis</article-title>
          <source>J. Am. Stat. Assoc.</source>
          <year>2000</year>
          <volume>95</volume>
          <fpage>89</fpage>
        </element-citation>
      </ref>
      <ref id="CR139">
        <label>139.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duval</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tweedie</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Trim and Fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title>
          <source>Biometrics</source>
          <year>2000</year>
          <volume>56</volume>
          <fpage>455</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0006-341X.2000.00455.x</pub-id>
          <pub-id pub-id-type="pmid">10877304</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Vaccine</journal-id>
      <journal-id journal-id-type="iso-abbrev">Vaccine</journal-id>
      <journal-title-group>
        <journal-title>Vaccine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0264-410X</issn>
      <issn pub-type="epub">1873-2518</issn>
      <publisher>
        <publisher-name>Elsevier Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31447125</article-id>
      <article-id pub-id-type="pmc">6739625</article-id>
      <article-id pub-id-type="publisher-id">S0264-410X(19)31009-6</article-id>
      <article-id pub-id-type="doi">10.1016/j.vaccine.2019.07.088</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
          <article-title>The art of <b>partnership</b> for vaccines<sup><xref ref-type="fn" rid="d31e147">&#x2606;</xref></sup><sup><xref ref-type="fn" rid="d31e152">&#x2606;&#x2606;</xref></sup></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pagliusi</surname>
            <given-names>Sonia</given-names>
          </name>
          <email>s.pagliusi@dcvmn.net</email>
          <xref rid="af005" ref-type="aff">a</xref>
          <xref rid="cor1" ref-type="corresp">&#x204E;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Che</surname>
            <given-names>Yanchun</given-names>
          </name>
          <email>cheyanchun@imbcams.com.cn</email>
          <xref rid="af010" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>Shaozhong</given-names>
          </name>
          <email>dsz@imbcams.com.cn</email>
          <xref rid="af010" ref-type="aff">b</xref>
        </contrib>
      </contrib-group>
      <aff id="af005"><label>a</label>DCVMN International, Route de Crassier 7, 1262 Eysins-Nyon, Switzerland</aff>
      <aff id="af010"><label>b</label>Institute for Medical Biotechnology, Chinese Academy of Medical Sciences, China</aff>
      <author-notes>
        <corresp id="cor1"><label>&#x204E;</label>Corresponding author. <email>s.pagliusi@dcvmn.net</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>20</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <day>20</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <volume>37</volume>
      <issue>40</issue>
      <fpage>5909</fpage>
      <lpage>5919</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>1</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>7</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>7</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2019</copyright-year>
      </permissions>
      <abstract id="ab005">
        <p>The Developing Countries Vaccine Manufacturers Network (DCVMN) convened vaccine manufacturing experts and leaders from local and global public health organizations for its 19th Annual General Meeting. Lectures and panel discussions centered on international cooperation for better access to vaccines, and partnerships in areas ranging from vaccine research and process development, to clinical studies, regulatory, supply chain and emergency preparedness and response.</p>
        <p>Global vaccine market trends and changes that will impact vaccine financing and procurement methods were discussed as well as capital sources, including funding, for the development of new or improved vaccines.</p>
        <p>DCVMN members presented their progress in developing novel Hexavalent, Meningitis, Pneumococcal Conjugate Vaccine, Shigella, Mumps, Rotavirus, Yellow Fever, Polio, Hepatitis E and Dengue vaccines, and a novel monoclonal antibody cocktail for post-bite prophylaxis against rabies infections.</p>
        <p>Access to and availability of vaccines is enhanced through sharing of best practices for vaccine quality control, reducing redundant testing and promoting development of harmonized common standards. Eligible stakeholders were encouraged to join the WHO-National Control Laboratory Network for Biologicals which serves as a platform for collaboration and technical exchange in this area.</p>
        <p>Increasing regulatory convergence at the regional and global levels through mechanisms such as joint dossier review and the WHO Collaborative Registration Procedure can help to accelerate vaccine access globally. Additionally, four proposals for streamlining procedures and alignment of dossiers were discussed.</p>
        <p>Successful partnerships between a broad range of stakeholders, including international organizations, manufacturers, academic research institutes and regulators have provided support for, and in some cases accelerated, vaccine innovation, clinical trials and registration, WHO prequalification, vaccine introduction and access. Strong partnerships, based on experience and trust, help leverage opportunities and are critically important to advancing the shared goal of providing quality vaccines for all people.</p>
      </abstract>
      <kwd-group id="kg005">
        <title>Keywords</title>
        <kwd>Public-private partnerships</kwd>
        <kwd>Immunization</kwd>
        <kwd>Vaccine market trends</kwd>
        <kwd>Technology innovation</kwd>
        <kwd>Developing countries</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <label>1</label>
      <title>Introduction</title>
      <p id="p0005">The 19th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) in Kunming, China, gathered around 315 professionals - 30% of which were female - from 34 countries, 41 corporate manufacturers, 14 corporate partners, and local and global health organizations. The meeting aimed to tighten collaborations, deepen understanding, and enhance partnerships, contributing to future vaccine development and manufacturing. This report provides a summary of major points discussed throughout the meeting.</p>
      <p id="p0010">DCVMN President, M. Datla, thanked the Institute of Medical Biology, Chinese Academy of Medical Sciences, for hosting the event and welcomed representatives from WHO, UNICEF, PAHO, PATH, CEPI, CHAI, Gavi, IVI, GHIF, AVAREF, NIBSC, Intravacc, Imperial College London, and BMGF<xref rid="fn1" ref-type="fn">1</xref>. In 2018, three new companies joined the Network, bringing the total to 54 corporate members; six vaccines from five member companies received WHO prequalification (WHO PQ); and members endorsed a five-year strategy to strengthen capabilities to produce a sustainable supply of vaccines.</p>
      <p id="p0015">C. Lou (Science and Technology Department), Y. Xu (Yunnan Health Commission) and J. Ju (Medical Product Administration of Yunnan Province) encouraged experts and entrepreneurs to advance industrial technology systems, promote international certification of vaccines and establish a production and supply base that meets international standards. Working together, international organizations, national health administrations and vaccine manufacturers can strengthen partnerships for health.</p>
      <p id="p0020">M. Simao (WHO) noted that life expectancy was extended by 25&#x202F;years in the last decade; however, health inequities persist within and between countries, and challenges have expanded to industrialized countries. WHO&#x2019;s new strategy 2019&#x2013;2023 <xref rid="b0005" ref-type="bibr">[1]</xref> aims to address inequities to ensure higher healthcare coverage, prevent emergencies and promote better health for a further three billion people, at all ages. As of October 2018, there were Ebola, Cholera, Yellow Fever (YF) and Meningitis outbreaks in nine countries <xref rid="b0010" ref-type="bibr">[2]</xref>. Vaccines can address health emergencies; however, only 30% of national regulatory authorities (NRAs) globally can perform core regulatory functions to provide efficient oversight of registration, including the assessment, quality control and post-marketing surveillance of vaccines. This can lead to delayed, access to prevention in emergency situations, thus the need to rely on international mechanisms for product regulation, including the WHO Collaborative Registration Procedure (CRP) <xref rid="b0015" ref-type="bibr">[3]</xref>.</p>
    </sec>
    <sec id="s0010">
      <label>2</label>
      <title>Public and private partnerships to enhance access to vaccines</title>
      <p id="p0025">A. Oswald (BMGF) interviewed Bill Gates (by recorded video), reflecting on achievements of the first Decade of Vaccines. Since the 1990s, annual child mortality decreased from over 11 million to around 5 million currently<xref rid="fn2" ref-type="fn">2</xref>. &#x201C;In saving children&#x2019;s lives there is nothing as phenomenal as vaccines&#x201D;, said Mr. Gates. In this context, ensuring simple procurement practices and guaranteed supply, avoiding fragmentation, working on policies and technical advice for countries, as well as stockpiles, should help drive global and regional vaccine uptake, increasing access to vaccines for everyone. In general, some redundancy in manufacturing is needed to ensure economies of scale and sustainable global supply capacity if one factory goes offline. He commended DCVMN companies for exploring state-of-the-art manufacturing technologies and stated that BMGF is committed to a strong dialogue and willing to share risks that make a difference to global health. Mr. Gates concluded: &#x201C;we are looking forward to the partnerships we can have over the next decade&#x201D;.</p>
      <p id="p0030">S. Davis (PATH) explained how PATH&#x2019;s extensive vaccine innovation and access capabilities can support manufacturers and other partners through end-to-end partnerships, from lead identification and preclinical studies, to process development, clinical trials and registration, to WHO prequalification, introduction and global access efforts. Examples included partnerships with Serum Institute of India (SII) on MenAfriVac, Bharat Biotech on Rotavirus, CDIBP<xref rid="fn3" ref-type="fn">3</xref> on Japanese encephalitis (JE) and Beijing Biotech Institute on Oral Polio Vaccine (OPV) to achieve WHO PQ and supply global markets. PATH relies on its partnerships with industry, research institutes, foundations, and regulators, and success is based on experience and trust.</p>
      <p id="p0035">E. Kadilli (UNICEF) highlighted significant progress on reducing child mortality over the past 30&#x202F;years, with immunizations as key contributor. Achievements have been facilitated through strong partnerships, including with vaccine manufacturers, across four streams of work: procurement and market shaping; supply planning and coordination; country support and sustainability; and strengthening country ownership and long-term immunization sustainability through funding e.g. Gavi co-financing. However, achieving the Sustainable Development Goal targets for child mortality by 2030 <xref rid="b0020" ref-type="bibr">[4]</xref> requires innovations, including programmatic intelligence, understanding the barriers and deepening insights to leverage partnerships with the private sector to increase immunization rates (<xref rid="f0005" ref-type="fig">Fig. 1</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>Illustration of 15 global immunization targets set by UNICEF and global stakeholders to further reduce child mortality, to be achieved from 2020 to 2030. Based on these examples of desirable outcomes, UNICEF is shifting its approach to also engage pre-licensure, including with the private sector and at the executive level, advocating for required investments to meet the future needs of children and adolescents, and to consider the entire ecosystem. The relative level of difficulty to achieve these targets is reflected on the Y axis and time to achievement is shown on the X axis. The size of bubbles denotes the potential impact should goals/targets be achieved. Access to affordable PCV for middle income countries may be the next high impact achievement. Size of bubbles denotes the potential impact should goals/targets be achieved. All information subjectively estimated. Abbreviations: PCV: Pneumococcal Conjugate Vaccine; UIFP: user-independent freeze prevention; HPV: Human Papillomavirus; IPV: Inactivated Polio Vaccine; OPV: Oral Polio Vaccine; MERS: Middle East Respiratory Syndrome. (Figure courtesy of E. Kadilli).</p></caption><graphic xlink:href="gr1"/></fig></p>
      <p id="p0040">J. Chu (CHAI) led a discussion on enhancing partnerships to accelerate vaccine innovation, by illustrating that lives could be saved through improved success in the development of innovative vaccines (<xref rid="f0010" ref-type="fig">Fig. 2</xref>).<fig id="f0010"><label>Fig. 2</label><caption><p>Graphic illustration of lives that could be saved annually through the development of innovative vaccines and improved global availability of vaccines. Bar chart illustrates the mortality of global disease burden due to 12 diseases that could be prevented through innovations in vaccines against TB, HIV, Malaria, Shigella, Typhoid, RSV, GBS, ETEC, Norovirus and Dengue vaccines to save 3.3 million lives. Higher availability of Pneumococcal and new generation Rotavirus vaccines could save additional lives, bringing the total estimated lives saved to 3.8 million annually. Bar sizes are only subjectively estimated, indicative of the number of deaths reported in 132 countries. Coloured areas divide the vaccines into three main categories: green&#x202F;=&#x202F;most needed vaccines; orange&#x202F;=&#x202F;not yet available vaccines; grey&#x202F;=&#x202F;vaccines available at limited supply. Improving vaccines manufacturing, supply capacity and availability would save 3.8 million lives. All rates reported here are age-standardised and derived from WHO and Lancet disease burden estimates, represented in a simple illustrative manner, as to data published in 2017 (at the time of the meeting). The purpose of GBD 2017 is to serve as a global public good, freely available for policy makers and the public seeking to improve human health. A detailed description of Data and statistical modelling tools are available at <ext-link ext-link-type="uri" xlink:href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32203-7/fulltext" id="ir005">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32203-7/fulltext</ext-link>. (*) Note that new typhoid vaccines became globally available after 2018. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0045">M. Zuma (BioManguinhos) described three success factors for technology transfer initiatives to introduce new vaccines: innovation throughout the transfer process when establishing manufacturing in a new location; mutual trust between partners to share development information, production capacity, industry expertise and capabilities to innovate; and a supportive environment, including large public markets and government purchasing power.</p>
      <p id="p0050">S. Davis (PATH) added that innovation also includes packaging, distribution tools and addressing next-generation technology transfer and business models. He stressed that manufacturers need incentives to innovate, even with open-source intellectual property approaches and tiered pricing models.</p>
      <p id="p0055">M. Simao (WHO) commented that collaborations to achieve WHO PQ are partnerships that help encourage innovation.</p>
      <p id="p0060">P. Tippoo shared Biovac&#x2019;s engagements with WHO, PATH, and BMGF towards building vaccine development and manufacturing capacity in South Africa. He highlighted that building partnerships takes time, explaining that it took more than three years before launching the development of a novel Group B Streptococcus vaccine. Access to training and experts allowed the project to ramp up quickly.</p>
      <p id="p0065">H. Iyer (BMGF) highlighted that a key challenge for manufacturers is to assess the potential of new vaccines. Future challenges include mRNA vaccines, biomarkers, adaptive clinical trial design and human challenge models for infection.</p>
      <p id="p0070">Panelists encouraged manufacturers to leverage their innovation capabilities through partnerships.</p>
    </sec>
    <sec id="s0015">
      <label>3</label>
      <title>Procurement and globalization of vaccines</title>
      <p id="p0075">E. Baker (Gavi) discussed major global vaccine market trends and estimated changes that will impact vaccine financing and procurement methods (<xref rid="f0015" ref-type="fig">Fig. 3A</xref>, <xref rid="f0020" ref-type="fig">Fig. 3B</xref>). It will become increasingly challenging for global actors to operate in this environment, not only due to changes in source of financing and increasing costs of immunization programs, but also due to uncertainties around procurement channels (see also <xref rid="f0015" ref-type="fig">Fig. 3A</xref>, <xref rid="f0020" ref-type="fig">Fig. 3B</xref> legend).<fig id="f0015"><label>Fig. 3A</label><caption><p>Illustration of forecasted global demand of vaccines analyzed by routine or campaign use and vaccine type. The columns chart illustrates the estimated total required supply of vaccines, in billions of doses, displayed in the Y axis. The years included in the forecast are reflected in the X axis (2018&#x2013;2030). Total global demand for vaccines is expected to grow from 3 billion doses annually presently, to 4 billion doses annually in 2030. Vaccines are color-coded according to the routine or campaign use and vaccine type. Traditional vaccines represent the largest number of doses and are depicted in dark purple and light purple colors, on the bottom of the columns. Innovative or novel vaccines are depicted in dark blue and light blue, represented on the top of each column. Vaccines targeting regional tropical diseases (Cholera, Japanese Encephalitis, Typhoid fever, Dengue fever) are depicted in pink and blue areas. Demand for traditional vaccines (e.g. Pentavalent) may grow the least, while newer vaccines (PCV, Rotavirus, HPV) and vaccines targeting regional tropical diseases are likely to grow more. Note that the number of doses of traditional vaccines used in catchup campaigns, such as measles, are likely to decrease over time, as routine vaccine coverage becomes more stable. Note: volumes exclude OPV demand. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr3a"/></fig><fig id="f0020"><label>Fig. 3B</label><caption><p>Illustration of forecasted global routine demand by country income group and Gavi eligibility. The total required supply of vaccines, in billions of doses, is displayed in the Y axis. Vaccines are color coded according to Gavi eligibility and World Bank status. Gavi countries (fully eligible, transitioning, self-financing) are depicted in yellow and light green shading, while non-Gavi High Income Countries (HICs) are depicted in dark green colors, on the top of the columns. The years included in the forecast are reflected in the&#x202F;X&#x202F;axis (2018&#x2013;2030). Demand by income group may change considerably over the next decade as many Gavi-eligible countries transition to become self-financing. As a result, non-Gavi self-financing Middle Income Countries (MICs) will comprise the majority proportion of global demand by 2028. Supply requirements are unlikely to change in non-Gavi MICs and HICs. Abbreviations: WB: World Bank; HIC: high income countries; UMIC: upper-middle income countries; LMIC: lower-middle income countries. Source: Global Vaccine Market Model, owned by Linksbridge, July 2018. (Figures courtesy of E. Baker). Note: volumes include routine vaccine program demand only. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr3b"/></fig></p>
      <p id="p0080">B. Giersing (WHO) remarked that Gavi financing played a big role in access to traditional and newer vaccines. Financing will be crucially important for vaccines lacking a dual market (public and private markets or developing and industrialized markets). However, as Gavi countries develop self-financing capacity, a lower rate of vaccine uptake was observed in the past <xref rid="b0025" ref-type="bibr">[5]</xref> and can be addressed through new procurement mechanisms.</p>
      <p id="p0085">A. Ottosen (UNICEF) mentioned innovative procurement approaches such as shifting to multi-year tenders, 10-year contracts for pneumococcal conjugate vaccines (PCV) and multi-phased tenders, all implemented following consultations with industry, aiming to achieve vaccine security, including a diverse supplier base. UNICEF procurement considers price, but also other factors that contribute to ensure sustainability of markets and access to vaccines for immunization programmes.</p>
      <p id="p0090">J. Fitzsimmons (PAHO Revolving Fund) commented on collaborative approaches for shared demand forecasting of vaccines against regional epidemics, illustrated by WHO&#x2019;s Eliminate Yellow Fever Epidemics (EYE)<xref rid="fn4" ref-type="fn">4</xref> Initiative and the International Coordinating Group on Vaccine Provision<xref rid="fn5" ref-type="fn">5</xref>. In 2017, this mechanism facilitated access to additional supply of YF vaccines for procurement during a constrained global supply situation.</p>
      <p id="p0095">D. Hein (Gavi) emphasized that the global vaccine market value doubled in the last decade because of innovative vaccines and attractive prices in high income countries (HICs). However, the value of traditional vaccines stagnated and some outbreak vaccines lack markets in HICs. Manufacturers operating in these segments face volatility and unpredictability, besides regulatory fragmentation. Gavi&#x2019;s approach is aggregation and long-term visibility for financing.</p>
      <p id="p0100">R. Iqbal (BMGF) reflected on supply factors that shape globalization. BMGF invests in vaccines to ensure an adequate supply base, aligning with Gavi principles for healthy markets, minimizing shortage risks and increasing market sharing among manufacturers, fostering multiple supply options. BMGF also invests in manufacturing technology platforms that reduce production costs.</p>
    </sec>
    <sec id="s0020">
      <label>4</label>
      <title>Funding landscape for vaccines</title>
      <p id="p0105">G. Rockman (GHIF) introduced examples of capital sources for the development of new vaccines, noting the difference between funding, that doesn&#x2019;t need repayment, and financing, that seeks a financial return. He outlined the profile of CEPI, BMGF-SIF and GHIF funding (<xref rid="t0005" ref-type="table">Table 1</xref>) before opening the discussion, noting that GHIF will scale up its efforts to finance global health technologies with new sources of capital in 2019, and will rebrand itself as Adjuvant.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Comparative overview of CEPI, BMGF-SIF and GHIF funding assessments across six aspects (listed in the first column), including funding nature, targeted products, focus areas, typical value range of funds, funding structures and early/late phases of development funded. (Table courtesy of G. Rockman).</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Coalition Epidemic Preparedness Innovations (CEPI)</th><th>Bill &amp; Melinda Gates Foundation Strategic Investment Fund (BMGF SIF)</th><th>Adjuvant The Global Health Investment Fund</th></tr></thead><tbody><tr><td>Profile</td><td>Primarily a Grant Funder to Support R&amp;D for Interventions Against Epidemic Threats. Has the flexibility to develop other investment tools going forward.</td><td>BMGF SIF uses a variety of financing tools to stimulate private-sector innovation, encourage market-driven efficiencies and attract external capital to initiatives that support BMGF&#x2019;s charitable mission</td><td>Adjuvant is an impact investment fund that uses venture capital and private equity strategies to support global health R&amp;D projects with commercial financial return prospects</td></tr><tr><td>Interventions they Fund</td><td>Primarily Vaccines</td><td>Vaccines, Therapeutics, Diagnostics, and Other Technologies</td><td>Vaccines, Therapeutics, Diagnostics, and Other Technologies</td></tr><tr><td>Areas of Focus</td><td>WHO R&amp;D Blueprint Priority Pathogens; e.g. Ebola, Lassa, MERS, Nipah, &#x201C;Disease X&#x201D;</td><td>HIV, TB, Malaria, and Other Neglected Infectious Diseases, Maternal and Child Health Challenges</td><td>HIV, TB, Malaria, and Other Neglected Infectious Diseases, Maternal and Child Health Challenges</td></tr><tr><td>Typical R&amp;D Funding Amounts per Project</td><td>$10&#x2013;50 Million</td><td>$5&#x2013;100 Million</td><td>$5&#x2013;50 Million</td></tr><tr><td>Funding Structure(s) Available</td><td>Milestone-Based Grants. Flexibility to develop other investment tools. Also entering into &#x201C;Development partnerships&#x201D; with aligned non-profit organizations. Also putting in place tools for surge funding to expedite R&amp;D during outbreaks.</td><td>Loans, Equity Investments, Project Financing, Volume Guarantees, and Other Innovative Finance Mechanisms (note that BMGF&#x2019;s Global Health Program makes traditional grants as well; SIF capital is used when an investment structure is more suitable)</td><td>Loans, Equity Investments, Project Financing</td></tr><tr><td>Phases of Development Funded</td><td>Early Stage (Preclinical, Phase I, and Phase II)</td><td>Early Stage, Late Stage, Commercialization/Scale-Up</td><td>Late Stage (Validating Phase II Data or Later Required), Commercialization/Scale-Up</td></tr></tbody></table></table-wrap></p>
      <p id="p0110">F. Kristensen (CEPI) provided an overview of the coalition&#x2019;s development of vaccines against priority pathogens &#x2013; the Middle East Respiratory Syndrome (MERS), Lassa and Nipah viruses, and platforms for rapid vaccine development against any new threat. CEPI&#x2019;s mission is to enable equitable access to these vaccines for affected populations during outbreaks through being both a funder and a facilitator for improved preparedness, response and sustainability.</p>
      <p id="p0115">J. Yip (BMGF) shared the features of SIF in guarantees, loans, fund investments, and equity investments in addition to core grants and contracts with manufacturers for R&amp;D and other product improvements. SIF investments focus on infectious diseases affecting disadvantaged populations. Since 2009, SIF has invested US$1.9 billion in over 70 companies and academic laboratories, fostering product development and delivery.</p>
      <p id="p0120">M. Datla (Biological E) commented on R&amp;D funding and financing changes over the last decade in India. Previously, there was no venture capital for vaccines, so grants were critical. Grant funding is mission-oriented, restrictive, with financial objectives, usually leading to access agreements to lower prices for a specific volume or time window. Private equity requires 3&#x2013;5-year cycles and is therefore not ideal for vaccines.</p>
      <p id="p0125">S. Prasad (Bharat Biotech) stated that one significant grant helped to advance manufacturing of Rotavirus vaccines. Investments are based on predictability; however, it is often difficult to measure financial success parameters, leading to unpredictable rate of return on investments on vaccines without long-term supply contracts.</p>
    </sec>
    <sec id="s0025">
      <label>5</label>
      <title>Vaccine research and development</title>
      <p id="p0130">V. Pavliak (IVI) invited experts to comment on innovations to foster vaccine affordability.</p>
      <p id="p0135">D. Robinson (BMGF) commented that innovative simplified processes can translate into capital savings and product costs in the developing world. Further, the recently founded Gates Medical Research Institute (GMRI) will take a small biotech approach to innovation for drugs, diagnostics and vaccines, to be transferred to manufacturers, focusing on diseases affecting the developing world, prioritizing TB, HIV, and malaria.</p>
      <p id="p0140">R. Shattock (Imperial College London) noted that industry typically finalizes the manufacturing process before conducting clinical trials, which are expensive and time consuming. Trials that do not require fixed manufacturing processes, applying adaptive clinical trial design, offer a promising alternative.</p>
      <p id="p0145">D. Dat added that Vabiotech transferred Oral Cholera Vaccine (OCV) technology to IVI, to develop a high-quality vaccine through clinical trials in various populations. The optimized manufacturing technology expanded the manufacturing capacity and was transferred to other interested manufacturers.</p>
      <p id="p0150">A. Tomar (Cadila Biologicals) explained that efficient and low-cost manufacturing must ensure enough production capacity to achieve economies of scale. Procurement systems influence the manufacturing process, thus it is critical to engage with the appropriate stakeholders to increase awareness and ensure a market for new products. Cadila will license a new Rabies vaccine thanks to successful partnerships.</p>
      <p id="p0155">R. Suri (Panacea) added that affordable vaccines require a longer-term approach that considers sustainable manufacturing costs. An innovative example is a process change for Inactivated Polio Vaccine (IPV) which reduces the cost by tenfold.</p>
      <p id="p0160">Panelists concluded that manufacturers can add value to future vaccines.</p>
    </sec>
    <sec id="s0030">
      <label>6</label>
      <title>Future vaccines</title>
      <p id="p0165">D. Robinson (BMGF) illustrated innovation through supported proof-of-concept studies of Univercells&#x2019; modular manufacturing platforms for vaccines, antibodies or proteins <xref rid="b0030" ref-type="bibr">[6]</xref>. The low capital costs of the platforms facilitate engagement of regional and local manufacturers. GMRI will also address proof-of-concept studies to develop new diagnostics, drugs, and bioproducts. Furthermore, a well-trained workforce will ensure that high quality is top priority for manufacturers.</p>
      <p id="p0170">R. Suri (Panacea) summarized the ten-year effort to bring a fully liquid wP<xref rid="fn6" ref-type="fn">6</xref>-IPV-based Hexavalent vaccine to the market. After proving safety and tolerability, an open-label, randomized, multicenter study showed non-inferiority seroprotection in 6&#x2013;10-week-old infants, achieving broad and long-term protection compared to licensed combination vaccines <xref rid="b0035" ref-type="bibr">[7]</xref>. The vaccine was approved by the Indian NRA.</p>
      <p id="p0175">R. Dhere (SII) mentioned that thermostable ACYWX Meningitis vaccines are most suitable to prevent future outbreaks. Despite a significant drop of Meningitis type A cases through vaccination since 2010, increased cases related to serogroups C-Y-W-X were observed in Africa <xref rid="b0040" ref-type="bibr">[8]</xref>. Thus, polysaccharide conjugation <xref rid="b0045" ref-type="bibr">[9]</xref> and serogroup-specific cell banking were developed for uniform high-yield growth kinetics. Safety and immunogenicity of the ACYWX vaccine was confirmed <xref rid="b0050" ref-type="bibr">[10]</xref>. Efficacy studies will start in 2019, aiming for WHO PQ in 2020. Preliminary studies to add serotype B have started.</p>
      <p id="p0180">S. Yang (Walvax) revealed the immunogenicity and safety profile of a 13-valent PCV for infants in a randomized, double-blind controlled clinical study, demonstrating non-inferiority compared to Prevnar 7, the only licensed vaccine in China in 2016. The vaccine is likely to be licensed by 2019. A lot-to-lot consistency and non-inferiority study of the PCV-13, will compare it to Prevnar 13, licensed in China last year.</p>
      <p id="p0185">L. Du (Zhifei) described the development of a vaccine against Shigella, the second leading cause of diarrhea worldwide, causing 1.31 million deaths annually <xref rid="b0055" ref-type="bibr">[11]</xref>. A bivalent Shigella conjugate vaccine candidate is being developed, using the O-polysaccharide from LPS conjugated to carrier protein with two strains: Shigella flexneri 2a and <italic>Plesiomonas shigelloides</italic>. Early studies in healthy subjects to identify dosage and immunization schedule are underway.</p>
      <p id="p0190">Y. Che (IMBCAMS) presented a new live attenuated Mumps vaccine to address re-emerging outbreaks related to F genotype SP viral strain. Virus shedding studies indicated a favorable safety and immunogenicity profile. In 2017, a Phase II trial demonstrated non-inferiority of seroconversion of neutralizing and hemagglutination-inhibiting antibodies, and significant increase in cellular immunity. Efficacy studies will follow.</p>
      <p id="p0195">C. Kirkwood (BMGF) acknowledged the Rotavirus vaccines-driven improvement in child health and highlighted efforts towards improving vaccine performance and delivery. Despite the good safety profile of four WHO PQ live attenuated oral rotavirus vaccines, 90 million children worldwide still lack access <xref rid="b0055" ref-type="bibr">[11]</xref>, and intussusception and lower efficacy remain a concern in some countries. Biofarma is developing a G3P <xref rid="b0030" ref-type="bibr">[6]</xref> strain oral vaccine with 3-dose schedule, showing excellent protection against rotavirus gastroenteritis <xref rid="b0060" ref-type="bibr">[12]</xref>. Injectable non-replicating vaccines may improve the safety and efficacy and could be used in combination vaccines. Two candidates are being developed: a trivalent non-replicating rotavirus vaccine expressed in <italic>E. coli</italic>, developed by PATH - SK Bioscience as partner- showed good safety and immunogenicity (e.g. neutralizing antibodies) in human clinical studies <xref rid="b0065" ref-type="bibr">[13]</xref>, clinical protection will be evaluated. The inactivated whole-virus particle Rotavirus vaccine developed by the U.S. CDC - SII as partner - showed protective immunity in animals.</p>
      <p id="p0200">S. Kumar (Zydus Cadila) introduced a novel monoclonal antibody (mAb) cocktail for post-bite prophylaxis against rabies infections. The rabies virus progresses from peripheral tissues to the spinal cord, causing brain inflammation and fatal paralysis. Immediate wound wash followed by rabies vaccine and anti-rabies-immunoglobulin (RIG) neutralize the virus and protect against the disease. RabiMabs is a cocktail of two serum-free, anti-G protein, monoclonal antibodies, IgG1 and IgG2b, neutralizing viruses isolated from many countries and animals. Clinical data from a randomized, multicentre, open label comparator-controlled study demonstrated safety, tolerability and efficacy when co-administered with rabies vaccine, VaxiRab N, indicating non-inferiority to Imogam <xref rid="b0070" ref-type="bibr">[14]</xref>.</p>
      <p id="p0205">S. Missailidis (BioManguinhos) described a new YF vaccine production process aimed at doubling its capacity, and the development of a purified YF vaccine made from 17DD virus strain in Vero cell culture, inactivated with &#x3B2;-propiolactone. Production capacity of the latter was increased through a scale-up process optimized by GE Healthcare technology, and antibiotic-free formulation improved its quality. Furthermore, BioManguinhos initiated three parallel Zika vaccine projects to allow comparative clinical trials: a Vero-cells inactivated virus vaccine for pregnant women during epidemics, an attenuated vaccine and a recombinant chimeric virus of the YF 17DD strain expressing Zika virus proteins. Immunogenicity and neurovirulence in non-human primates were studied.</p>
      <p id="p0210">W. Meng (Sinovac) shared the clinical development of Sabin IPV (sIPV), facilitated by WHO. Two products were designed: pure sIPV and alum-adjuvanted sIPV for multi-dose vials. Phase 2 clinical studies showed &gt;95% seroconversion rate and high GMT values proportional to antigen dosage. Non-inferiority phase 3 studies comparing Sabin IPV to Salk IPV are underway, aiming for WHO PQ and approval in 2021.</p>
      <p id="p0215">J. Shih (Innovax) discussed Hepatitis E and cervical cancer vaccines. Hepatitis E outbreaks in Africa and Southeast Asia showed serious risks for pregnant women <xref rid="b0075" ref-type="bibr">[15]</xref>. The vaccine, produced in <italic>E. coli</italic> from genotype 1, showed cross protection against genotype 4, and is approved in China and Pakistan. A Phase I trial is planned in the United States. A bivalent HPV16/18 vaccine targeting 9&#x2013;45-year-old females, also produced in <italic>E. coli</italic>, showed safety and efficacy in clinical studies compared to similar bivalent and quadrivalent HPV vaccines. Studies in adolescent girls, with 2-dose schedule, showed comparable immunogenicity to 3 doses. A 9-valent vaccine is planned.</p>
      <p id="p0220">A. Precioso (Butantan) reported on a second-generation recombinant Dengue vaccine. Dengue is caused by antigenically distinct serotypes 1, 2, 3 and 4, with most endemic countries reporting circulation of all four serotypes. Infection with one serotype confers lifelong immunity to that serotype (homotypic protection) while cross immunity to other serotypes (heterotypic protection) persists for one or two years. Most severe dengue cases are observed with secondary heterotypic infection and antibody-dependent enhancement <xref rid="b0080" ref-type="bibr">[16]</xref>. The live attenuated lyophilized vaccine (<xref rid="f0025" ref-type="fig">Fig. 4</xref>) was safe, immunogenic and well tolerated and is undergoing a randomized, multicentre, double-blind, placebo-controlled Phase III trial in Brazil, with one dose given subcutaneously to subjects 2&#x2013;59&#x202F;years old. <xref rid="b0085" ref-type="bibr">[17]</xref> This vaccine has 32 antigens and is expected to confer at least 80% protection against symptomatic disease. Previous dengue exposure was not associated with adverse reactions.<fig id="f0025"><label>Fig. 4</label><caption><p>Butantan/NIH recombinant attenuated vaccine strategy for dengue. The upper diagram shows schematically the strategy used by the Butantan, in cooperation with the US National Institutes of Health (NIH), to develop a second-generation recombinant Dengue vaccine. The Dengue virus genome is about 11,000 bases of positive-sense, single stranded RNA (ssRNA) that codes for three structural proteins (capsid protein C, membrane protein M, envelope protein E) and seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5). It also includes short non-coding regions on both the 5&#x2032; and 3&#x2032; ends (black lines). The vaccine constructs comprise three full-length dengue viruses types 1, 3, 4 (depicted in blue, green and red in the lower diagram), attenuated by one or more 30-nucleotide deletions in the 3&#x2032; untranslated region (NS1 to NS5). The non-structural proteins are derived from type-1, type-3, and type-4 vaccines. The type-2 component is a chimeric virus, carrying virus type 2 structural M and E genes and capsid and non-structural genes of virus type 4 genome. Abbreviations: DENV-1: Dengue virus type 1; DENV-2: Dengue virus type 2; DENV-3: Dengue virus type 3; DENV-4: Dengue virus type 4. NS&#x202F;=&#x202F;non structural genes (Figure courtesy of A. Precioso). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr4"/></fig></p>
    </sec>
    <sec id="s0035">
      <label>7</label>
      <title>Future quality Control (QC) assays and international standards: Technology transfer initiatives</title>
      <p id="p0225">U. Rosskopf (WHO) introduced the Global WHO-National Control Laboratory (NCL) Network for Biologicals, established in 2016. Responsible NRAs/NCLs provide rigorous oversight of vaccines by testing thousands of vaccine lots against approved specifications. The Network promotes exchange of technical information, predominantly on testing of WHO PQ vaccines; efficient use of resources; and mutual recognition of lot release, thereby reducing costs, minimizing risk of inaccurate results and fostering 3R principles<xref rid="fn7" ref-type="fn">7</xref>
<xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>. In 2017, a shared electronic platform was created for Network members to exchange quality and technical information in a confidential setting. The Network comprises NCLs of vaccine-producing countries, WHO test laboratories, NRAs/NCLs of countries that receive UN-procured vaccines (and also non-prequalified vaccines), UN agencies, manufacturer associations and other stakeholders.</p>
      <p id="p0230">I. Feavers (NIBSC) discussed vaccine testing using new methods developed during the vaccine life cycle, exemplified by the NIBSC Meningitis Group working with a manufacturer to assure vaccine batch quality by introducing an <italic>in vitro</italic> test to measure the presence of pyrogens, thereby reducing the use of animals. Another example is the histamine sensitization test for acellular pertussis vaccines that evaluated the CHO cell intoxication clustering assay in a collaborative study <xref rid="b0105" ref-type="bibr">[21]</xref>. A third example is the evaluation of deep sequencing (DS) as an alternative for MAPREC<xref rid="fn8" ref-type="fn">8</xref>
<xref rid="b0110" ref-type="bibr">[22]</xref> in polio vaccines manufacturing. An international collaborative study with participating NCLs and vaccine manufacturers assessed consistency of OPV. Sabin poliovirus type 3 showed good correlation between MAPREC and DS. The study will build a database of mutational composition of seed viruses and vaccine batches from different manufacturers. The new approach could be applied to other licensed vaccines.</p>
      <p id="p0235">D. Boyle and N. Agarwal (PATH) expressed the need for high-quality antibodies to test and characterize PCV during R&amp;D and manufacturing processes. In collaboration with a manufacturer, hybridomas were generated and screened for quality (e.g. absence of cross-reactivity, and binding affinity). In 2019, a set of 12 affordable mAbs will be commercially available. A second set of mAbs will follow. The solution presented here is a globally accessible, commercially sustainable repository of high-quality affordable mAbs against 24 of the most common pneumococcal serotypes.</p>
      <p id="p0240">G. Kersten (Intravacc) proposed a testing scheme for DTP<xref rid="fn9" ref-type="fn">9</xref> based-vaccines, to reduce the use of animals in manufacturing by serological alternatives, such as cell culture and immune-physico-chemical methods. Potency tests for toxoid vaccines are based on a lethal challenge in animals although new methods for Tetanus <xref rid="b0115" ref-type="bibr">[23]</xref> and Diphtheria <xref rid="b0120" ref-type="bibr">[24]</xref> have received regulatory acceptance. An alternative serological potency test for Pertussis vaccines is proposed for use in conjunction with a T-helper cell responses (qualitative) assay. Alternatively, an ELISA<xref rid="fn10" ref-type="fn">10</xref> to quantify key antigens in wP vaccines could be used next to the serology assay. Such a consistency approach will support regulatory acceptance. A study outline is under consideration by stakeholders.</p>
      <p id="p0245">S. Boyle (BMGF) and K. Mahmood (PATH) jointly presented the establishment of international reference reagents for sIPV. In 2014, experts and vaccine manufacturers discussed assays to measure the D-antigen content of sIPV products and harmonization of potency tests. NIBSC assessed the suitability of WHO International Standard (IS) 12/104 for conventional IPV (cIPV) to measure sIPV products through a collaborative study including products from several manufacturers. Despite good performance of cIPV IS, it was considered unsuitable for sIPV. Assay validation and inter-laboratory variability for in-house methods improved when using a sIPV sample as reference. A second collaborative study confirmed that D-antigen measurements of sIPV improved when using sIPV samples as reference. Based on characterization and stability data, the first WHO IS for sIPV was endorsed by the WHO Expert Committee on Biological Standardization in October 2018 <xref rid="b0125" ref-type="bibr">[25]</xref>, and is available from NIBSC for use in potency testing.</p>
    </sec>
    <sec id="s0040">
      <label>8</label>
      <title>Fostering regulatory convergence</title>
      <p id="p0250">E. Cooke (WHO) introduced WHO regulatory activities, focusing on the CRP for accelerating registration in emerging countries. The CRP is based on principles of cooperation, reliance, harmonization and voluntary information sharing to avoid duplication of efforts, enabling faster and efficient access to quality vaccines while respecting sovereignty and national decision-making. Thus far, 34 countries have accepted the CRP. Since 2013, the CRP has enabled registration of 350 medicines within an average of 90&#x202F;days, and implementation of its principles contributed to achieving 26 vaccine registrations. In 2017, a Pentavalent was registered in Ethiopia within 6&#x202F;months, and cholera vaccines were registered in Nigeria and Caribbean countries in 3&#x2013;5&#x202F;months. Still, there is a need to optimize the CRP for vaccines by better defining priority vaccines and priority countries.</p>
      <p id="p0255">D. Ma&#xEF;ga (WHO/AFRO) explained the impact of joint scientific and ethics reviews of clinical trial applications in Africa, where growing public health needs require faster access to quality-assured medical products. AVAREF facilitated the development and use of several vaccines in Africa, particularly MenAfriVac and Ebola, serving as a Pan-African ethics and regulatory harmonization platform. In a joint review, experts from NRAs and/or Ethics Committees (ECs) of various countries review a common dossier and collectively prepare questions to discuss with the applicant. Fostering NRA convergence and harmonization of procedures between countries requires the agreement of the manufacturer and/or sponsor, as well as agreement of the target countries (NRAs and ECs) following WHO/AVAREF guidance <xref rid="b0130" ref-type="bibr">[26]</xref>.</p>
      <p id="p0260">H. Langar (WHO/EMRO) described the CRP-facilitated registration of polio vaccines through joint dossier review in Eastern Mediterranean Region (EMR) countries. In 2015, WHO recommended the introduction of IPV, and to ensure at least two available brands of IPV were registered in any of 21 EMR countries: two countries lacked registered IPV and five countries had only one registered IPV brand. The joint registration procedure was legally accepted by the countries for issuance of a marketing authorization (MA), with commitment to no further testing or site inspections before granting the MA. A joint evaluation meeting, focused on IPV vaccine dossiers as submitted to the NRAs, was conducted in October 2014. <xref rid="b0135" ref-type="bibr">[27]</xref> Participating NRAs reported to their respective registration committee for final decision, and five countries registered IPV in 2015. Notably, participation of manufacturers in the meeting accelerated the process, addressing questions and concerns expressed by NRAs.</p>
      <p id="p0265">N. Dellepiane (DCVMN) discussed possible improvements in vaccine registration procedures in emerging countries, addressing previously identified challenges. <xref rid="b0140" ref-type="bibr">[28]</xref> The joint industry Regulatory Experts Working Group developed four proposals for streamlining procedures and alignment of dossiers. First, registration procedures could rely on WHO PQ certificates or apply the CRP. Dossier evaluation could rely on batch release data of tests and inspections already conducted by WHO. Registration procedures for non-PQ vaccines could rely on dossiers and data provided by the manufacturing country&#x2019;s NRA, through mutual recognition agreements, or based on release tests conducted by WHO-contracted laboratories (see U. Rosskopf, above). Second, alignment of dossier numbering systems across countries and regions could be improved by following the ICH CTD<xref rid="fn11" ref-type="fn">11</xref> (EU Notice to Applicants) <xref rid="b0145" ref-type="bibr">[29]</xref>, also recognized by WHO. Third, use an application form template (proposed in tabular format), maintaining the three key sections and main subheadings. Fourth, consider pre-submission meetings between the applicant, regulators and post-marketing pharmacovigilance systems to improve registration procedures. Dr. Dellepiane concluded that more regulatory convergence practices can improve registrations and access to vaccines globally.</p>
    </sec>
    <sec id="s0045">
      <label>9</label>
      <title>Novel initiatives to improve vaccine coverage and equity</title>
      <p id="p0270">B. Giersing (WHO) introduced two new multi-stakeholder initiatives to improve vaccine delivery. Total Systems Effectiveness (TSE) is a framework that assists decision-makers to identify and select vaccine products according to attributes that best meet their needs. Vaccine Innovation Prioritisation Strategy (VIPS) aims to prioritize delivery technologies with identified product attributes, to clarify to manufacturers and other stakeholders regarding investment decisions. Both TSE and VIPS assume that differentiated delivery approaches are needed, given that most unvaccinated populations live in clustered areas, located in key countries (<xref rid="f0030" ref-type="fig">Fig. 5</xref>), focusing on poor and vulnerable populations.<fig id="f0030"><label>Fig. 5</label><caption><p>Top 10 countries with most under- and un-vaccinated children for DTP3, in 2017. Graphical bar chart representation of countries with the largest numbers of undervaccinated and unvaccinated children for the third dose of DTP, under one year old (0&#x2013;12&#x202F;months). The number of undervacccinated and unvaccinated children is reflected in the Y axis and the countries are listed along the X axis. Globally, 19.9 million infants are unimmunized, with the greatest numbers of unimmunized children under one year old concentrated in Nigeria and India. Source: WHO/UNICEF coverage estimates 2017 revision, July 2018. Immunization Vaccines and Biologicals (IVB), World Health Organization. 194 WHO Member States. Date of slide: 18 July 2018. (Figure courtesy of B. Giersing).</p></caption><graphic xlink:href="gr5"/></fig></p>
      <p id="p0275">Examples of such innovations include heat-stable/freeze-stable formulations, labelling to track temperature exposures, jet-injectors, powder-inhaler or nebulizer devices, compact pre-filled auto-disable devices/syringes, blow-fill-seal containers, integrated reconstitution devices, microarray patches and controlled temperature chain use of vaccines.</p>
      <p id="p0280">D. Kristensen (PATH) moderated a discussion on innovative technologies, TSE, and VIPS to help countries enhance coverage and equity through suitable vaccines for specific needs.</p>
      <p id="p0285">R. Park (EuBiologics) mentioned that a change in OCV vial presentation, from glass to plastic, reduced the storage volume/cold chain footprint by 50%, and cost of goods by 30%, and also facilitated vaccine administration by field workers, thereby increasing OCV coverage and achieving set goals.</p>
      <p id="p0290">V. Hsu (BMGF) explained that BMGF sees community needs as the priority, and investment decisions in supporting OCV product innovations were driven by policies to expand the OCV stockpile from 200,000 doses in 2013 to 12 million doses in 2018, saving many lives.</p>
      <p id="p0295">R. Kapoor (National University of Singapore) noted that the TSE framework guides LMICs<xref rid="fn12" ref-type="fn">12</xref> to identify criteria for product selection. In MICs<xref rid="fn13" ref-type="fn">13</xref>, TSE brings different groups together to better inform the decision-making process and improve transparency, enabling comparison between different vaccines for the same disease, e.g. Rotarix and Rotateq, besides comparison of vaccines across diseases. The framework informs countries on cost, feasibility, packaging, schedule, etc., and helps manufacturers understand the basis for decision-making and needs.</p>
      <p id="p0300">D. Hein (Gavi) confirmed that VIPS and TSE help Gavi drive vaccine innovation to meet country needs and support immunization coverage and equity. The process provides an aligned perspective and greater clarity to manufacturers to make informed investment decisions.</p>
      <p id="p0305">S. Jadhav (SII) stated that it may be costly for manufacturers to develop/produce many product variations driven by TSE and VIPS, therefore some uniformity based on the preferred product profiles defined by WHO, is needed. He added that introduction of new technologies should coexist with already established technologies for some time.</p>
      <p id="p0310">Global partners and DCVMN suppliers agreed that a stable vaccine supply is needed and that industry&#x2019;s understanding of demand and market evolution can help guide investment decisions.</p>
    </sec>
    <sec id="s0050">
      <label>10</label>
      <title>Progress toward securing future vaccine supply</title>
      <p id="p0315">Y. Momeni (UNICEF) provided an update for 2017 (<xref rid="f0035" ref-type="fig">Fig. 6</xref>), where around 100 countries were supplied 2.4 billion doses of vaccine through UNICEF, at a value of US$1.3 billion, reaching 45% of children under 5&#x202F;years of age. <xref rid="b0150" ref-type="bibr">[30]</xref> Eleven DCVMN companies supplied 1.3 billion doses (54%) of traditional vaccines at a value of US$400 million. The supply crises in early 2000, where UNICEF experienced severe vaccine shortages due to mergers, acquisitions and exits from the UNICEF market, highlighted the importance of longer-term forecasting for manufacturing planning to secure access to supply. Currently, UNICEF is experiencing insufficient supply of Rotavirus, IPV and HPV, and is relying on a limited supplier base for PCV, Typhoid and JE vaccines. UNICEF is in the process of implementing sustainable procurement approaches requiring manufacturing policies and encouraging innovations that reduce carbon footprint and waste disposal.<fig id="f0035"><label>Fig. 6</label><caption><p>Graphical representation of vaccines procured through the UNICEF Supply Division in 2017 (doses). The number of vaccine doses procured is reflected in the Y access (in millions of doses) while the 21 types of vaccines procured are listed in the X axis. The figure illustrates vaccines supplied by DCVMN companies (in yellow) and vaccines supplied by other vaccine companies (in blue). DCVMN companies supplied 1.3 billion doses (54%) of the 2.4 billion doses procured by UNICEF. Abbreviations: BCG: Bacille Calmette Gu&#xE9;rin; DT: Diphtheria and Tetanus; DTP: Diphtheria, Tetanus and Pertussis; DTP Hep B/Hib: Diphtheria, Tetanus, Pertussis, Hepatitis B, <italic>Haemophilus influenzae</italic> type b; Hep B: Hepatitis B; Hib: <italic>Haemophilus influenzae</italic> type b; HPV: Human Papillomavirus; IPV: Inactivated Polio Vaccine; JEV: Japanese Encephalitis Virus; Mening: Meningitis; MMR: Measles, Mumps and Rubella; MR: Measles and Rubella; PCV: Pneumococcal Conjugate Vaccine; Rota: Rotavirus; Td: Tetanus and Diphtheria; TT: Tetanus Toxoid; YF: Yellow Fever. (Figure courtesy of Y. Momeni).</p></caption><graphic xlink:href="gr6"/></fig></p>
      <p id="p0320">N. Steensma (CHAI) offered support to companies to help develop their business strategy including building a business case for entering a market and gathering market intelligence. In light of Gavi transition and more countries becoming Middle Income Countries (MICs), and in response to requests from DCVM manufacturers, CHAI will increase its support to provide market intelligence on MICs.</p>
      <p id="p0325">R. Suri (Panacea) highlighted trust, transparency and fairness as key characteristics through dealing with UNICEF for many years, requesting better demand visibility, including changes related to vaccination campaigns. Improvement in multi-phased tenders, which led to market exits in Pentavalent, could be considered. There is consensus among manufacturers that it is very challenging to negotiate contractual terms which are outside of UNICEF&#x2019;s standard contractual arrangements.</p>
      <p id="p0330">L. Yang (CNBG) appreciated the collaboration with UNICEF on processes and forecasting, including proactive problem-solving leading up to, and after, becoming a supplier. She requested aggregate forecasts across UNICEF and self-procuring countries, and support to work with governments to even out demand spikes. She highlighted the great potential of Chinese suppliers, with 48 registered vaccine manufacturers.</p>
      <p id="p0335">L. Shi (Walvax) said that the company is committed to achieving WHO PQ, ensuring products meet international standards. Walvax highlighted their concerns regarding country product preferences, or lack of preference.</p>
      <p id="p0340">The panel agreed that WHO prequalification is an important international label for quality assurance and compliance, irrespective of country of production. Participants also discussed the challenges surrounding country product preferences, registration requirements and conflicting priorities, especially for products newly prequalified by WHO, where country programs drive for earlier access despite increased complexity in legislation and regulatory requirements.</p>
    </sec>
    <sec id="s0055">
      <label>11</label>
      <title>Closing lecture and concluding remarks</title>
      <p id="p0345">C. Nannei and S. Goldin (WHO) delivered the closing lecture focused on the progress and challenges for sustainable influenza vaccine production to ensure pandemic preparedness. A holistic approach to preparedness should include surveillance, evidence-based policies, strategies to deploy influenza vaccines, and sufficient vaccine supply. Considerations for rapid deployment of vaccines in an emergency include regulatory capacity, distribution systems, monitoring systems, healthcare workers&#x2019; familiarity with influenza immunization, vaccination policies for target groups and communication strategies. From 2006 to 2016, global seasonal influenza vaccine manufacturing capacity tripled from 500 million doses to 1.5 billion doses. During the same period, the estimated global pandemic influenza production capacity grew from 1.46 billion to 6.37 billion potential doses. WHO is developing a new Global Influenza Strategy for 2019&#x2013;2030 to be launched in early 2019, highlighting the need for sustainable local production of influenza vaccines. DCVMN is a key partner in global influenza preparedness and response activities as an advocate for sustainable vaccine production capacity in developing countries.</p>
      <p id="p0350">Presentations and discussions throughout the meeting demonstrated progress and achievements made possible by international cooperation and highlighted the importance of partnerships in fostering innovations for public health, particularly in developing countries. Over the years, the support of the Bill and Melinda Gates Foundation, through PATH and other partners, unlocked economies of scale and sustainable vaccine supply capacity for developing countries, as exemplified by partnerships on MenAfriVac, Rotavirus, Japanese encephalitis and new Polio vaccines to achieve WHO PQ and supply global markets. Pooled procurement/financing mechanisms utilized by PAHO Revolving Fund, UNICEF and GAVI, in partnership with countries, help to protect people against known and emerging infectious diseases. Partnerships with WHO enhanced influenza vaccine manufacturing capacity, thereby increasing pandemic influenza preparedness. Enduring partnerships are the basis to innovation and strengthening industry in developing countries over the coming decades. Manufacturers and partners can take pride in their collective work.</p>
    </sec>
    <sec sec-type="COI-statement">
      <title>Declaration of Competing Interest</title>
      <p id="p0355">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
    </sec>
  </body>
  <back>
    <ref-list id="bi005">
      <title>References</title>
      <ref id="b0005">
        <label>1</label>
        <mixed-citation publication-type="other" id="h0005">WHO Thirteenth general programme of work 2019&#x2212;2023. Available at <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/324775/WHO-PRP-18.1-eng.pdf" id="ir030">https://apps.who.int/iris/bitstream/handle/10665/324775/WHO-PRP-18.1-eng.pdf</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0010">
        <label>2</label>
        <mixed-citation publication-type="other" id="h0010">WHO Emergencies. Availableat <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/crises/en/" id="ir035">http://www.who.int/emergencies/crises/en/</ext-link></mixed-citation>
      </ref>
      <ref id="b0015">
        <label>3</label>
        <mixed-citation publication-type="other" id="h0015">WHO Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines. TRS, No. 996, 2016, Annex 8 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_web.pdf" id="ce.inter-ref_dh2_5p5_q3b">https://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_web.pdf</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0020">
        <label>4</label>
        <mixed-citation publication-type="other" id="h0020">UN Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.un.org/sustainabledevelopment/health/" id="ir045">https://www.un.org/sustainabledevelopment/health/</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0025">
        <label>5</label>
        <element-citation publication-type="journal" id="h0025">
          <person-group person-group-type="author">
            <name>
              <surname>Cernuschi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gaglione</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bozzanic</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Challenges to sustainable immunization systems in Gavi transitioning countries</article-title>
          <source>Vaccine</source>
          <volume>36</volume>
          <issue>45</issue>
          <year>2018 Oct 29</year>
          <fpage>6858</fpage>
          <lpage>6866</lpage>
          <pub-id pub-id-type="pmid">30268735</pub-id>
        </element-citation>
      </ref>
      <ref id="b0030">
        <label>6</label>
        <mixed-citation publication-type="other" id="h0030">Univercells&#x2019; modular manufacturing platforms for vaccines, antibodies or proteins. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.univercells.com/our-technology/" id="ir050">https://www.univercells.com/our-technology/</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0035">
        <label>7</label>
        <element-citation publication-type="journal" id="h0035">
          <person-group person-group-type="author">
            <name>
              <surname>Mohanty</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix) to licensed combination vaccines in healthy infants</article-title>
          <source>Vaccine</source>
          <volume>36</volume>
          <issue>17</issue>
          <year>2018</year>
          <fpage>2378</fpage>
          <lpage>2384</lpage>
          <pub-id pub-id-type="pmid">29580640</pub-id>
        </element-citation>
      </ref>
      <ref id="b0040">
        <label>8</label>
        <element-citation publication-type="journal" id="h0040">
          <person-group person-group-type="author">
            <name>
              <surname>Mustapha</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>L.H.</given-names>
            </name>
          </person-group>
          <article-title>Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges</article-title>
          <source>Hum Vaccines Immunother</source>
          <volume>14</volume>
          <issue>5</issue>
          <year>2018</year>
          <fpage>1107</fpage>
          <lpage>1115</lpage>
        </element-citation>
      </ref>
      <ref id="b0045">
        <label>9</label>
        <element-citation publication-type="journal" id="h0045">
          <person-group person-group-type="author">
            <name>
              <surname>Chilukuri</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Process development and immunogenicity studies on a serogroup 'X' Meningococcal polysaccharide conjugate vaccine</article-title>
          <source>Biologicals</source>
          <volume>42</volume>
          <issue>3</issue>
          <year>2014</year>
          <fpage>160</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="pmid">24411634</pub-id>
        </element-citation>
      </ref>
      <ref id="b0050">
        <label>10</label>
        <element-citation publication-type="journal" id="h0050">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study</article-title>
          <source>Lancet Infect Dis</source>
          <volume>18</volume>
          <issue>10</issue>
          <year>2018</year>
          <fpage>1088</fpage>
          <lpage>1096</lpage>
          <pub-id pub-id-type="pmid">30120069</pub-id>
        </element-citation>
      </ref>
      <ref id="b0055">
        <label>11</label>
        <mixed-citation publication-type="other" id="h0055">Collaborators G.B.D.D.D. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18(11):p. 1211&#x2013;28.</mixed-citation>
      </ref>
      <ref id="b0060">
        <label>12</label>
        <element-citation publication-type="journal" id="h0060">
          <person-group person-group-type="author">
            <name>
              <surname>Bines</surname>
              <given-names>J.E.</given-names>
            </name>
          </person-group>
          <article-title>Human neonatal rotavirus vaccine (RV3-BB) to Target Rotavirus from Birth</article-title>
          <source>N Engl J Med</source>
          <volume>378</volume>
          <issue>8</issue>
          <year>2018</year>
          <fpage>719</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="pmid">29466164</pub-id>
        </element-citation>
      </ref>
      <ref id="b0065">
        <label>13</label>
        <element-citation publication-type="journal" id="h0065">
          <person-group person-group-type="author">
            <name>
              <surname>Groome</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial</article-title>
          <source>Lancet Infect Dis</source>
          <volume>17</volume>
          <issue>8</issue>
          <year>2017</year>
          <fpage>843</fpage>
          <lpage>853</lpage>
          <pub-id pub-id-type="pmid">28483414</pub-id>
        </element-citation>
      </ref>
      <ref id="b0070">
        <label>14</label>
        <mixed-citation publication-type="other" id="h0070">Sanofi Pasteur. Product monograph: IMOGAM&#xAE; Rabies Pasteurized - Rabies Immune Globulin, Pasteurized (Human) Solution for Injection. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.vaccineshoppecanada.com/document.cfm%3ffile%3dimogam_rabies_e.pdf" id="ir055">https://www.vaccineshoppecanada.com/document.cfm?file=imogam_rabies_e.pdf</ext-link></mixed-citation>
      </ref>
      <ref id="b0075">
        <label>15</label>
        <element-citation publication-type="journal" id="h0075">
          <person-group person-group-type="author">
            <name>
              <surname>Cooper</surname>
              <given-names>B.S.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: a modelling study</article-title>
          <source>PLoS Negl Trop Dis</source>
          <volume>12</volume>
          <issue>9</issue>
          <year>2018</year>
          <fpage>e0006807</fpage>
          <pub-id pub-id-type="pmid">30252843</pub-id>
        </element-citation>
      </ref>
      <ref id="b0080">
        <label>16</label>
        <mixed-citation publication-type="other" id="h0080">Katzelnick LC, Harris E, and Participants in the Summit on Dengue Immune Correlates of, Immune correlates of protection for dengue: state of the art and research agenda. Vaccine 2017;35(36):p. 4659&#x2013;69.</mixed-citation>
      </ref>
      <ref id="b0085">
        <label>17</label>
        <element-citation publication-type="journal" id="h0085">
          <person-group person-group-type="author">
            <name>
              <surname>Precioso</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine</article-title>
          <source>Vaccine</source>
          <volume>33</volume>
          <issue>50</issue>
          <year>2015</year>
          <fpage>7121</fpage>
          <lpage>7125</lpage>
          <pub-id pub-id-type="pmid">26458796</pub-id>
        </element-citation>
      </ref>
      <ref id="b0090">
        <label>18</label>
        <mixed-citation publication-type="other" id="h0090">WHO WHO-National Control Laboratory Network for Biologicals (WHO-NNB). Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/immunization_standards/vaccine_quality/who_nnb/en/" id="ir060">https://www.who.int/immunization_standards/vaccine_quality/who_nnb/en/</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0095">
        <label>19</label>
        <mixed-citation publication-type="other" id="h0095">WHO Collaboration &#x2013; Global network of national vaccine control laboratories. WHO Drug Information, 2017;31(1):p. 3&#x2013;10.</mixed-citation>
      </ref>
      <ref id="b0100">
        <label>20</label>
        <mixed-citation publication-type="other" id="h0100">WHO Regulatory networks &#x2013; Update on the WHO-National Control Laboratory Network for Biologicals. WHO Drug Information 2018;32(2):p. 189&#x2013;93.</mixed-citation>
      </ref>
      <ref id="b0105">
        <label>21</label>
        <element-citation publication-type="journal" id="h0105">
          <person-group person-group-type="author">
            <name>
              <surname>Isbrucker</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Transferability study of CHO cell clustering assays for monitoring of pertussis toxin activity in acellular pertussis vaccines</article-title>
          <source>Pharmeur Bio Sci Notes</source>
          <volume>2015</volume>
          <year>2016</year>
          <fpage>97</fpage>
          <lpage>114</lpage>
        </element-citation>
      </ref>
      <ref id="b0110">
        <label>22</label>
        <mixed-citation publication-type="other" id="h0110">WHO Standard Operating Procedure: Mutant Analysis by PCR And Restriction Enzyme Cleavage (MAPREC) for Oral Poliovirus (Sabin) Vaccine Types 1, 2 or 3 Version 5 (2012). Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/biologicals/vaccines/MAPREC_SOP_Final_09112012.pdf" id="ir065">https://www.who.int/biologicals/vaccines/MAPREC_SOP_Final_09112012.pdf</ext-link></mixed-citation>
      </ref>
      <ref id="b0115">
        <label>23</label>
        <mixed-citation publication-type="other" id="h0115">WHO Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927. WHO Technical Report Series No. 980, 2014 Annex 5.</mixed-citation>
      </ref>
      <ref id="b0120">
        <label>24</label>
        <mixed-citation publication-type="other" id="h0120">WHO Recommendations to assure the quality, safety and efficacy of diphtheria vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927. WHO Technical Report Series No. 980, 2014 Annex 4.</mixed-citation>
      </ref>
      <ref id="b0125">
        <label>25</label>
        <mixed-citation publication-type="other" id="h0125">NIBSC &amp; WHO International Standard - Sabin Inactivated Polio Vaccine (sIPV). Instructions for use - Version 2.0; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nibsc.org/documents/ifu/17-160.pdf" id="ir070">https://www.nibsc.org/documents/ifu/17-160.pdf</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0130">
        <label>26</label>
        <mixed-citation publication-type="other" id="h0130">AVAREF Publications: Guideline for Joint and Assisted Reviews of Clinical Trial Applications. AVAREF 2017-JRCTA; Available from: <ext-link ext-link-type="uri" xlink:href="http://afro.who.int/about-us/leadership/avaref" id="ir075">http://afro.who.int/about-us/leadership/avaref</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0135">
        <label>27</label>
        <element-citation publication-type="journal" id="h0135">
          <person-group person-group-type="author">
            <name>
              <surname>Langar</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Dehaghi</surname>
              <given-names>R.O.A.</given-names>
            </name>
            <name>
              <surname>Dellepiane</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Joint evaluation of marketing authorization files of inactivated polio vaccines in countries of the Eastern Mediterranean Region</article-title>
          <source>East Mediterr Health J</source>
          <volume>24</volume>
          <issue>6</issue>
          <year>2018</year>
          <fpage>588</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">30079954</pub-id>
        </element-citation>
      </ref>
      <ref id="b0140">
        <label>28</label>
        <mixed-citation publication-type="other" id="h0140">Dellepiane N, Pagliusi S, and Registration Experts Working Group., Challenges for the registration of vaccines in emerging countries: differences in dossier requirements, application and evaluation processes. Vaccine 2018;36(24):p. 3389&#x2013;96.</mixed-citation>
      </ref>
      <ref id="b0145">
        <label>29</label>
        <mixed-citation publication-type="other" id="h0145">European Commission. EU Volume 2 B Notice to applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD). Available from: <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/health/documents/eudralex/vol-2_en" id="ir080">https://ec.europa.eu/health/documents/eudralex/vol-2_en</ext-link>.</mixed-citation>
      </ref>
      <ref id="b0150">
        <label>30</label>
        <mixed-citation publication-type="other" id="h0150">UNICEF Supply Annual Report 2017. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.unicef.org/supply/files/Unicef_External_Annual_Report_2017.pdf" id="ir085">https://www.unicef.org/supply/files/Unicef_External_Annual_Report_2017.pdf</ext-link>.</mixed-citation>
      </ref>
    </ref-list>
    <ack id="ak005">
      <title>Acknowledgements</title>
      <p>We are grateful to all speakers and moderators whose contributions made the meeting possible and contributed to its success. We are particularly thankful to the experts who graciously served as session rapporteurs: W. Bakker (Intravacc), K. Balaji (PATH), Clarke Cole (CHAI), J. Li (IMBCAMS) and A. Ottonsen (UNICEF). We thank Ms. S. Ramirez for editorial assistance. We thank corporate partners for supporting DCVMN with unrestricted educational grants: Alfa Wasserman, Applikon Biotechnology, Bausch &amp; Stroebel, Bioengineering, Biozeen, Bosch, GEA, GE Healthcare, Gihon, IQVIA, Merck Group, Munters, OMPI (Stevanato Group), Rommelag, Temptime Corporation and Univercells. This meeting was partly supported by a grant from the <funding-source id="gp005">Bill &amp; Melinda Gates Foundation</funding-source>, Grant no. OPP1153279.</p>
    </ack>
    <fn-group>
      <fn id="d31e147">
        <label>&#x2606;</label>
        <p id="np005">Report on the 19th annual general meeting of the Developing Countries Vaccine Manufacturers Network, 29&#x2013;31st October 2018, Kunming, China.</p>
      </fn>
      <fn id="d31e152">
        <label>&#x2606;&#x2606;</label>
        <p id="np010">IMPORTANT NOTE: This report summarizes the views of an international group of experts as presented at a scientific conference in a given time and context and does not necessarily represent the decisions or the stated policy of any institution or corporation.</p>
      </fn>
      <fn id="fn1">
        <label>1</label>
        <p id="np015">Acronyms: WHO: World Health Organization; UNICEF: United Nations International Children&#x2019;s Fund; PAHO: Pan American Health Organization; PATH: Program for Appropriate Technology in Health; CEPI: Coalition for Epidemic Preparedness Innovations; CHAI: Clinton Health Access Initiative; Gavi: Gavi, the Vaccine Alliance; IVI: International Vaccine Institute; GHIF: Global Health Investment Fund; AVAREF: African Vaccine Regulatory Forum; NIBSC: National Institute for Biological Standards and Control; BMGF: Bill &amp; Melinda Gates Foundation.</p>
      </fn>
      <fn id="fn2">
        <label>2</label>
        <p id="np020">Data based on United Nations Sustainable Development Goals report 2017, page 21, available at <ext-link ext-link-type="uri" xlink:href="https://unstats.un.org/sdgs/report/2017/" id="ir010">https://unstats.un.org/sdgs/report/2017/</ext-link>.</p>
      </fn>
      <fn id="fn3">
        <label>3</label>
        <p id="np025">CDIBP: Cheng-Du Institute of Biological Products.</p>
      </fn>
      <fn id="fn4">
        <label>4</label>
        <p id="np030">Cf. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/yellowfev/meeting-demand-for-vaccines/en/" id="ir015">https://www.who.int/csr/disease/yellowfev/meeting-demand-for-vaccines/en/</ext-link>.</p>
      </fn>
      <fn id="fn5">
        <label>5</label>
        <p id="np035">Cf. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/icg/qa/en/" id="ir020">https://www.who.int/csr/disease/icg/qa/en/</ext-link>.</p>
      </fn>
      <fn id="fn6">
        <label>6</label>
        <p id="np040">wP = whole cell Pertussis.</p>
      </fn>
      <fn id="fn7">
        <label>7</label>
        <p id="np045">The principles of the 3Rs (Replacement, Refinement and reduction) of animals in research is a European-led initiative that provides an internationally recognized framework for more ethical animal use in testing. The 3Rs principles encourage alternatives to animal testing and, where the use of animals cannot be avoided, aim to reducing their use and improve animal welfare. For more information see <ext-link ext-link-type="uri" xlink:href="https://www.nc3rs.org.uk/the-3rs" id="ir025">https://www.nc3rs.org.uk/the-3rs</ext-link>.</p>
      </fn>
      <fn id="fn8">
        <label>8</label>
        <p id="np050">MAPREC: Mutant Analysis by PCR and Restriction Enzyme Cleavage.</p>
      </fn>
      <fn id="fn9">
        <label>9</label>
        <p id="np055">DTP&#xA0;: Diphtheria-Tetanus-Pertussis.</p>
      </fn>
      <fn id="fn10">
        <label>10</label>
        <p id="np060">ELISA: enzyme-linked immunosorbent assay.</p>
      </fn>
      <fn id="fn11">
        <label>11</label>
        <p id="np065">ICH CTD: The International Council for Harmonisation (ICH) Common Technical Document (CTD).</p>
      </fn>
      <fn id="fn12">
        <label>12</label>
        <p id="np070">LMIC: low and middle-income countries.</p>
      </fn>
      <fn id="fn13">
        <label>13</label>
        <p id="np075">MIC: middle income countries.</p>
      </fn>
    </fn-group>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id>
      <journal-title-group>
        <journal-title>BMC Complementary and Alternative Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1472-6882</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31533688</article-id>
      <article-id pub-id-type="pmc">6751638</article-id>
      <article-id pub-id-type="publisher-id">2629</article-id>
      <article-id pub-id-type="doi">10.1186/s12906-019-2629-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anti-viral activity of culinary and medicinal mushroom extracts against dengue virus serotype 2: an in-vitro study</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9413-5739</contrib-id>
          <name>
            <surname>Ellan</surname>
            <given-names>Kavithambigai</given-names>
          </name>
          <address>
            <email>e_kavi8@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thayan</surname>
            <given-names>Ravindran</given-names>
          </name>
          <address>
            <email>rthayan@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Raman</surname>
            <given-names>Jegadeesh</given-names>
          </name>
          <address>
            <email>ramanjegadeesh@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hidari</surname>
            <given-names>Kazuya I. P. J.</given-names>
          </name>
          <address>
            <email>hidari@jc.u-aizu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ismail</surname>
            <given-names>Norizah</given-names>
          </name>
          <address>
            <email>norizah_ismail@moh.gov.my</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sabaratnam</surname>
            <given-names>Vikineswary</given-names>
          </name>
          <address>
            <email>viki@um.edu.my</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0690 5255</institution-id><institution-id institution-id-type="GRID">grid.415759.b</institution-id><institution>Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, </institution><institution>Ministry of Health, </institution></institution-wrap>Kuala Lumpur, Malaysia </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2308 5949</institution-id><institution-id institution-id-type="GRID">grid.10347.31</institution-id><institution>Mushroom Research Centre, Institute of Biological Sciences, Faculty of Science, </institution><institution>University of Malaya, </institution></institution-wrap>Kuala Lumpur, Malaysia </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0690 5255</institution-id><institution-id institution-id-type="GRID">grid.415759.b</institution-id><institution>Virology Unit, Disease Department, National Public Health Laboratory, </institution><institution>Ministry of Health, </institution></institution-wrap>Sungai Buloh, Selangor Malaysia </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1763 0236</institution-id><institution-id institution-id-type="GRID">grid.265880.1</institution-id><institution>Department of Food and Nutrition, Junior College Division, </institution><institution>University of Aizu, </institution></institution-wrap>Fukushima, Japan </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0636 2782</institution-id><institution-id institution-id-type="GRID">grid.420186.9</institution-id><institution>Mushroom Research Division, National Institute of Horticultural and Herbal Science, </institution><institution>Rural Development Administration, </institution></institution-wrap>Eumsung, Republic of Korea </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2019</year>
      </pub-date>
      <volume>19</volume>
      <elocation-id>260</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>6</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>8</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2019</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Dengue is a mosquito-borne viral infection that has become a major public health concern worldwide. Presently, there is no specific vaccine or treatment available for dengue viral infection.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2"><italic>Lignosus rhinocerotis</italic>, <italic>Pleurotus giganteus</italic>, <italic>Hericium erinaceus, Schizophyllum commune</italic> and <italic>Ganoderma lucidium</italic> were selected for evaluation of their in-vitro anti-dengue virus serotype 2 (DENV-2) activities. Hot aqueous extracts (HAEs), ethanol extracts (EEs), hexane soluble extracts (HSEs), ethyl acetate soluble extracts (ESEs) and aqueous soluble extracts (ASEs) were prepared from&#xA0;the selected mushrooms. The cytotoxic effects of the&#xA0;extracts were evaluated by&#xA0;the MTT assay. The&#xA0;anti-DENV-2 activities of the&#xA0;extracts were evaluated in three different assays: simultaneous, attachment and penetration assays were perfomed using plaque reduction assays and RT-qPCR assays. The effect of the&#xA0;addition time on viral replication was assessed by the&#xA0;time of addition assay, and a&#xA0;virucidal assay was carried out to evaluate the direct effect of each&#xA0;mushroom extract on DENV-2. The chemical composition of glucans, and the&#xA0;protein and phenolic acid contents&#xA0;in the&#xA0;extracts were estimated.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">We found that the HAEs and ASEs of <italic>L. rhinocerotis</italic>, <italic>P. giganteus</italic>, <italic>H. erinaceus</italic> and <italic>S. commune</italic> were the&#xA0;least toxic to Vero cells and showed very prominent anti-DENV2 activity. The 50% inhibitory concentration (IC<sub>50</sub>) values of the&#xA0;ASEs ranged between 399.2&#x2013;637.9&#x2009;&#x3BC;g/ml, while for the&#xA0;HAEs the range was 312.9&#x2013;680.6&#x2009;&#x3BC;g/ml during simultaneous treatment. Significant anti-dengue activity was also detected in the penetration assay of ASEs (IC<sub>50</sub>: 226.3&#x2013;315.4&#x2009;&#x3BC;g/ml) and HAEs (IC<sub>50</sub>: 943.1&#x2013;2080.2&#x2009;&#x3BC;g/ml). Similarly, we observed a marked reduction in the expression levels&#xA0;of the&#xA0;ENV and NS5 genes in&#xA0;the simultaneous and penetration assays of the&#xA0;ASEs and HAEs. Time-of-addition experiments showed that the highest percent of anti-DENV2 activity was observed when the&#xA0;mushroom extracts were added immediately after virus adsorption. None of the extracts exhibited virucidal effect. Chemical composition analysis showed that the major components in the&#xA0;mushroom HAEs and ASEs were glucan (beta D-glucan) and proteins, however,&#xA0;there was no significant correlation between the&#xA0;anti-dengue activity and the concentration of glucans and proteins.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p id="Par4">These findings demonstrated the potential of mushroom extracts as anti-dengue therapeutic agents with less toxic effects.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Dengue virus</kwd>
        <kwd>Mushrooms</kwd>
        <kwd>Anti-dengue activity</kwd>
        <kwd>Mushroom extracts</kwd>
        <kwd>Cytotoxicity</kwd>
        <kwd>Plaque reduction assay</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par27">Dengue is a critical mosquito-borne viral disease that&#xA0;continues to cause substantial public health burdens in Asia and the Pacific. The reported number of dengue cases has increased over the past decade. In 2017, there were 407,199 dengue cases and 874 dengue deaths reported from countries in the Western Pacific Region [<xref ref-type="bibr" rid="CR1">1</xref>]. In Malaysia, the number of dengue cases was 82,840 and 171 deaths, the third highest among the&#xA0;countries in the Western Pacific region. Dengue virus (DENV) exists in nature as four antigenically distinct but closely related virus serotypes known as DENV-1, 2, 3 and 4, which can be transmitted to humans by the mosquito species&#xA0;<italic>Aedes aegypti</italic> and <italic>Aedes albopictus</italic>. The clinical syndrome of DENV infection had been classified into dengue with or without warning signs and severe dengue. Attempts regarding vaccine development for dengue have been a continuous challenge for many years due to the inability of the vaccines to concurrently protect&#xA0;against all four antigenically distinct dengue serotypes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Effective antiviral therapies are currently unavailable for DENV. Dengue patients are usually managed through supportive therapies until they recover without any specific treatment measures. The search for new antiviral agents is vital for&#xA0;the prompt treatment of dengue infection to avoid further development of severe dengue, to control the&#xA0;spread of the outbreak and to enhance possible vaccination programmes&#xA0;in the future.</p>
      <p id="Par28">Culinary and medicinal mushrooms have great prospects in the drug and nutraceutical industries. They possess a wide range of pharmacological properties, including&#xA0;antimicrobial, antiviral, antitumour, anti-inflammatory, immunomodulatory, hypoglycaemic and hepatoprotective properties, and thus can be considered a functional food. Mushroom antiviral activities have been reported towards human immunodeficiency virus (HIV) using lectin isolated from <italic>Hericium erinaceus</italic> [<xref ref-type="bibr" rid="CR4">4</xref>] and laccase isolated from <italic>Clitocybe maxima</italic> [<xref ref-type="bibr" rid="CR5">5</xref>]. An acidic protein bound polysaccharide isolated from <italic>Ganoderma lucidium</italic> [<xref ref-type="bibr" rid="CR6">6</xref>] and a&#xA0;protein from <italic>Grifola frondosa</italic> [<xref ref-type="bibr" rid="CR7">7</xref>] inhibited the replication of the&#xA0;herpes simplex virus (HSV). Influenza viruses have been inhibited by ganomycins A and B from <italic>Ganoderma pfeifferi</italic> [<xref ref-type="bibr" rid="CR8">8</xref>] and polysaccharides isolated from <italic>Agaricus brasiliensis</italic> showed antiviral activity against polioviruses [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p id="Par29">In this study, five culinary and medicinal mushrooms that are commercially grown in Malaysia, <italic>Lignosus rhinocerotis (Cooke) Ryvarden</italic>, <italic>Pleurotus giganteus (Berk) Karunarathna &amp; K.D.Hyde</italic>, <italic>Hericium erinaceus (Bull) Persoon, Schizophyllum commune</italic> (Fr.) and <italic>Ganoderma lucidium</italic> (Curtis) P. Karst were selected for in-vitro screening for their&#xA0;anti-dengue serotype 2 (DENV-2) activity. Two types of extraction protocols were used to isolate chemical components from selected mushrooms. Initially, hot aqueous extracts and ethanol extracts were prepared from the&#xA0;dry powdered mushroom fruiting body. Hot aqueous extraction was employed to obtain the&#xA0;polar components such as polysaccharides and proteins. The non-polar components in the&#xA0;ethanol extracts were isolated through solvent extraction, using hexane and ethyl acetate as&#xA0;solvents. Before evaluating the anti-dengue effect of the&#xA0;extracts, the cytotoxic properties of the&#xA0;extracts were identified with the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. The non-cytotoxic concentrations of each extract were screened for their&#xA0;inhibitory effects on in-vitro dengue infection. To our knowledge, this is the first report on the&#xA0;anti-DENV2 activities of culinary and medicinal mushrooms.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Culinary and medicinal mushrooms</title>
        <p id="Par30">Five mushrooms that&#xA0;are known for their culinary and medicinal value were selected for this study. Four of the mushrooms were authenticated by mycologists from the Mushroom Research Centre, University of Malaya and voucher specimens were deposited in the Herbarium of University of Malaya (KLU-M). The fruiting bodies of <italic>H. erinaceus</italic> (KLU-M 1232) were purchased from Highland Mushroom Farm (Genting Highlands, Pahang). The fruiting bodies of <italic>P. giganteus</italic> (KLU-M 1227) were obtained from Nas Agro Farm (Sepang, Selangor). Fruiting bodies of <italic>S. commune</italic> (KLU-M 1389) were purchased from Glami Lemi Biotechnology research centre (Jelebu, Negeri Sembilan). <italic>Ganoderma lucidium</italic> (KLU-M 1233) was purchased in dried form from Vita Agrotech Sdn. Bhd. (Tanjung Sepat, Selangor). The fruiting bodies were sliced, freeze-dried (Christ, Germany) for 1-2&#x2009;days and powdered. The <italic>L. rhinocerotis</italic> was purchased in freeze dried form from Ligno Biotek Sdn. Bhd. (Balakong Jaya, Selangor).</p>
      </sec>
      <sec id="Sec4">
        <title>Cells and viruses</title>
        <p id="Par31">African green monkey kidney cells (Vero, ATCC&#xAE; CCL-81&#x2122;) and <italic>Aedes albopictus</italic> clone (C6/36, ATCC&#xAE; CRL-1660&#x2122;) were obtained from National Public Health Laboratory, Sungai Buloh, Malaysia. Vero cells were propagated in Eagle&#x2019;s minimum essential medium (Sigma aldrich, St. Louis, MO) containing 2.5% sodium bicarbonate, 1% HEPES 1&#x2009;M, 1% penicillin &amp; streptomycin and 10% heat-inactivated foetal bovine serum (FBS) (Gibco, USA). The C6/36 mosquito cell line was cultured in RPMI 1640 (Gibco, USA) supplemented with 1% sodium bicarbonate and 10% FBS. The cell growth was maintained in medium containing 2% serum concentration. The&#xA0;DENV-2 strain New Guinea C (GeneBank Accession No. M29095) was obtained from the Institute of Medical Research, Kuala Lumpur, Malaysia. The viruses were cultured and propagated in the C6/36 cell line with RPMI 1640 medium containing 2% FBS at 30&#x2009;&#xB0;C. The supernatants were collected by centrifugation after two rounds of freeze-thawing and were stored at &#x2212;&#x2009;80&#x2009;&#xB0;C for further experiments.</p>
      </sec>
      <sec id="Sec5">
        <title>Preparation of crude hot aqueous extract, ethanol extract and fractions</title>
        <p id="Par32">The hot aqueous extraction method was carried out as described previously [<xref ref-type="bibr" rid="CR10">10</xref>]. The mushroom powder was soaked overnight in distilled water (1:20 ratio, w/v). The suspension was double boiled in a water bath for 30&#x2009;min and then filtered and freeze-dried to collect the&#xA0;hot aqueous extract (HAE). For ethanol extraction, the mushroom powder was soaked in 80% ethanol (1:10 ratio, w/v) (Merck, Germany) for two&#x2009;days at room temperature. The suspension was vacuum filtered. The whole procedure was repeated twice. The pooled supernatant was evaporated under reduced pressure using a rotary evaporator (Eyela N-1000, US) to collect the&#xA0;ethanol extract (EE). Ten grams of EE were fractionated with 100&#x2009;mL of hexane (Merck, Germany) to collect hexane soluble (HSE) and hexane insoluble extracts. One hundred millilitres of ethyl acetate (Merck, Germany) and water (1:2) mixture was added to the insoluble hexane extract to collect the&#xA0;ethyl acetate soluble (ESE) and aqueous soluble extract (ASE). This solvent extraction was repeated three times, the extracts were pooled, and the excess solvent was evaporated under reduced pressure using a rotary evaporator. The ASE was freeze dried. All the extracts were kept at 4&#x2009;&#xB0;C until further use.</p>
      </sec>
      <sec id="Sec6">
        <title>Cytotoxicity assay</title>
        <p id="Par33">Preceding the screening of the&#xA0;mushroom extracts for their antiviral properties, a cytotoxicity assay was carried out to identify the cytotoxic effects of the&#xA0;extracts on Vero cells. The cytotoxicity assay was carried out using the colourimetric MTT method using a&#xA0;Cell Titre 96 Non-Radioactive Cell Proliferation assay kit (Promega, USA), according to the manufacturer&#x2019;s instructions. The HAE and ASE stock solutions (10,000&#x2009;&#x3BC;g/mL) were freshly prepared in a 2% maintenance medium and filter sterilized. The EE, HSE and ESE were diluted in dimethyl sulfoxide (Amresco, USA), filter sterilized and further diluted with distilled water to obtain a&#xA0;5000&#x2009;&#x3BC;g/mL stock solution. Serial dilutions of each mushroom extract were prepared in 2% maintenance medium.</p>
        <p id="Par34">Vero cells were grown in 96-well culture plates (TPP, Switzerland) at a density of 1&#x2009;&#xD7;&#x2009;10<sup>5</sup> cells/mL. After overnight incubation, the growth medium was discarded and replaced with serially diluted HAE/ASE (250&#x2013;10,000&#x2009;&#x3BC;g/mL) or EE/HSE/ESE (12.5&#x2013;500&#x2009;&#x3BC;g/mL) in triplicate. Blank control wells with growth medium only and cell control wells containing cells with growth medium without extracts were also included in the assay. A known antiviral drug, ribavirin (Sigma Aldrich, St. Louis, MO) at concentrations ranging from 25 to 1000&#x2009;&#x3BC;g/mL was included in the test. Microplates were incubated for 48&#x2009;h at 37&#x2009;&#xB0;C with 5% CO<sub>2</sub>. The absorbance was measured at 570&#x2009;nm using a&#xA0;96-well plate reader (TECAN, Switzerland) which was directly proportional to the number of living cells in the wells. The 50% cytotoxic concentration (CC<sub>50</sub>) was estimated as the concentration of the extracts capable of decreasing the absorbance by 50% in comparison to the negative controls by probit analysis of the dose-response curve generated from the data. The maximum non-cytotoxic concentration (MNCC) was established from the concentration that showed the&#xA0;least cytotoxic effect towards Vero cells compared with the&#xA0;negative control. The concentrations below the&#xA0;MNCC were selected to evaluate the&#xA0;anti-dengue activity of the&#xA0;mushroom extract using a&#xA0;plaque reduction assay.</p>
      </sec>
      <sec id="Sec7">
        <title>Evaluation of anti-dengue activity of mushroom extracts using a&#xA0;plaque reduction assay</title>
        <p id="Par35">Anti-dengue assays were evaluated in three different assays, simultaneous, attachment and penetration, using plaque reduction assay [<xref ref-type="bibr" rid="CR11">11</xref>]. During the&#xA0;simultaneous assay, the&#xA0;Vero cell monolayer was infected with 80&#x2013;100 plaque forming units (PFU) of DENV-2. The plates were incubated in 5% CO<sub>2</sub> at 37&#x2009;&#xB0;C for l h and then overlaid with 1% carboxymethylcellulose overlay medium containing various concentrations of HAE, EE, ESE or ASE&#xA0;below the&#xA0;MNCC. For the&#xA0;attachment assay, Vero cells were infected with 500 PFU of DENV-2 in the absence or presence of mushroom extracts. After viral adsorption for 60&#x2009;min at 4&#x2009;&#xB0;C, both the&#xA0;extract and unabsorbed viruses were removed and overlaid with carboxymethylcellulose [<xref ref-type="bibr" rid="CR12">12</xref>]. In the&#xA0;penetration assay, Vero cells were adsorbed with 500 PFU of DENV-2 for 1&#x2009;h at 4&#x2009;&#xB0;C. Unbound viruses were removed, and the plates were shifted to 37&#x2009;&#xB0;C to allow for&#xA0;penetration. Cells were treated with mushroom extracts and incubated for 1&#x2009;h at 37&#x2009;&#xB0;C. The extracts were discarded, and&#xA0;cells were treated with 0.1&#x2009;ml of citrate-buffer (40&#x2009;mM citric acid, 10&#x2009;mM potassium chloride, 135&#x2009;mM sodium chloride, pH&#x2009;3) for 1&#x2009;min to inactivate the&#xA0;adsorbed but not internalized viruses. Cells were washed and overlaid with carboxymethylcellulose [<xref ref-type="bibr" rid="CR12">12</xref>]. For all the treatments mentioned above, after the addition of carboxymethylcellulose, the&#xA0;plates were incubated for 7&#x2009;days at 37&#x2009;&#xB0;C, the infected cells were stained with naphthalene blue black solution, and the number of plaques was counted. The concentration of extract required to inhibit up to 50% of viral growth (IC<sub>50</sub>) compared with the control group were calculated by probit analysis of the dose&#x2013;response curves generated from the data. The selectivity index (SI) values of each extract were calculated as SI&#x2009;=&#x2009;CC<sub>50</sub>/IC<sub>50</sub>.</p>
        <p id="Par36">The effect of the&#xA0;addition time of the&#xA0;mushroom HAE and ASE on the replication of DENV2 was determined as described previously [<xref ref-type="bibr" rid="CR9">9</xref>]. The&#xA0;overlay containing&#xA0;the MNCC of 2000&#x2009;&#x3BC;g/ml was then added to the Vero cell monolayer either 2&#x2009;h before viral adsorption or 1, 2, 3 or 5&#x2009;h after viral adsorption (80-100PFU). Percentage of inhibitory activity of the&#xA0;extracts was determined.</p>
        <p id="Par37">To study&#xA0;the direct effect of the&#xA0;mushroom extract on DENV-2, assays were performed according to the previously described method [<xref ref-type="bibr" rid="CR13">13</xref>]. Virus suspensions containing 500 PFU of the&#xA0;DENV-2 strain were incubated with or without mushroom extract for 2&#x2009;h at 37&#x2009;&#xB0;C. A total of&#xA0;100&#x2009;&#x3BC;l of treated viral suspension was adsorbed onto confluent Vero cells for 1&#x2009;h at 37&#x2009;&#xB0;C. Percentage of inhibitory activity of the&#xA0;mushroom extract was determined.</p>
      </sec>
      <sec id="Sec8">
        <title>Effect of mushroom extract on the expression levels&#xA0;of dengue envelope (ENV) and non-structural protein 5 (NS5)&#xA0;genes</title>
        <p id="Par38">The inhibitory activities of the&#xA0;mushroom extracts in the&#xA0;simultaneous, attachment and penetration assays were further evaluated by RT-qPCR to study the expression levels&#xA0;of the&#xA0;dengue envelope (ENV) and non-structural protein 5 (NS5) genes. Vero cells were grown to approximately 90% confluency, infected with DENV-2 and cultured in the presence of 2000&#x2009;&#x3BC;g/ml MNCC&#xA0;of the&#xA0;mushroom extracts. After 48&#x2009;h post infection, the infected cells were collected by centrifugation at 1500&#x2009;rpm for 10&#x2009;min. Viral ribonucleic acid (RNA) was extracted from cell pellets according to the instructions provided by the&#xA0;Nucleospin RNA extraction kit (MACHEREY-NAGEL, Germany). The purity and concentration of the&#xA0;extracted RNA were assessed using a&#xA0;BioSpectrophotometer (EPPENDORF, Hamburg, Germany). The absorbance ratios were between 1.8&#x2013;2.0 at 260/280&#x2009;nm, indicating that the&#xA0;RNA samples were&#xA0;free from protein.</p>
        <p id="Par39">The extracted viral RNA was reverse transcribed into complementary DNA (cDNA) using the iScriptTM cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). Real-time PCR was carried out on CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The reaction mixture contained 10&#x2009;&#x3BC;L&#xA0;of SsoAdvanced SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA), 2&#x2009;&#x3BC;L of&#xA0;cDNA template, 7&#x2009;&#x3BC;L of&#xA0;RNase/DNase free sterile water and 0.5&#x2009;&#x3BC;L (0.25&#x2009;&#x3BC;M final concentration) of ENV or NS5 forward and reverse primers (Bioneer Corp., South Korea) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The amplification was carried out with hot start activation for 5&#x2009;min at 95&#x2009;&#xB0;C followed by 40&#x2009;cycles of 10&#x2009;s denaturation at 95&#x2009;&#xB0;C and 30&#x2009;s annealing at 55&#x2009;&#xB0;C. Melting curve analysis was generated to verify the specificity of the PCR product. The experiments were performed in duplicate. Gene expression analysis was performed using Bio-Rad CFX Manager Software 1.6. The&#xA0;results were expressed as normalized fold expression compared to the virus infected cells and normalized to the reference gene of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primer sequences of the&#xA0;dengue ENV, NS5 and GAPDH genes are shown in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>The primer sequences of GAPDH, NS5 and ENV</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Target gene</th><th>Sequence</th><th>Tm</th></tr></thead><tbody><tr><td>GAPDH-F</td><td>5&#x2032; GTG GAC CTG ACC TGC CGT CT 3&#x2032;</td><td>58.4</td></tr><tr><td>GAPDH-R</td><td>5&#x2032; GGA GGA GTG GGT GTC GCT GT 3&#x2032;</td><td>58.4</td></tr><tr><td>ENV-F</td><td>5&#x2032; ACA AGT CGA ACA ACC TGG TCC AT 3&#x2032;</td><td>58.3</td></tr><tr><td>ENV-R</td><td>5&#x2032; GCC GCA CCA TTG GTC TTC TC 3&#x2032;</td><td>59.0</td></tr><tr><td>NS5-F</td><td>5&#x2032; GGA AGG AGA AGG ACT GCA CA-3&#x2032;</td><td>53.8</td></tr><tr><td>NS5-R</td><td>5&#x2032; ATT CTT GTG TCC CAT CCT GCT 3&#x2032;</td><td>54.7</td></tr></tbody></table><table-wrap-foot><p>The nucleotide sequences for primers were obtained from Poh et al. [<xref ref-type="bibr" rid="CR14">14</xref>] and Kong et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec9">
        <title>Estimation of the&#xA0;chemical composition of the&#xA0;mushroom extracts</title>
        <p id="Par40">The chemical compositions of the&#xA0;mushroom extracts that exhibited anti-dengue activity were studied. Mushroom extracts were diluted in distilled water to prepare a&#xA0;10&#x2009;mg/mL solution. The composition of total glucan, &#x3B1;-glucan, &#x3B2;-glucan, protein and phenolic content were estimated. The amount of total and &#x3B1;-glucan in the mushroom extracts were evaluated using the&#xA0;Mushroom and Yeast &#x3B2;-glucan assay procedure K-YBGL 07/11 (Megazyme, Ireland). The &#x3B2;-glucan content was calculated by deducting the &#x3B1;-glucan content&#xA0;from the total glucan content. The&#xA0;Bradford assay was used to&#xA0;estimate the&#xA0;protein content and bovine serum albumin (Sigma Aldrich, St. Louis, MO) was used as a standard [<xref ref-type="bibr" rid="CR16">16</xref>]. Folin-Ciocalteu's reagent (Sigma Aldrich, St. Louis, MO) was utilized to determine the&#xA0;total phenolic content by using gallic acid (Sigma Aldrich, St. Louis, MO) as a standard [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Statistical analyses</title>
        <p id="Par41">Statistical analyses were conducted using SPSS version 20. All data are expressed as the mean&#xA0;&#xB1;&#xA0;standard deviation (SD). ANOVA with post hoc comparison was used to evaluate the statistically significant differences between a treated group and untreated group. The CC<sub>50</sub> and IC<sub>50</sub> values were calculated by probit analysis. <italic>P</italic>-values of less than 0.05 (*) or 0.01 (**) were defined as statistically significant.</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Results</title>
      <sec id="Sec12">
        <title>The yield of the&#xA0;mushroom extracts</title>
        <p id="Par42">To isolate as many active components from mushrooms&#xA0;as possible, a very extensive extraction procedure was carried out on mushroom powder. Initially, the&#xA0;HAE and EE were prepared from mushroom freeze-dried powder. The EE was further refined using ethyl acetate and hexane to separate the&#xA0;ESE and HSE, respectively. Finally, the insoluble substances were collected as the&#xA0;ASE. The extraction yields of the&#xA0;mushroom extracts are shown in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>. The extraction yield of the&#xA0;HAE was higher than that of the&#xA0;EE. Separation of EE produced a higher yield of ASE, followed by HSE and ESE.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>The percentage of extraction yield of the&#xA0;mushroom extracts</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">HAE</th><th rowspan="2">EE</th><th colspan="3">Separation of EE</th></tr><tr><th>ASE</th><th>ESE</th><th>HSE</th></tr></thead><tbody><tr><td>
<italic>P. giganteus</italic>
</td><td>34.4</td><td>23.4</td><td>15.0</td><td>0.7</td><td>0.2</td></tr><tr><td>
<italic>L.rhinocerotis</italic>
</td><td>23.1</td><td>4.7</td><td>2.6</td><td>0.4</td><td>0.7</td></tr><tr><td>
<italic>H. erinaceus</italic>
</td><td>34.8</td><td>11.7</td><td>8.3</td><td>0.5</td><td>1.8</td></tr><tr><td>
<italic>S. commune</italic>
</td><td>24</td><td>13.8</td><td>8.8</td><td>0.2</td><td>3.5</td></tr><tr><td>
<italic>G. lucidium</italic>
</td><td>4.5</td><td>3.3</td><td>0.9</td><td>0.4</td><td>0.7</td></tr></tbody></table><table-wrap-foot><p>The percentage of extraction yield was calculated using the following&#xA0;formula: Weight of extract/Weight of mushroom powder &#xD7;&#x2009;100</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec13">
        <title>Cytotoxic effect and anti-dengue activity of the&#xA0;mushroom extracts in Vero cells</title>
        <p id="Par43">The&#xA0;mushroom ASEs and HAEs were less cytotoxic compared to the&#xA0;EEs, HSEs and ESEs (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>). The ASE of <italic>P. giganteus</italic>, <italic>H. erinaceus</italic> and <italic>S. commune</italic> showed no alteration in cell viability at concentrations up to 10,000&#x2009;&#x3BC;g/mL. Their CC<sub>50</sub> values were considered greater than 10,000&#x2009;&#x3BC;g/mL. The HAEs of <italic>P. giganteus</italic>, <italic>L. rhinocerotis</italic>, <italic>H. erinaceus</italic> and <italic>S. commune</italic> were moderately cytotoxic; their CC<sub>50</sub> values were between 3599.2&#xA0;and 5171.4&#x2009;&#x3BC;g/mL. The greatest cytotoxic effects were noted in the&#xA0;EEs, ESEs and HSEs; the CC<sub>50</sub> values were 175.3&#x2013;1967.2&#x2009;&#x3BC;g/mL, 150.7&#x2013;500&#x2009;&#x3BC;g/mL and 60.6&#x2013;500&#x2009;&#x3BC;g/mL, respectively.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Cytotoxic effects of the&#xA0;mushroom extract in Vero cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HAE</th><th>EE</th><th>ASE</th><th>ESE</th><th>HSE</th></tr></thead><tbody><tr><td>
<italic>P. giganteus</italic>
</td><td>4211.8&#xA0;&#xB1;&#xA0;185.6**</td><td>319.5&#x2009;&#xB1;&#x2009;38.8**</td><td>&gt;&#x2009;10,000</td><td>171.8&#x2009;&#xB1;&#x2009;16.2**</td><td>163.8&#x2009;&#xB1;&#x2009;15**</td></tr><tr><td>
<italic>L. rhinocerotis</italic>
</td><td>3599.2&#xA0;&#xB1;&#xA0;417.8**</td><td>1967.2&#x2009;&#xB1;&#x2009;580.7*</td><td>3051&#x2009;&#xB1;&#x2009;244.6**</td><td>343.6&#x2009;&#xB1;&#x2009;5.3**</td><td>184.5&#x2009;&#xB1;&#x2009;19.2**</td></tr><tr><td>
<italic>S. commune</italic>
</td><td>4262.8&#xA0;&#xB1;&#xA0;1345.7*</td><td>&gt; 500</td><td>&gt;&#x2009;10,000</td><td>&gt;500</td><td>&gt;500</td></tr><tr><td>
<italic>H. erinaceus</italic>
</td><td>5171.4&#xA0;&#xB1;&#xA0;1309.7*</td><td>817&#x2009;&#xB1;&#x2009;229.7*</td><td>&gt;&#x2009;10,000</td><td>150.7&#x2009;&#xB1;&#x2009;25.7**</td><td>60.6&#x2009;&#xB1;&#x2009;14.5*</td></tr><tr><td>
<italic>G. lucidium</italic>
</td><td>1748.1&#xA0;&#xB1;&#xA0;189.8**</td><td>175.3&#x2009;&#xB1;&#x2009;1.7**</td><td>779.1&#x2009;&#xB1;&#x2009;125**</td><td>&gt;500</td><td>354.2&#x2009;&#xB1;&#x2009;3.6**</td></tr></tbody></table><table-wrap-foot><p>The cytotoxicities of the&#xA0;mushroom extracts were measured at the&#xA0;end-point (48&#x2009;h) by MTT assay. The&#xA0;CC<sub>50</sub>, 50% cytotoxic concentrations capable of reducing the absorbance by 50% in comparison to the negative control cells without extract, were estimated from dose response curves of three independent experiment using probit analysis (<italic>n</italic>&#x2009;=&#x2009;3). Statistical differences compared to untreated cell control group are noted with asterisk (*<italic>P</italic>&#x2009;&lt;&#x2009;0.05) or (**<italic>p</italic>&#x2009;&lt;&#x2009;0.01)</p></table-wrap-foot></table-wrap></p>
        <p id="Par44">The anti-dengue activity was prominent in the&#xA0;HAEs and ASEs during the&#xA0;simultaneous (s) and penetration (p)&#xA0;assays (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>). The EEs, HSEs and ESEs did not show anti-dengue activity (data not shown). The most prominent anti-dengue activities were detected in the&#xA0;ASE of <italic>L. rhinocerotis</italic> (IC<sub>50 S:</sub> 399.2&#x2009;&#x3BC;g/ml; IC<sub>50 P:</sub> 226.3&#x2009;&#x3BC;g/ml), followed by <italic>S. commune</italic> (IC<sub>50 S:</sub> 424.9&#x2009;&#x3BC;g/ml; IC<sub>50 P:</sub> 279.3&#x2009;&#x3BC;g/ml), <italic>H. erinaceus</italic> (IC<sub>50 S:</sub> 574.4&#x2009;&#x3BC;g/ml; IC<sub>50 P:</sub> 278.7&#x2009;&#x3BC;g/ml) and <italic>P. giganteus</italic> (IC<sub>50 S:</sub> 637.9&#x2009;&#x3BC;g/ml; IC<sub>50 P:</sub> 315.4&#x2009;&#x3BC;g/ml). Higher SI values were noted in the&#xA0;ASEs of <italic>S. commune</italic> (SIs: 24.1; SI<sub>P:</sub> 36), <italic>H erinaceus</italic> (SIs: 17.7; SI<sub>P:</sub> 38.2) and <italic>P. giganteus</italic> (SIs: 15.7; SI<sub>P:</sub> 32.3). Although <italic>L. rhinocerotis</italic> gave the highest IC<sub>50</sub> value, due to its&#xA0;cytotoxic effects, <italic>L. rhinocerotis</italic>&#xA0;produced the lowest SI values during simultaneous (SIs:7.6) and penetration assays (SIp: 17.5). Weak inhibitory activity was observed from the <italic>G. lucidium</italic> HAE and activity was&#xA0;not detected in its ASE (data not shown). Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> shows the dose dependent activity of <italic>S. commune</italic> HAE from the plaque reduction assay. We found that the SI values of the&#xA0;ASEs were greater than those of&#xA0;ribavirin during the&#xA0;simultaneous and penetration assays.
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Inhibitory activities of the&#xA0;mushroom HAEs and ASEs during&#xA0;screening, attachment and penetration assays</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Screening</th><th colspan="2">Attachment</th><th colspan="2">Penetration</th></tr><tr><th>IC<sub>50</sub> (&#x3BC;g/ml)</th><th>SI</th><th>IC<sub>50</sub> (&#x3BC;g/ml)</th><th>SI</th><th>IC<sub>50</sub> (&#x3BC;g/ml)</th><th>SI</th></tr></thead><tbody><tr><td><italic>P. giganteus</italic> HAE</td><td>344.8&#xA0;&#xB1;&#xA0;35.4**</td><td>12.4&#xA0;&#xB1;&#xA0;2.2**</td><td>&#x2013;</td><td>&#x2013;</td><td>1731&#x2009;&#xB1;&#x2009;160**</td><td>2.5&#x2009;&#xB1;&#x2009;0.3**</td></tr><tr><td><italic>L. rhinocerotis</italic> HAE</td><td>485.9&#xA0;&#xB1;&#xA0;69.5**</td><td>7.4&#xA0;&#xB1;&#xA0;0.4**</td><td>&#x2013;</td><td>&#x2013;</td><td>&#x2013;</td><td>&#x2013;</td></tr><tr><td><italic>S. commune</italic> HAE</td><td>312.9&#xA0;&#xB1;&#xA0;14.1**</td><td>13.7&#xA0;&#xB1;&#xA0;4.8*</td><td>&#x2013;</td><td>&#x2013;</td><td>943.1&#x2009;&#xB1;&#x2009;70.4**</td><td>4.5&#x2009;&#xB1;&#x2009;0.4**</td></tr><tr><td><italic>H. erinaceus</italic> HAE</td><td>680.6&#xA0;&#xB1;&#xA0;79.3**</td><td>7.8&#xA0;&#xB1;&#xA0;2.6*</td><td>&#x2013;</td><td>&#x2013;</td><td>2080.2&#x2009;&#xB1;&#x2009;252.7**</td><td>2.5&#x2009;&#xB1;&#x2009;0.3**</td></tr><tr><td><italic>P. giganteus</italic> ASE</td><td>637.9&#xA0;&#xB1;&#xA0;40.3**</td><td>15.7&#xA0;&#xB1;&#xA0;1**</td><td>872&#x2009;&#xB1;&#x2009;63.2**</td><td>11.5&#x2009;&#xB1;&#x2009;0.9**</td><td>315.4&#x2009;&#xB1;&#x2009;52.4**</td><td>32.3&#x2009;&#xB1;&#x2009;5.7**</td></tr><tr><td><italic>L. rhinocerotis</italic> ASE</td><td>399.2&#xA0;&#xB1;&#xA0;18.9**</td><td>7.6&#xA0;&#xB1;&#xA0;0.6**</td><td>261.2&#x2009;&#xB1;&#x2009;38.3**</td><td>11.9&#x2009;&#xB1;&#x2009;1.7**</td><td>226.3&#x2009;&#xB1;&#x2009;157.1</td><td>17.5&#x2009;&#xB1;&#x2009;8.7</td></tr><tr><td><italic>S. commune</italic> ASE</td><td>424.9&#xA0;&#xB1;&#xA0;76.6**</td><td>24.1&#xA0;&#xB1;&#xA0;4.4**</td><td>1245.8&#x2009;&#xB1;&#x2009;73.7**</td><td>8.1&#x2009;&#xB1;&#x2009;0.5**</td><td>279.3&#x2009;&#xB1;&#x2009;27.3**</td><td>36&#x2009;&#xB1;&#x2009;3.7**</td></tr><tr><td><italic>H. erinaceus</italic> ASE</td><td>574.4&#xA0;&#xB1;&#xA0;83.4**</td><td>17.7&#xA0;&#xB1;&#xA0;2.7**</td><td>327.6&#x2009;&#xB1;&#x2009;29.2**</td><td>30.7&#x2009;&#xB1;&#x2009;2.9**</td><td>278.7&#x2009;&#xB1;&#x2009;87*</td><td>38.2&#x2009;&#xB1;&#x2009;11.4*</td></tr><tr><td>Ribavirin</td><td>80.7&#xA0;&#xB1;&#xA0;1.8**</td><td>10.9&#xA0;&#xB1;&#xA0;2.8**</td><td>&#x2013;</td><td>&#x2013;</td><td>205&#x2009;&#xB1;&#x2009;15.2**</td><td>4.3&#x2009;&#xB1;&#x2009;0.5**</td></tr></tbody></table><table-wrap-foot><p>The anti-DENV2 activities of the&#xA0;mushroom extracts in Vero cells were evaluated in three different assays: simultaneous, attachment and penetration by the&#xA0;plaque reduction assay.&#xA0;The IC<sub>50</sub> value, the concentration of extract required to inhibit 50% of virus growth compared with the virus control group, was calculated from the&#xA0;dose response curve of three independent experiments using probit analysis (<italic>n</italic>&#x2009;=&#x2009;3). The&#xA0;selectivity index (SI) was calculated as the&#xA0;CC<sub>50</sub>/IC<sub>50</sub>. Statistical differences compared to the&#xA0;untreated virus control group are noted with asterisk (*<italic>P</italic>&#x2009;&lt;&#x2009;0.05) or (**<italic>p</italic>&#x2009;&lt;&#x2009;0.01)</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Dose dependent inhibition of <italic>S. commune</italic> HAE by plaque reduction assay: <bold>a</bold> Uninfected Vero cells, <bold>b</bold> Vero cells infected with DENV2 (NGC strain) (80&#x2013;100 PFU), <bold>c</bold> Infected cell after treated with Ribavirin (250&#x2009;&#x3BC;g/ml), <bold>d</bold>, <bold>e</bold> and <bold>f</bold> Infected cell after treated with <italic>S. commune</italic> HAE (2500&#x2009;&#x3BC;g/ml, 1500&#x2009;&#x3BC;g/ml and 500&#x2009;&#x3BC;g/ml)</p></caption><graphic xlink:href="12906_2019_2629_Fig1_HTML" id="MO1"/></fig></p>
        <p id="Par45">The antiviral mechanisms of the&#xA0;mushroom extracts were further assessed by the&#xA0;time of addition assay. We selected <italic>P. giganteus </italic>and&#xA0;<italic>S.commune</italic> HAE and ASE to study this effect. We&#xA0;found that the extracts showed the&#xA0;highest percentage of inhibitory activity against DENV-2 infection when&#xA0;the extract was added immediately after virus adsorption (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). The&#xA0;percentage of plaque inhibition decreased when the&#xA0;extracts were added 2&#x2009;h, 3&#x2009;h or 5&#x2009;h after viral adsorption. Pre-treating the Vero cells with extract for 2&#x2009;h prior to dengue infection did not significantly inhibit dengue plaque formation. To investigate the direct inactivating effect of the&#xA0;active mushroom extracts against DENV2, the&#xA0;virus suspension was treated for 2&#x2009;h at 37&#x2009;&#xB0;C with the&#xA0;mushroom extracts. From this study, we observed that none of the tested concentrations were capable of interfering with the infectivity of DENV2, and&#xA0;no significant differences were detected between the&#xA0;dengue virus treated with extract and dengue infected control wells.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Time of addition effect of active mushroom extracts on dengue virus replication in vero cells by the plaque reduction assay. Overlay containing 2000&#x2009;&#x3BC;g/ml of mushroom extracts were added to the Vero cell monolayer either 2&#x2009;h before viral adsorption or 1, 2, 3 or 5&#x2009;h after viral adsorption (80-100PFU). Percentage of inhibitory activity of extracts was determined by plaque reduction assay. Data are expressed as mean&#x2009;&#xB1;&#x2009;standard deviation of three independent experiment (<italic>n</italic>&#x2009;=&#x2009;3)</p></caption><graphic xlink:href="12906_2019_2629_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec14">
        <title>The expression of the NS5 and ENV genes after treated with mushroom extracts</title>
        <p id="Par46">The&#xA0;mushroom ASEs were further selected to access their inhibitory effect on the expression of dengue ENV and NS5 genes through real-time RT-qPCR. In mock infected cells, the&#xA0;ENV and NS5 genes were not expressed. The upregulation of these genes was noted in virus infected cells. The results were normalized to GAPDH expression and the data are presented as the&#xA0;relative normalized expression to virus infected cells, which was defined as 1. All selected ASEs showed a significant reduction in the expression levels&#xA0;of the&#xA0;ENV (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a) and NS5 genes (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b) compared with the&#xA0;virus control (**<italic>P</italic>&#x2009;&lt;&#x2009;0.01; *<italic>P</italic>&#x2009;&lt;&#x2009;0.05). Similar to the plaque reduction assay, infected cells treated with ASEs showed a higher reduction in the expression of the&#xA0;NS5 and ENV genes in&#xA0;the simultaneous and penetration assays. The highest reductions were found in the&#xA0;ASEs of <italic>S. commune</italic> and <italic>L. rhinocerotis</italic>. In simultaneous assay, the&#xA0;<italic>S. commune</italic> ASE showed a 25-fold reduction in ENV gene expression and a 33-fold reduction in NS5 gene expression. Moreover, we observed 33 and a 50-fold reduction in ENV and NS5 gene expression in cells treated with <italic>L. rhinocerotis</italic> ASE, respectively. The positive control, ribavirin, gave a&#xA0;100 fold reduction in ENV and a&#xA0;167 fold reduction in NS5 gene expression. In the&#xA0;penetration assay, the&#xA0;<italic>S. communae</italic> ASE showed a&#xA0;500-fold reduction in the expression of the&#xA0;ENV and NS5 genes. Additionally, the&#xA0;<italic>L. rhinocerotis</italic> ASE gave a&#xA0;250-fold reduction in ENV gene expression and a&#xA0;333 fold reduction in NS5 gene expression. For ribavirin, a&#xA0;significant reduction was found only in the&#xA0;penetration assay, and no inhibition was&#xA0;detected in the&#xA0;attachment assay. However, the level of reduction in&#xA0;the penetration assay was not as prominent as the&#xA0;mushroom ASEs, as&#xA0;this antiviral drug only showed a&#xA0;3 to 4-fold reduction. In the&#xA0;attachment assay, a&#xA0;weak reduction was observed for the ASEs, while no inhibitory effect was&#xA0;detected in the&#xA0;HAEs. We noticed that downregulation of NS5 gene expression was more prominent than down regulation of&#xA0;ENV gene expression.
<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>a</bold> Expression of ENV gene in DENV infected cell after treated with mushroom extract. <bold>b </bold>Expression of NS5 gene in DENV infected cell after treated with mushroom extract. DENV-2 infected Vero cells were treated with 2000&#x2009;&#x3BC;g/ml mushroom extracts according to the protocol of simultaneous, attachment and penetration assay. After 48&#x2009;h post infection, supernatants were collected to extract viral RNA of the mock infected cells, infected cells and treated infected cells. RT-qPCR was carried out to access the expression of ENV and NS5 gene. Gene expression was calculated using the algorithm provided by Bio-Rad CFX Manager Software 1.6. Results were normalized by GAPDH expression and were presented as relative normalized fold expression to virus infected cells which was defined as 1. Data are expressed as mean normalised fold expression &#xB1; SEM of two independent experiment (<italic>n</italic>&#x2009;=&#x2009;2). Statistical differences compared to mock infected cells are noted with asterisk (*<italic>P</italic>&#x2009;&lt;&#x2009;0.05) or (**<italic>P</italic>&#x2009;&lt;&#x2009;0.01)</p></caption><graphic xlink:href="12906_2019_2629_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec15">
        <title>Correlation between the&#xA0;chemical composition of the&#xA0;mushroom extracts and anti-dengue activity</title>
        <p id="Par47">The majority of anti-viral substances in mushroom extracts have been polysaccharides or proteins and phenolics, similar to in some natural products. We evaluated the correlation between anti-dengue activity and these components. As an anti-dengue effect was prominent in HAEs and ASEs, the chemical compositions of these extracts were studied. The main chemical composition of mushroom HAEs and ASEs was glucan and protein (Table&#xA0;<xref rid="Tab5" ref-type="table">5</xref>). Only trace amounts of phenolic acids were detected in the&#xA0;HAEs and ASEs. However, the concentration and type of glucan and protein varied between the method of extraction and mushrooms specimens. Total glucan and &#x3B2;-glucan contents were mostly higher in the&#xA0;mushroom ASEs than in the&#xA0;HAEs, except for <italic>L. rhinocerotis</italic>, where&#xA0;the level of glucans was higher in the&#xA0;HAE. Moreover, the majority of the&#xA0;HAEs contained a higher concentration of &#x3B1;-glucan and protein content than the&#xA0;ASEs. Among all the selected mushrooms, we found that <italic>L. rhinocerotis</italic> contained the highest concentration of total glucan (71.8%) and &#x3B2;-glucan (58.4%) in its&#xA0;HAE, and the&#xA0;protein content&#xA0;was the&#xA0;highest in its ASE (27.6%). The highest concentration of &#x3B1;-glucan was found in the&#xA0;HAE of <italic>P. giganteus</italic> (17.6%). No significant correlation was found between the concentration of glucan or protein and anti-dengue activity, because these&#xA0;mushroom specimens, even those&#xA0;with low glucan or protein content, also exhibited prominent anti-dengue activity.
<table-wrap id="Tab5"><label>Table 5</label><caption><p>The percentage of total glucan, &#x3B1;-glucan, &#x3B2;-glucan, protein and phenolic acid content&#xA0;in mushroom HAEs and ASEs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Extract</th><th>Total glucan<sup>a</sup></th><th>&#x3B1;-glucan<sup>b</sup></th><th>&#x3B2;-glucan<sup>c</sup></th><th>Protein<sup>d</sup></th><th>Phenolic acid<sup>e</sup></th></tr></thead><tbody><tr><td><italic>P. giganteus</italic> HAE</td><td>27.6&#xA0;&#xB1;&#xA0;0.2</td><td>17.6&#xA0;&#xB1;&#xA0;0.1</td><td>10.1&#xA0;&#xB1;&#xA0;0.1</td><td>18.2&#xA0;&#xB1;&#xA0;2.3</td><td>0.33&#xA0;&#xB1;&#xA0;0.01</td></tr><tr><td><italic>P. giganteus</italic> ASE</td><td>31.6&#xA0;&#xB1;&#xA0;0.4</td><td>3.5&#xA0;&#xB1;&#xA0;0.3</td><td>28.1&#xA0;&#xB1;&#xA0;0.5</td><td>12.6&#xA0;&#xB1;&#xA0;0.9</td><td>0.18&#xA0;&#xB1;&#xA0;0.01</td></tr><tr><td><italic>L. rhinocerotis</italic> HAE</td><td>71.8&#xA0;&#xB1;&#xA0;4</td><td>13.5&#xA0;&#xB1;&#xA0;1.1</td><td>58.4&#xA0;&#xB1;&#xA0;1.1</td><td>16.5&#xA0;&#xB1;&#xA0;2.5</td><td>0.32&#xA0;&#xB1;&#xA0;0.06</td></tr><tr><td><italic>L. rhinocerotis</italic> ASE</td><td>23.4&#xA0;&#xB1;&#xA0;0</td><td>7.8&#xA0;&#xB1;&#xA0;0.3</td><td>15.6&#xA0;&#xB1;&#xA0;0.3</td><td>27.6&#xA0;&#xB1;&#xA0;0.4</td><td>0.25&#xA0;&#xB1;&#xA0;0.03</td></tr><tr><td><italic>S. communae</italic> HAE</td><td>4.8&#xA0;&#xB1;&#xA0;0.3</td><td>0.2&#xA0;&#xB1;&#xA0;0</td><td>4.6&#xA0;&#xB1;&#xA0;0.3</td><td>18&#xA0;&#xB1;&#xA0;1.9</td><td>0.33&#xA0;&#xB1;&#xA0;0.06</td></tr><tr><td><italic>S. communae</italic> ASE</td><td>35.8&#xA0;&#xB1;&#xA0;0.3</td><td>1.4&#xA0;&#xB1;&#xA0;0.1</td><td>34.4&#xA0;&#xB1;&#xA0;0.4</td><td>15&#xA0;&#xB1;&#xA0;0.4</td><td>0.31&#xA0;&#xB1;&#xA0;0.05</td></tr><tr><td><italic>H. erinaceus</italic> HAE</td><td>2.0&#xA0;&#xB1;&#xA0;0</td><td>0.5&#xA0;&#xB1;&#xA0;0.1</td><td>1.6&#xA0;&#xB1;&#xA0;0.1</td><td>20.6&#xA0;&#xB1;&#xA0;1.7</td><td>0.32&#xA0;&#xB1;&#xA0;0.06</td></tr><tr><td><italic>H. erinaceus</italic> ASE</td><td>2.9&#xA0;&#xB1;&#xA0;1.7</td><td>0.3&#xA0;&#xB1;&#xA0;0.1</td><td>2.7&#xA0;&#xB1;&#xA0;0.1</td><td>12.7&#xA0;&#xB1;&#xA0;0.8</td><td>0.2&#xA0;&#xB1;&#xA0;0.02</td></tr><tr><td><italic>G. lucidium</italic> HAE</td><td>9.4&#xA0;&#xB1;&#xA0;1.3</td><td>4.5&#xA0;&#xB1;&#xA0;0.4</td><td>4.9&#xA0;&#xB1;&#xA0;1.8</td><td>22&#xA0;&#xB1;&#xA0;3.7</td><td>1.28&#xA0;&#xB1;&#xA0;0.16</td></tr><tr><td><italic>G. lucidium</italic> ASE</td><td>11.1&#xA0;&#xB1;&#xA0;0</td><td>1.3&#xA0;&#xB1;&#xA0;0.1</td><td>9.8&#xA0;&#xB1;&#xA0;0.1</td><td>19&#xA0;&#xB1;&#xA0;1.9</td><td>0.73&#xA0;&#xB1;&#xA0;0.08</td></tr></tbody></table><table-wrap-foot><p>Percentages of &#x3B1;-glucan, &#x3B2;-glucan, protein, phenolic content in 10&#x2009;mg/ml mushroom extracts were calculated as the&#xA0;mean&#x2009;&#xB1;&#x2009;standard deviation of three independent experiments using the&#xA0;formula listed below:</p><p><sup>a</sup>Total glucan: <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Absorbance}\times \frac{100\ \left(\upmu \mathrm{g}\ \mathrm{of}\ \mathrm{the}\ \mathrm{D}\hbox{-} \mathrm{g}\mathrm{lucose}\ \mathrm{standard}\right)}{\mathrm{GOPOD}\ \mathrm{absorbance}\ \mathrm{for}\ 100\;\upmu \mathrm{g}\ \mathrm{of}\ \mathrm{D}\hbox{-} \mathrm{g}\mathrm{lucose}\ \mathrm{standard}}/\mathrm{weight}\ \mathrm{of}\ \mathrm{sample}\times 90 $$\end{document}</tex-math><mml:math id="M2" display="inline"><mml:mtext>Absorbance</mml:mtext><mml:mo>&#xD7;</mml:mo><mml:mfrac><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#x3BC;g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of the</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#x2010;</mml:mo><mml:mtext>glucose standard</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mtext>GOPOD absorbance for</mml:mtext><mml:mspace width="0.25em"/><mml:mn>100</mml:mn><mml:mspace width="0.12em"/><mml:mi>&#x3BC;g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#x2010;</mml:mo><mml:mtext>glucose standard</mml:mtext></mml:mrow></mml:mfrac><mml:mo>/</mml:mo><mml:mtext>weight of sample</mml:mtext><mml:mo>&#xD7;</mml:mo><mml:mn>90</mml:mn></mml:math><inline-graphic xlink:href="12906_2019_2629_Article_IEq1.gif"/></alternatives></inline-formula></p><p><sup>b</sup>&#x3B1;-glucan: <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Absorbance}\times \frac{100\ \left(\upmu \mathrm{g}\ \mathrm{of}\ \mathrm{the}\ \mathrm{D}\hbox{-} \mathrm{g}\mathrm{lucose}\ \mathrm{standard}\right)}{\mathrm{GOPOD}\ \mathrm{absorbance}\ \mathrm{for}\ 100\;\upmu \mathrm{g}\ \mathrm{of}\ \mathrm{D}\hbox{-} \mathrm{g}\mathrm{lucose}\ \mathrm{standard}}/\mathrm{weight}\ \mathrm{of}\ \mathrm{sample}\times 9.27 $$\end{document}</tex-math><mml:math id="M4" display="inline"><mml:mtext>Absorbance</mml:mtext><mml:mo>&#xD7;</mml:mo><mml:mfrac><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#x3BC;g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of the</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#x2010;</mml:mo><mml:mtext>glucose standard</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mtext>GOPOD absorbance for</mml:mtext><mml:mspace width="0.25em"/><mml:mn>100</mml:mn><mml:mspace width="0.12em"/><mml:mi>&#x3BC;g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>of</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#x2010;</mml:mo><mml:mtext>glucose standard</mml:mtext></mml:mrow></mml:mfrac><mml:mo>/</mml:mo><mml:mtext>weight of sample</mml:mtext><mml:mo>&#xD7;</mml:mo><mml:mn>9.27</mml:mn></mml:math><inline-graphic xlink:href="12906_2019_2629_Article_IEq2.gif"/></alternatives></inline-formula></p><p><sup>c</sup>&#x3B2;-glucan: Total glucan &#x2013; &#x3B1;-glucan</p><p><sup>d</sup>Total protein content estimated from the&#xA0;bovine serum albumin standard curve (Absorbance at 595&#x2009;nm&#x2009;=&#x2009;0.001 (concentration of protein) - 0.166). % protein: concentration of protein (mg)/concentration of extract (10&#x2009;mg) &#xD7;&#x2009;100</p><p><sup>e</sup>Total phenolic content estimated from the&#xA0;gallic acid standard curve (Absorbance at 650&#x2009;nm&#x2009;=&#x2009;0.939 {concentration of phenolic (mM)} - 0.055). % phenolic: concentration of phenolic (mM) &#xD7;&#x2009;170/conc of extract (10&#x2009;mg) &#xD7;&#x2009;100</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec16">
      <title>Discussion</title>
      <p id="Par48">Culinary and medicinal mushrooms are&#xA0;known as functional foods for their bioactive compounds that have various valuable impacts on human well-being. However,&#xA0;there are very few studies on the&#xA0;antiviral activities of mushroom bioactive compounds. Here, we selected a few culinary and medicinal mushrooms that are commercially available in Malaysia and evaluated their anti-viral activity against DENV. The higher yields of the&#xA0;HAEs and ASEs proved that there was an abundance of polar constituents, such as polysaccharides and proteins, in mushrooms. The lower yield from ethyl acetate and hexane in this study correlated with the presence of only trace amounts of fatty acids, sterols, alkaloids reported in the&#xA0;mushroom fruiting bodies [<xref ref-type="bibr" rid="CR18">18</xref>&#x2013;<xref ref-type="bibr" rid="CR22">22</xref>].</p>
      <p id="Par49">The result of the&#xA0;cytotoxicity assay of the&#xA0;mushroom extracts indicated that the&#xA0;ASEs and HAEs were less toxic than the&#xA0;EEs, ESEs and HSEs. Hot water extracts prepared from mushrooms have been reported to have a less toxic effect than the&#xA0;ethanol extracts [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The CC<sub>50</sub> values of the&#xA0;ASEs and HAEs obtained from <italic>L. rhinocerotis</italic>, <italic>P. giganteus, H. erinaceus</italic> and <italic>S. commune</italic> were above 3000&#x2009;&#x3BC;g/mL. The&#xA0;<italic>G. lucidium</italic> HAE and ASE showed a moderate toxic effect. The cytotoxic effect of these selected culinary and medicinal mushrooms have been studied in mouse neuroblastoma cells (N2a) and mouse embryonic fibroblast (BALB/3&#x2009;T3) [<xref ref-type="bibr" rid="CR23">23</xref>]. The CC<sub>50</sub> values of the&#xA0;aqueous extracts of <italic>L. rhinocerotis</italic>, <italic>P. giganteus</italic> and <italic>H. erinaceus</italic> in N2a were 3270&#x2009;&#x3BC;g/mL, 4070&#x2009;&#x3BC;g/mL and 2600&#x2009;&#x3BC;g/mL, respectively. Moreover, their toxic effects in 3&#x2009;T3 cells were 5630&#x2009;&#x3BC;g/mL for <italic>L. rhinocerotis</italic>, 3430&#x2009;&#x3BC;g/mL for <italic>H. erinaceus</italic> and 2160&#x2009;&#x3BC;g/mL for <italic>P. giganteus</italic>. A&#xA0;moderate toxic effect has also been reported for the <italic>G. lucidium</italic> aqueous extract, which was 1350&#x2009;&#x3BC;g/mL in N2a cells and 1190&#x2009;&#x3BC;g/mL in 3&#x2009;T3 cells. These result suggest that mushroom extracts are safe for use even at high doses. Recent studies had proven that <italic>P. giganteus</italic> and <italic>L. rhinocerotis</italic> had no toxic effect on experimental rats at a daily dose of up to 5000&#x2009;mg/kg and 1000&#x2009;mg/kg, respectively [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, hot aqueous extracts of <italic>S. commune</italic> have been safely consumed as complementary therapies for cancer patients in Japan [<xref ref-type="bibr" rid="CR26">26</xref>]. The aqueous extract of <italic>H. erinaceus</italic> at a concentration of&#xA0;1000&#x2009;mg/kg had no toxicity in a rodent model and showed no adverse effects on the haematological and biochemical parameters [<xref ref-type="bibr" rid="CR27">27</xref>]. Although <italic>G. lucidium</italic> showed a moderate toxic effect, a previous report had proven that no adverse effects were observed after oral administration of&#xA0;5000&#x2009;mg/kg of <italic>Ganoderma</italic> extract in mice [<xref ref-type="bibr" rid="CR28">28</xref>]. The lower toxic effects of the&#xA0;selected mushrooms imply that there is a possibility to develop an antiviral agent for dengue virus, that is less toxic than other natural product extracts that have been tested against dengue virus, such as bioflavonoid [<xref ref-type="bibr" rid="CR29">29</xref>], neem aqueous extract [<xref ref-type="bibr" rid="CR30">30</xref>] and <italic>Houttuynia cordata</italic> aqueous extract [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
      <p id="Par50">The anti-viral activities of mushroom extracts have been&#xA0;extensively studied against herpes simplex virus [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x2013;<xref ref-type="bibr" rid="CR34">34</xref>] and HIV-1 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x2013;<xref ref-type="bibr" rid="CR38">38</xref>]. Among the selected mushrooms, <italic>P. giganteus</italic>, <italic>H. erinaceus</italic> and <italic>S. commune</italic> had been investigated for anti-HIV activities. Based on previous studies, the antiviral compounds of mushrooms were mainly polysaccharide [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], proteoglycan [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] and protein [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] which are water soluble.</p>
      <p id="Par51">These findings support our study, as prominent anti-dengue activities were found mostly in the&#xA0;HAEs and ASEs. Among the steps involved in DENV infection and replication, attachment and penetration have been considered as potential targets for the&#xA0;developing of&#xA0;antiviral drugs against the&#xA0;dengue virus. Here, we had proven the anti-viral potential of mushroom extracts by inhibiting of viral attachment and penetration of DENV. Extracts showed a&#xA0;more prominent inhibitory effect during the&#xA0;penetration assay tested using the&#xA0;plaque reduction assay and real time RT-PCR. We assume that the inhibitory activity may be initiated from attachment and gradually increases during the&#xA0;penetration stage. The findings presented here are&#xA0;in agreement with those published by other authors, who stated that the mechanism underlying the anti-viral activity of mushroom extracts may be related to the inhibition of viral adsorption and penetration [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Mushroom protein-bound glycan isolated from <italic>Polystictus Versicolor</italic>, PSK or Krestin, which are&#xA0;currently used as adjunctive therapies for various types of cancers in Japan, showed promising potential as anti-HIV agents by downregulating viral replication and promoting the upregulation of specific antiviral chemokines (RANTES, MIP-1<italic>&#x3B1;</italic>/<italic>&#x3B2;</italic>, and SDF-1<italic>&#x3B1;</italic>) known to block HIV-1 coreceptors in THP1 cells and human PBMCs [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
      <p id="Par52">In-depth study on the actual anti-dengue mechanisms of mushroom extracts is still minimal. The mechanism of the inhibition of dengue viral entry has been extensively studied on sulphated polysaccharides obtained from algae [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Talarico and Damonte, [<xref ref-type="bibr" rid="CR42">42</xref>] reported that the&#xA0;anti-DENV2 activity&#xA0;of carrageenan extended not only to adsorption but also to a post-adsorption event blocking the viral nucleocapsid internalization into the cytoplasm. They suggested that&#xA0;the fusion event leading to uncoating of the nucleocapsid and escape from the endosome was blocked, probably due to the association of carrageenan with the E virion glycoprotein. Zhang et al., [<xref ref-type="bibr" rid="CR33">33</xref>] stated that entry inhibition occurs due to the interaction between negatively charged sulphated polysaccharides and the positively charged glycoproteins of the viral envelope, which could inhibit the adsorption of the positively charged viral particles to the negatively charged host cells. In another study, Poh et al., [<xref ref-type="bibr" rid="CR14">14</xref>] reported that the compounds blocking the &#x3B2;OG (n-octyl-&#x3B2;-d-glucoside) pocket, which is&#xA0;located at a hinge between domain I and II of the envelope protein, are thought to interfere with conformational changes in the DENV envelope protein that are essential for fusion.</p>
      <p id="Par53">From these result, we found that all the selected mushroom extracts were more effective when added simultaneously with the virus, and&#xA0;the anti-dengue activity decreased with increasing time of infection. This shows that the&#xA0;inhibitory activity is&#xA0;dependent on the&#xA0;time point of exposure. These observations support our results obtained from the&#xA0;attachment and penetration assays, indicating&#xA0;that the mushroom extracts might inhibit the initial stage of DENV2 infection. Similarly, the anti-viral activity against HSV 1 and 2 using fractions obtained from &#x3B2;-glucan isolated from <italic>Pleurotus tuber-regium</italic> were more effective when added simultaneously with the virus at the time of viral infection [<xref ref-type="bibr" rid="CR33">33</xref>]. A polysaccharide isolated from <italic>G. lucidum</italic> mycelia has been shown to possess better antiherpetic activity in cells with&#xA0;pre-treatment or treatment during the infection, instead of treatment after the infection [<xref ref-type="bibr" rid="CR43">43</xref>]. We found that pre-treatment with mushroom extract did not protect the cells from DENV2 infection. These data suggested that there is no benefit to give the extract before infection. Mushroom extracts have no virucidal effects. This indicates that the antidengue activity was not due to an interaction with cell-free virion. Similarly, the&#xA0;<italic>A. brasiliensis</italic> aqueous extract, ethanol extract and polysaccharide also did not show virucidal activity against poliovirus [<xref ref-type="bibr" rid="CR9">9</xref>]. Additionally,&#xA0;sulphated polysaccharides did not show direct inhibition of DENV&#xA0;activity [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p id="Par54">Analysis of the chemical composition showed no significant correlation between the&#xA0;total glucans, protein or phenolic contents of mushroom extracts and their anti-dengue activities. The difference in anti-dengue properties between these two extracts might be due to the structural characteristics of the extracts. Ghosh et al., [<xref ref-type="bibr" rid="CR44">44</xref>] reported that the antiherpetic properties of sulfated polysaccharides are determined by a combination of structural features such as the&#xA0;molecular mass, branching degree, charge density, and molecular composition of uncharged portions. Cardozo et al., [<xref ref-type="bibr" rid="CR32">32</xref>] also recommended that a&#xA0;larger molecular mass and complexity of branching of sulphated polysaccharide of <italic>Agaricus brasiliensis</italic> are important for the inhibition of the herpes virus penetration. Based on previous findings, we could assume that the&#xA0;prominent anti-dengue effect of the&#xA0;ASE might be&#xA0;due to the higher molecular mass and more complex branching than that in the&#xA0;HAE.</p>
    </sec>
    <sec id="Sec17">
      <title>Conclusion</title>
      <p id="Par55">In conclusion, this is the&#xA0;first study to reveal that mushroom aqueous extracts have an in-vitro anti-dengue effect by interfering with&#xA0;the initial stage of DENV-2 infection, which includes the attachment and penetration of the virus through the cell membrane. Further research is needed to elucidate the structural characteristics of glucan and protein complexes that might trigger the anti-dengue effect, to prove the anti-viral effect of the mushroom on human monocytes, and suitable murine model to evaluate the&#xA0;oral bioavailability and metabolism of selected doses by in vivo pharmacokinetics profiling that is&#xA0;necessary for selecting potential anti-dengue candidate for future clinical development.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>anti-DENV2</term>
          <def>
            <p id="Par5">Anti-dengue virus serotype &#x2212;&#x2009;2</p>
          </def>
        </def-item>
        <def-item>
          <term>ASE</term>
          <def>
            <p id="Par6">Aqueous soluble extract</p>
          </def>
        </def-item>
        <def-item>
          <term>CC<sub>50</sub></term>
          <def>
            <p id="Par7">50% cytotoxic concentration</p>
          </def>
        </def-item>
        <def-item>
          <term>cDNA</term>
          <def>
            <p id="Par8">Complementary DNA</p>
          </def>
        </def-item>
        <def-item>
          <term>DENV</term>
          <def>
            <p id="Par9">Dengue virus</p>
          </def>
        </def-item>
        <def-item>
          <term>EE</term>
          <def>
            <p id="Par10">Ethanol extract</p>
          </def>
        </def-item>
        <def-item>
          <term>ENV</term>
          <def>
            <p id="Par11">Envelope gene</p>
          </def>
        </def-item>
        <def-item>
          <term>ESE</term>
          <def>
            <p id="Par12">Ethyl acetate soluble extract</p>
          </def>
        </def-item>
        <def-item>
          <term>FBS</term>
          <def>
            <p id="Par13">Foetal bovine serum</p>
          </def>
        </def-item>
        <def-item>
          <term>GAPDH</term>
          <def>
            <p id="Par14">Glyceraldehyde 3-phosphate dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>HAE</term>
          <def>
            <p id="Par15">Hot aqueous extract</p>
          </def>
        </def-item>
        <def-item>
          <term>HIV</term>
          <def>
            <p id="Par16">Human immunodeficiency virus</p>
          </def>
        </def-item>
        <def-item>
          <term>HSE</term>
          <def>
            <p id="Par17">Hexane soluble extract</p>
          </def>
        </def-item>
        <def-item>
          <term>HSV</term>
          <def>
            <p id="Par18">Herpes Simplex Virus</p>
          </def>
        </def-item>
        <def-item>
          <term>IC<sub>50</sub></term>
          <def>
            <p id="Par19">Concentration inhibit 50% of virus plaque</p>
          </def>
        </def-item>
        <def-item>
          <term>MNCC</term>
          <def>
            <p id="Par20">Maximum non-cytotoxic concentration</p>
          </def>
        </def-item>
        <def-item>
          <term>NS5</term>
          <def>
            <p id="Par21">Non-structural protein 5 gene</p>
          </def>
        </def-item>
        <def-item>
          <term>PFU</term>
          <def>
            <p id="Par22">Plaque forming units</p>
          </def>
        </def-item>
        <def-item>
          <term>RNA</term>
          <def>
            <p id="Par23">Ribonucleic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>RT-qPCR</term>
          <def>
            <p id="Par24">Real-time reverse transcription polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>SD</term>
          <def>
            <p id="Par25">Standard deviation</p>
          </def>
        </def-item>
        <def-item>
          <term>SI</term>
          <def>
            <p id="Par26">Selectivity index</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We would like to thank the Director General of Health Malaysia for his permission to publish this article. We also would like to thank the Director of the National Public Health Laboratory, Sungai Buloh for permitting us to use the lab facilities in the Virology unit, Infectious Disease department to conduct this study and the&#xA0;laboratory staff for their support throughout the experiment.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>KE, RT, JR and VS were involved in designing of the study. KE participated in the acquisition of funding, carried out the experiment, performed the data collection, data management, statistical analysis, data interpretation, and manuscript writing. RT, JR, KIPJH and VS were involved in monitoring of research and manuscript editing. NI was involved in verification and monitoring the purchasing from the grant and manuscript editing. All authors have seen and approved the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>The authors declare that this work was funded by the Ministry of Health Malaysia research grant (NMRR-11-953-10736) and Mushroom Research Centre, University of Malaya grant (J-21001-76536). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>The datasets generated and/or analysed during the current study are not publicly available due to being part of another study but are available from the corresponding author on reasonable request.</p>
    </notes>
    <notes>
      <title>Ethics approval and consent to participate</title>
      <p id="Par56">Not applicable</p>
    </notes>
    <notes>
      <title>Consent for publication</title>
      <p id="Par57">Not applicable</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par58">The authors declare that they have no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">World Health Organization. Dengue situation update number 533:Update on the Dengue situation in the Western Pacific Region. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.reliefweb.int/sites/reliefweb.int/files/resources/dengue_biweekly_report_20180102.pdf">https://reliefweb.int/sites/reliefweb.int/files/resources/dengue_b iweekly_report_20180102.pdf</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Halloran</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Durbin</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Longini</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>The dengue vaccine pipeline: implications for the future of dengue control</article-title>
          <source>Vaccine.</source>
          <year>2015</year>
          <volume>33</volume>
          <issue>29</issue>
          <fpage>3293</fpage>
          <lpage>3298</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.010</pub-id>
          <pub-id pub-id-type="pmid">25989449</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McArthur</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sztein</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Edelman</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Dengue vaccines: recent developments, ongoing challenges and current candidates</article-title>
          <source>Expert Rev Vaccines</source>
          <year>2013</year>
          <volume>12</volume>
          <issue>8</issue>
          <fpage>933</fpage>
          <lpage>953</lpage>
          <pub-id pub-id-type="doi">10.1586/14760584.2013.815412</pub-id>
          <pub-id pub-id-type="pmid">23984962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>A novel lectin with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from dried fruiting bodies of the monkey head mushroom <italic>Hericium erinaceum</italic></article-title>
          <source>J Biomed Biotechnol</source>
          <year>2010</year>
          <volume>2010</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>GQ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>XQ</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HX</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of a novel laccase from the edible mushroom <italic>Clitocybe maxima</italic></article-title>
          <source>Process Biochem</source>
          <year>2010</year>
          <volume>45</volume>
          <issue>5</issue>
          <fpage>627</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.1016/j.procbio.2009.12.010</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eo</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Antiviral activities of various water and methanol soluble substances isolated from <italic>Ganoderma lucidum</italic></article-title>
          <source>J Ethnopharmacol</source>
          <year>1999</year>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>129</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1016/S0378-8741(99)00067-7</pub-id>
          <pub-id pub-id-type="pmid">10624872</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gu</surname>
              <given-names>CQ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>XW</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>ZQ</given-names>
            </name>
          </person-group>
          <article-title>Isolation, identification and function of a novel anti-HSV-1 protein from <italic>Grifola frondosa</italic></article-title>
          <source>Antivir Res</source>
          <year>2007</year>
          <volume>75</volume>
          <issue>3</issue>
          <fpage>250</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1016/j.antiviral.2007.03.011</pub-id>
          <pub-id pub-id-type="pmid">17475344</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mothana</surname>
              <given-names>RAA</given-names>
            </name>
            <name>
              <surname>Awadh Ali</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wegner</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Mentel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lindequist</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Antiviral lanostanoid triterpenes from the fungus <italic>Ganoderma pfeifferi</italic></article-title>
          <source>Fitoterapia.</source>
          <year>2003</year>
          <volume>74</volume>
          <issue>1</issue>
          <fpage>177</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="doi">10.1016/S0367-326X(02)00305-2</pub-id>
          <pub-id pub-id-type="pmid">12628419</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faccin</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Benati</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rinc&#xE3;o</surname>
              <given-names>VP</given-names>
            </name>
            <name>
              <surname>Mantovani</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Gonzaga</surname>
              <given-names>ML</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiviral activity of aqueous and ethanol extracts and of an isolated polysaccharide from <italic>Agaricus brasiliensis</italic> against poliovirus type 1</article-title>
          <source>Lett Appl Microbiol</source>
          <year>2007</year>
          <volume>45</volume>
          <issue>1</issue>
          <fpage>24</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1472-765X.2007.02153.x</pub-id>
          <pub-id pub-id-type="pmid">17594456</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eik</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Naidu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Sabaratnam</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title><italic>Lignosus rhinocerus</italic> (Cooke) ryvarden: a medicinal mushroom that stimulates neurite outgrowth in PC-12 cells</article-title>
          <source>Evid Based Complement Alternat Med</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1155/2012/320308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malewicz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jenkin</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Development of dengue virus plaques under serum-free overlay medium</article-title>
          <source>J Clin Microbiol</source>
          <year>1979</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>609</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="pmid">39085</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pujol</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Damonte</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
          <article-title>Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides</article-title>
          <source>Int J Biol Macromol</source>
          <year>2012</year>
          <volume>51</volume>
          <issue>4</issue>
          <fpage>412</fpage>
          <lpage>416</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2012.05.028</pub-id>
          <pub-id pub-id-type="pmid">22652218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barnard</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Huffman</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>JLB</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Sidwell</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus</article-title>
          <source>Antivir Res</source>
          <year>1992</year>
          <volume>17</volume>
          <issue>1</issue>
          <fpage>63</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1016/0166-3542(92)90091-I</pub-id>
          <pub-id pub-id-type="pmid">1310583</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poh</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Yip</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Priestle</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A small molecule fusion inhibitor of dengue virus</article-title>
          <source>Antivir Res</source>
          <year>2009</year>
          <volume>84</volume>
          <issue>3</issue>
          <fpage>260</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.09.011</pub-id>
          <pub-id pub-id-type="pmid">19800368</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kong</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Thay</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Tin</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Devi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Rapid detection, serotyping and quantitation of dengue viruses by TaqMan real-time one-step RT-PCR</article-title>
          <source>J Virol Methods</source>
          <year>2006</year>
          <volume>138</volume>
          <issue>1</issue>
          <fpage>123</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jviromet.2006.08.003</pub-id>
          <pub-id pub-id-type="pmid">17000012</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bradford</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title>
          <source>Anal Biochem</source>
          <year>1976</year>
          <volume>72</volume>
          <issue>1&#x2013;2</issue>
          <fpage>248</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="doi">10.1016/0003-2697(76)90527-3</pub-id>
          <pub-id pub-id-type="pmid">942051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slinkard</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Singleton</surname>
              <given-names>VL</given-names>
            </name>
          </person-group>
          <article-title>Total phenol analysis: automation and comparison with manual methods</article-title>
          <source>Am J Enol Vitic</source>
          <year>1977</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>49</fpage>
          <lpage>55</lpage>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phan</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Naidu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sabaratnam</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title><italic>Pleurotus giganteus</italic> (Berk.) Karunarathna &amp; K.D. Hyde: nutritional value and in vitro neurite outgrowth activity in rat pheochromocytoma cells</article-title>
          <source>BMC Complement Altern Med</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>102</fpage>
          <pub-id pub-id-type="doi">10.1186/1472-6882-12-102</pub-id>
          <pub-id pub-id-type="pmid">22812497</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yap</surname>
              <given-names>HYY</given-names>
            </name>
            <name>
              <surname>Aziz</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>NH</given-names>
            </name>
          </person-group>
          <article-title>Energy and nutritional composition of tiger milk mushroom (<italic>Lignosus tigris</italic> Chon S. Tan) sclerotia and the antioxidant activity of its extracts</article-title>
          <source>Int J Med Sci</source>
          <year>2014</year>
          <volume>11</volume>
          <issue>6</issue>
          <fpage>602</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="doi">10.7150/ijms.8341</pub-id>
          <pub-id pub-id-type="pmid">24782649</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heleno</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Barros</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Queiroz</surname>
              <given-names>MJRP</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fern&#xE1;ndez-Ruiz</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chemical composition, antioxidant activity and bioaccessibility studies in phenolic extracts of two <italic>Hericium</italic> wild edible species</article-title>
          <source>LWT Food Sci Technol</source>
          <year>2015</year>
          <volume>63</volume>
          <issue>1</issue>
          <fpage>475</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lwt.2015.03.040</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Longvah</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Deosthale</surname>
              <given-names>YG</given-names>
            </name>
          </person-group>
          <article-title>Compositional and nutritional studies on edible wild mushroom from northeast India</article-title>
          <source>Food Chem</source>
          <year>1998</year>
          <volume>63</volume>
          <issue>3</issue>
          <fpage>331</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="doi">10.1016/S0308-8146(98)00026-0</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hung</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Nhi</surname>
              <given-names>NNY</given-names>
            </name>
          </person-group>
          <article-title>Nutritional composition and antioxidant capacity of several edible mushrooms grown in the southern Vietnam</article-title>
          <source>Int Food Res J</source>
          <year>2012</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>611</fpage>
          <lpage>615</lpage>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phan</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Naidu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Sabaratnam</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Neurite outgrowth stimulatory effects of culinary-medicinal mushrooms and their toxicity assessment using differentiating neuro-2a and embryonic fibroblast BALB/3T3</article-title>
          <source>BMC Complement Altern Med</source>
          <year>2013</year>
          <volume>13</volume>
          <issue>1</issue>
          <fpage>261</fpage>
          <pub-id pub-id-type="doi">10.1186/1472-6882-13-261</pub-id>
          <pub-id pub-id-type="pmid">24119256</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Wong WL, Abdulla MA, Chua KH, Rani U, Tan YS, Sabaratnam V. Hepatoprotective effects of <italic>Panus giganteus</italic> ( Berk .) corner against thioacetamide ( TAA ) -induced liver injury in rats. Evid Based Complement Alternat Med. 2012;2012:1&#x2013;25.</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Enchang</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Pailoor</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Preclinical toxicological evaluations of the sclerotium of <italic>Lignosus rhinocerus</italic> (Cooke), the Tiger Milk mushroom</article-title>
          <source>J Ethnopharmacol</source>
          <year>2013</year>
          <volume>147</volume>
          <fpage>157</fpage>
          <lpage>163</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jep.2013.02.027</pub-id>
          <pub-id pub-id-type="pmid">23458920</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Cheung</surname>
              <given-names>PCK</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity</article-title>
          <source>Trends Food Sci Technol</source>
          <year>2007</year>
          <volume>18</volume>
          <issue>1</issue>
          <fpage>4</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tifs.2006.07.013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lakshmanan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Raman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Naidu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sabaratnam</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Haematological, biochemical and histopathological aspects of <italic>Hericium erinaceus</italic> ingestion in a rodent model: a sub-chronic toxicological assessment</article-title>
          <source>J Ethnopharmacol</source>
          <year>2016</year>
          <volume>194</volume>
          <fpage>1051</fpage>
          <lpage>1059</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jep.2016.10.084</pub-id>
          <pub-id pub-id-type="pmid">27816657</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Shim</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
          <article-title>Studies on safety of <italic>Ganoderma lucidum</italic></article-title>
          <source>Korean J Mycol</source>
          <year>1986</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>49</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.4489/KJM.2012.40.1.049</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zandi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Teoh</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Sam</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Mustafa</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Abubakar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Antiviral activity of four types of bioflavonoid against dengue virus type-2</article-title>
          <source>Virol J</source>
          <year>2011</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>560</fpage>
          <pub-id pub-id-type="doi">10.1186/1743-422X-8-560</pub-id>
          <pub-id pub-id-type="pmid">22201648</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parida</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Upadhyay</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pandya</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jana</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Inhibitory potential of neem (Azadirachta indica Juss) leaves on dengue virus type-2 replication</article-title>
          <source>J Ethnopharmacol</source>
          <year>2002</year>
          <volume>79</volume>
          <issue>2</issue>
          <fpage>273</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1016/S0378-8741(01)00395-6</pub-id>
          <pub-id pub-id-type="pmid">11801392</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leardkamolkarn</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sirigulpanit</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Phurimsak</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kumkate</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Himakoun</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sripanidkulchai</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The inhibitory actions of <italic>houttuynia cordata</italic> aqueous extract on dengue virus and dengue-infected cells</article-title>
          <source>J Food Biochem</source>
          <year>2012</year>
          <volume>36</volume>
          <issue>1</issue>
          <fpage>86</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1745-4514.2010.00514.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardozo</surname>
              <given-names>FTG</given-names>
            </name>
            <name>
              <surname>Camelini</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mascarello</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Monte Barardi</surname>
              <given-names>CR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiherpetic activity of a sulfated polysaccharide from <italic>Agaricus brasiliensis</italic> mycelia</article-title>
          <source>Antivir Res</source>
          <year>2011</year>
          <volume>92</volume>
          <issue>1</issue>
          <fpage>108</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.07.009</pub-id>
          <pub-id pub-id-type="pmid">21787804</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cheung</surname>
              <given-names>PCK</given-names>
            </name>
            <name>
              <surname>Ooi</surname>
              <given-names>VEC</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of sulfated fungal &#x3B2;-glucans from the sclerotium of <italic>Pleurotus tuber-regium</italic> as a potential water-soluble anti-viral agent</article-title>
          <source>Carbohydr Res</source>
          <year>2004</year>
          <volume>339</volume>
          <issue>13</issue>
          <fpage>2297</fpage>
          <lpage>2301</lpage>
          <pub-id pub-id-type="doi">10.1016/j.carres.2004.07.003</pub-id>
          <pub-id pub-id-type="pmid">15337458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piraino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Isolation and partial characterization of an antiviral, RC-183, from the edible mushroom <italic>Rozites caperata</italic></article-title>
          <source>Antivir Res</source>
          <year>1999</year>
          <volume>43</volume>
          <issue>2</issue>
          <fpage>67</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1016/S0166-3542(99)00035-2</pub-id>
          <pub-id pub-id-type="pmid">10517309</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itoh</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sugawara</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tabata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kojima</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunopharmacological study of sulfaded schizophyllan (SPG) I. - its action as a mitogen and anti-HIV agent</article-title>
          <source>Int J Immunopharmacol</source>
          <year>1990</year>
          <volume>12</volume>
          <issue>2</issue>
          <fpage>225</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="doi">10.1016/0192-0561(90)90057-T</pub-id>
          <pub-id pub-id-type="pmid">1970338</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collins</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>TB</given-names>
            </name>
          </person-group>
          <article-title>Polysaccharopeptide from <italic>Coriolus versicolor</italic> has potential for use against human immunodeficiency virus type 1 infection</article-title>
          <source>Life Sci</source>
          <year>1997</year>
          <volume>60</volume>
          <issue>25</issue>
          <fpage>PL383</fpage>
          <lpage>PL387</lpage>
          <pub-id pub-id-type="doi">10.1016/S0024-3205(97)00294-4</pub-id>
          <pub-id pub-id-type="pmid">9194694</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lv</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Leng</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Bian</surname>
              <given-names>HJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nebrodeolysin, a novel hemolytic protein from mushroom <italic>Pleurotus nebrodensis</italic> with apoptosis-inducing and anti-HIV-1 effects</article-title>
          <source>Phytomedicine.</source>
          <year>2009</year>
          <volume>16</volume>
          <issue>2</issue>
          <fpage>198</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="doi">10.1016/j.phymed.2008.07.004</pub-id>
          <pub-id pub-id-type="pmid">18722099</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>A laccase with HIV-1 reverse transcriptase inhibitory activity from the broth of mycelial culture of the mushroom <italic>Lentinus tigrinus</italic></article-title>
          <source>J Biomed Biotechnol</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">21836813</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eo</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from <italic>Ganoderma lucidum</italic> on herpes simplex viruses</article-title>
          <source>J Ethnopharmacol</source>
          <year>2000</year>
          <volume>72</volume>
          <issue>3</issue>
          <fpage>475</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="doi">10.1016/S0378-8741(00)00266-X</pub-id>
          <pub-id pub-id-type="pmid">10996289</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodr&#xED;guez-Valent&#xED;n</surname>
              <given-names>Madeline</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez</surname>
              <given-names>Sheila</given-names>
            </name>
            <name>
              <surname>Rivera</surname>
              <given-names>Mariela</given-names>
            </name>
            <name>
              <surname>R&#xED;os-Olivares</surname>
              <given-names>Eddy</given-names>
            </name>
            <name>
              <surname>Cubano</surname>
              <given-names>Luis</given-names>
            </name>
            <name>
              <surname>Boukli</surname>
              <given-names>Nawal M.</given-names>
            </name>
          </person-group>
          <article-title>Naturally Derived Anti-HIV Polysaccharide Peptide (PSP) Triggers a Toll-Like Receptor 4-Dependent Antiviral Immune Response</article-title>
          <source>Journal of Immunology Research</source>
          <year>2018</year>
          <volume>2018</volume>
          <fpage>1</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1155/2018/8741698</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de SF-Tischer</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Talarico</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Noseda</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Guimar&#xE3;es</surname>
              <given-names>SMPB</given-names>
            </name>
            <name>
              <surname>Damonte</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>MER</given-names>
            </name>
          </person-group>
          <article-title>Chemical structure and antiviral activity of carrageenans from <italic>Meristiella gelidium</italic> against herpes simplex and dengue virus</article-title>
          <source>Carbohydr Polym</source>
          <year>2006</year>
          <volume>63</volume>
          <issue>4</issue>
          <fpage>459</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="doi">10.1016/j.carbpol.2005.09.020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talarico</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Damonte</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
          <article-title>Interference in dengue virus adsorption and uncoating by carrageenans</article-title>
          <source>Virology</source>
          <year>2007</year>
          <volume>363</volume>
          <issue>2</issue>
          <fpage>473</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="doi">10.1016/j.virol.2007.01.043</pub-id>
          <pub-id pub-id-type="pmid">17337028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>XJ</given-names>
            </name>
            <name>
              <surname>Timani</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Possible mode of action of antiherpetic activities of a proteoglycan isolated from the mycelia of <italic>Ganoderma lucidum in vitro</italic></article-title>
          <source>J Ethnopharmacol</source>
          <year>2004</year>
          <volume>95</volume>
          <issue>2</issue>
          <fpage>265</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jep.2004.07.010</pub-id>
          <pub-id pub-id-type="pmid">15507347</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghosh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chattopadhyay</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Marschall</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karmakar</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mandal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation</article-title>
          <source>Glycobiology.</source>
          <year>2009</year>
          <volume>19</volume>
          <issue>1</issue>
          <fpage>2</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1093/glycob/cwn092</pub-id>
          <pub-id pub-id-type="pmid">18815291</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31533658</article-id>
      <article-id pub-id-type="pmc">6751791</article-id>
      <article-id pub-id-type="publisher-id">4464</article-id>
      <article-id pub-id-type="doi">10.1186/s12879-019-4464-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rubella transmission and the risk of congenital rubella syndrome in Liberia: a need to introduce rubella-containing vaccine in the routine immunization program</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3585-1625</contrib-id>
          <name>
            <surname>Woyessa</surname>
            <given-names>Abyot Bekele</given-names>
          </name>
          <address>
            <phone>+231770496214</phone>
            <email>abyotbekelephem@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ali</surname>
            <given-names>Mohammed Seid</given-names>
          </name>
          <address>
            <email>mohazeyni@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Korkpor</surname>
            <given-names>Tiala K.</given-names>
          </name>
          <address>
            <email>korkportialakou@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tuopileyi</surname>
            <given-names>Roland</given-names>
            <suffix>II</suffix>
          </name>
          <address>
            <email>tuopileyiiir@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kohar</surname>
            <given-names>Henry T.</given-names>
          </name>
          <address>
            <email>thkohar@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dogba</surname>
            <given-names>John</given-names>
          </name>
          <address>
            <email>dogba484@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baller</surname>
            <given-names>April</given-names>
          </name>
          <address>
            <email>ballera@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Monday</surname>
            <given-names>Julius</given-names>
          </name>
          <address>
            <email>drmondayj@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdullahi</surname>
            <given-names>Suleman</given-names>
          </name>
          <address>
            <email>abdullahis@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagbe</surname>
            <given-names>Thomas</given-names>
          </name>
          <address>
            <email>tnknue31112@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mulbah</surname>
            <given-names>Gertrude</given-names>
          </name>
          <address>
            <email>mulbahg@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kromah</surname>
            <given-names>Mohammed</given-names>
          </name>
          <address>
            <email>kromahml@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sesay</surname>
            <given-names>Jeremy</given-names>
          </name>
          <address>
            <email>jeremysesay@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yealue</surname>
            <given-names>Kwuakuan</given-names>
          </name>
          <address>
            <email>k34yealue@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nyenswah</surname>
            <given-names>Tolbert</given-names>
          </name>
          <address>
            <email>imschair@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gebrekidan</surname>
            <given-names>Mesfin Zbelo</given-names>
          </name>
          <address>
            <email>mesfing@who.int</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>World Health Organization Country office for Liberia, Monrovia, Liberia </aff>
        <aff id="Aff2"><label>2</label>Republic of Liberia Ministry of Health, Monrovia, Liberia </aff>
        <aff id="Aff3"><label>3</label>National Public Health Institute of Liberia, Monrovia, Liberia </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2019</year>
      </pub-date>
      <volume>19</volume>
      <elocation-id>813</elocation-id>
      <history>
        <date date-type="received">
          <day>6</day>
          <month>3</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>9</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2019</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Rubella is an RNA virus in the genus <italic>Rubivirus</italic> within the <italic>Matonaviridae</italic> family. Rubella remains a leading vaccine-preventable cause of birth defects. Most African countries including Liberia do not currently provide rubella-containing vaccine (RCV) in their immunization program. We analyzed the existing surveillance data to describe rubella cases and identify the at-risk population.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">We conducted a retrospective descriptive statistics on the suspected-measles case-based surveillance data that obtained from the national database. Suspected-measles cases who were negative and indeterminate for measles IgM and tested for rubella IgM were extracted from the database. We used only rubella IgM positive cases to calculate trends and percentages by person, place and time. The cumulative-percent curve was used to visually describe the age distribution of rubella cases.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">During 2017&#x2013;2018, a total of 2027 suspected-measles cases with known laboratory results were reported; of which, 1307 were tested for rubella IgM. Among tested cases, 472 (36%) were positive, 769 (59%) were negative and 66 (5%) were indeterminate for rubella IgM. Female contributed 269 (57%) of the confirmed rubella cases respectively. The median age was 7&#x2009;years with an interquartile range of 5&#x2013;10&#x2009;years. From the total rubella cases, 6 (1%) were under 1 year, 109 (23%) were 1&#x2013;4&#x2009;years, 207 (44%) were 5&#x2013;9&#x2009;years, 87 (18%) were 10&#x2013;14&#x2009;years and 56 (12%) were more than or equal to 15&#x2009;years. Women in their reproductive-age contributed 23 (5%) of rubella cases with 17% positivity rate. Two-thirds or 307 (65%) of the cases were reported from February to May which is dry season in Liberia.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">Our analysis revealed that rubella was widely circulating in Liberia. Majority of the cases were reported among children &lt;&#x2009;15&#x2009;years. However, rubella was also reported among women of reproductive age and infants &lt;&#x2009;1&#x2009;year with no report of congenital rubella syndrome (CRS). Detail investigation of rubella cases among infants of &lt;&#x2009;1&#x2009;year and women of reproductive age is important to uncover CRS. Establishment of CRS surveillance and the introduction of RCV in the immunization program are crucial to prevent rubella infection and avert the risk of CRS.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Rubella</kwd>
        <kwd>Measles case-based surveillance</kwd>
        <kwd>Women of childbearing age</kwd>
        <kwd>Epidemiology</kwd>
        <kwd>Pre-vaccine era</kwd>
        <kwd>Liberia</kwd>
        <kwd>West Africa</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par18">Rubella is an RNA virus belongs to <italic>Rubivirus</italic> genus within the <italic>Matonaviridae</italic> family [<xref ref-type="bibr" rid="CR1">1</xref>] . The rubella virus is a human disease with no known animal reservoir and transmits to a healthy person through air droplet shed when an infected person sneezes or coughs [<xref ref-type="bibr" rid="CR2">2</xref>]. Rubella symptoms are usually mild, and up to 50% of infections may be clinically in-apparent [<xref ref-type="bibr" rid="CR3">3</xref>]. An Infected person is infectious and transmits the virus to healthy people starting 7 days before to 7 days after the onset of rash [<xref ref-type="bibr" rid="CR4">4</xref>]. Infection occurs a few weeks before conception and in early pregnancy especially during the first trimester may result in miscarriage, fetal death, or congenital deformities known as congenital rubella syndrome (CRS) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p id="Par19">The likelihood of CRS is high, 90%, among infants born from mothers infected by rubella virus during their early pregnancy [<xref ref-type="bibr" rid="CR7">7</xref>]. Globally, an estimation of 100,000 babies is born with CRS every year [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. CRS incidence rate varies from 0.1&#x2013;0.2 during an endemic and 0.8&#x2013;4 during an epidemic per 1000 live births [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. An infant with CRS or congenital rubella infection (CRI) sheds live rubella virus for a prolonged time [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p id="Par20">Regardless of the availability of safe and effective vaccine, rubella virus remains a leading vaccine-preventable cause of birth defects, especially in developing countries [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. As of 2009, only 130 (67%) of global and 2 (4%) of African countries introduced rubella-containing vaccine (RCV) in their routine immunization programs [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. As of 2017, 84% of the World Health Organization (WHO) member countries introduced rubella-containing vaccine in their program, whereas member countries in Africa region lack largely [<xref ref-type="bibr" rid="CR15">15</xref>]. Following the introduction of rubella vaccine in many countries, global rubella vaccination coverage increased from 26% in 2007 to 52% in 2017 [<xref ref-type="bibr" rid="CR16">16</xref>] and reported rubella cases declined by 97%, from 670,894 cases in 2000 to 22,361 cases in 2016 [<xref ref-type="bibr" rid="CR17">17</xref>]. Rubella cases reduction mostly documented in countries providing rubella vaccine [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In Africa, the rubella virus is still widely circulating with limited evidence of CRS [<xref ref-type="bibr" rid="CR19">19</xref>]. Rubella incidence decreased by 48&#x2013;96% in five countries in the Africa region in the post RCV introduction period as compared to the average incidence in the years before vaccine introduction [<xref ref-type="bibr" rid="CR20">20</xref>]. To prevent rubella and CRS all WHO member countries are expected to introduce rubella vaccine in routine immunization program and reach more than 90% coverage at the national and 80% at the district level by 2020 [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
      <p id="Par21">In Liberia, an expanded program on immunization (EPI) was first launched in 1978 in accordance with WHO recommendation to all member countries. EPI have implemented in all counties and districts of Liberia as per the WHO recommendations. Children less than 1 year, as well as women of childbearing age and pregnant women, are the target groups for routine immunization. Currently, Bacillus Calmette-Gu&#xE9;rin (BCG), pentavalent vaccine (Tetanus, Haemophilus Influenza, Diphtheria, Pertussis and Hepatitis B), oral polio vaccine (OPV), pneumococcal conjugate vaccine, measles (MCV1), yellow fever vaccine, rota vaccine, and inactivated polio vaccine (IPV) are antigens in immunization schedule for children under 1 year while tetanus toxoid is being given to every woman of childbearing age (14&#x2013;49&#x2009;years) in Liberia [<xref ref-type="bibr" rid="CR22">22</xref>]. However, a rubella-containing vaccine has not yet introduced in the routine immunization program in the country. In Liberia, the routine MCV1 coverage was 80% in 2016 and 87% in 2017 according to joint WHO and United Nations Children&#x2019;s Emergency Fund (UNICEF) estimation [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
      <p id="Par22">In Liberia and in all other African countries, rubella surveillance is integrated into measles case-based surveillance system. The surveillance data is collected according to the national integrated diseases surveillance and response (IDSR) technical guideline using a standard case definition for a suspected-measles case, which is an illness with fever and maculopapular generalized rash and cough, coryza or conjunctivitis or any person in whom a clinician suspects measles [<xref ref-type="bibr" rid="CR24">24</xref>]. Blood specimen from the first five-ten suspected measles cases collected within 28&#x2009;days after the onset of rash [<xref ref-type="bibr" rid="CR24">24</xref>]. The specimens collected by the health facility&#x2019;s laboratory technicians and transported to the national laboratory by a rider for health within 72&#x2009;h after collection. The blood specimens are first tested for measles-specific immunoglobulin M (IgM) antibody using enzyme-linked immunosorbent assay (ELISA) and in accordance with WHO African region guideline [<xref ref-type="bibr" rid="CR25">25</xref>] all IgM negative and indeterminate result for measles are further tested for rubella-specific IgM antibody using ELISA technique at the national reference laboratory. In Liberia, the burden, trend and transmission pattern of rubella has not clearly described. Here, we analyzed rubella data obtained from the national measles case-based surveillance database to describe rubella transmission pattern and identify at-risk population to pinpoint and recommend preventive public health interventions.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <p id="Par23">We obtained 2 years, 2017&#x2013;2018, measles case-based surveillance data from the National Public Health Institute of Liberia (NPHIL). We extracted the suspected-measles cases with known laboratory test results from the database. For this analysis, we used only Laboratory-confirmed rubella IgM positive cases as rubella cases. Descriptive statistics such as count, percentage, median and interquartile range were used to summarize each of the socio-demographic and clinical variables included in the dataset. The cumulative percentage was used to graphically describe the age distribution of rubella cases by sex. We have further categorized rubella cases into five age groups (under 1&#x2009;year, 1&#x2013;4&#x2009;years, 5&#x2013;9&#x2009;years, 10&#x2013;14&#x2009;years and&#x2009;&#x2265;&#x2009;15&#x2009;years). Rubella IgM positivity rate has calculated by dividing rubella IgM positive cases to total specimens tested for rubella IgM and expressed in 100 in each category. We calculated the annualized rubella incidence rate by dividing the average of the 2 years rubella IgM positive cases to mid-year population and expressed in 100,000. To describe the possible risk of CRS, we separately analyzed rubella among women of childbearing age (15&#x2013;49&#x2009;years). Quantum Geographic Information System (QGIS) was used to visually demonstrate district level geographical distribution of rubella cases.</p>
    </sec>
    <sec id="Sec3">
      <title>Results</title>
      <p id="Par24">During 2017&#x2013;2018, a total of 2027 suspected-measles cases with laboratory result was extracted from the national database; among them, 1307 specimens which were primarily negative and indeterminate for Measles IgM were further tested to detect rubella-specific IgM antibody. Among those tested, 472 (36%) were positive, 769 (59%) were negative and 66 (5%) were indeterminate for rubella IgM (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Laboratory results for rubella-specific immunoglobulin M antibody testing of suspected measles cases, 2017&#x2013;2018, Liberia</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2"><sup>a</sup>Suspected measles cases</th><th rowspan="2"><sup>b</sup>Rubella IgM tested</th><th colspan="4">Rubella IgM result</th></tr><tr><th>IgM&#x2009;+&#x2009;<sup>c</sup> (%)</th><th>IgM -</th><th>Indeterminate</th><th><sup>d</sup>Positivity %</th></tr></thead><tbody><tr><td>Total cases</td><td>2027</td><td>1307</td><td>472</td><td>769</td><td>66</td><td>36</td></tr><tr><td colspan="7">Year</td></tr><tr><td>&#x2003;2017</td><td>1191</td><td>882</td><td>353 (75)</td><td>478</td><td>51</td><td>40</td></tr><tr><td>&#x2003;2018</td><td>836</td><td>425</td><td>119 (25)</td><td>291</td><td>15</td><td>28</td></tr><tr><td colspan="7">Sex</td></tr><tr><td>&#x2003;Female</td><td>1050</td><td>703</td><td>269 (57)</td><td>404</td><td>30</td><td>38</td></tr><tr><td>&#x2003;Male</td><td>977</td><td>604</td><td>203 (43)</td><td>365</td><td>36</td><td>34</td></tr><tr><td colspan="7">Age Group</td></tr><tr><td>&#x2003;&lt;&#x2009;1&#x2009;Year</td><td>81</td><td>37</td><td>6 (1)</td><td>29</td><td>2</td><td>16</td></tr><tr><td>&#x2003;1&#x2013;4&#x2009;Years</td><td>525</td><td>287</td><td>109 (23)</td><td>172</td><td>6</td><td>38</td></tr><tr><td>&#x2003;5&#x2013;9&#x2009;Years</td><td>647</td><td>460</td><td>207 (44)</td><td>221</td><td>32</td><td>45</td></tr><tr><td>&#x2003;10&#x2013;14&#x2009;Years</td><td>329</td><td>249</td><td>87 (18)</td><td>145</td><td>17</td><td>35</td></tr><tr><td>&#x2003;&gt;&#x2009;14&#x2009;Years</td><td>420</td><td>258</td><td>56 (12)</td><td>195</td><td>7</td><td>22</td></tr><tr><td>&#x2003;NA</td><td>25</td><td>16</td><td>7 (1)</td><td>7</td><td>2</td><td>44</td></tr><tr><td>Women of Childbearing Age</td><td>211</td><td>133</td><td>23 (5)</td><td>106</td><td>4</td><td>17</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Suspected measles cases with known laboratory result, <sup>b</sup>suspected measles cases which are negative and indeterminate for measles IgM and tested for Rubella IgM, <sup>c</sup>Proportion of confirmed rubella cases from total rubella positive cases in each category, <sup>d</sup>Rubella IgM positivity rate was calculated by dividing the number of Rubella IgM positive cases to specimen tested for rubella IgM with specific variables, <italic>IgM</italic> Immunoglobulin M, <italic>NA</italic> Not available</p></table-wrap-foot></table-wrap></p>
      <p id="Par25">Among the confirmed cases 353 (75%) were reported in 2017 and 119(25%) were reported in 2018. Female and male contributed 269 (57%) and 203 (43%) confirmed rubella cases respectively. Rubella cases have detected in all age groups with median age 7&#x2009;years and interquartile ranges 5&#x2013;10&#x2009;years. Among the total rubella cases, 6 (1%) were under 1 year, 109 (23%) were 1&#x2013;4&#x2009;years, 207 (44%) were 5&#x2013;9&#x2009;years, 87 (18%) were 10&#x2013;14&#x2009;years, 56 (12%) were&#x2009;&#x2265;&#x2009;15&#x2009;years while the rest 7 (1%) of the cases had no age data. Women in the reproductive age group contributed 23 (5%) of the total rubella cases with a positivity rate of 17% (23/133) (Table <xref rid="Tab1" ref-type="table">1</xref> and Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>Frequency of laboratory-confirmed rubella-specific immunoglobulin M antibody testing result by age and sex with a cumulative age distribution curve, 2017&#x2013;2018, Liberia, <italic>N</italic>&#x2009;=&#x2009;472 (6&#x2009;months to 61&#x2009;years old)</p></caption><graphic xlink:href="12879_2019_4464_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par26">From the total rubella cases, about two-thirds or 307 (65%) of them were detected from February to May. The highest cases were detected in February (26%) followed by March 82 (17%), April 59 (13%) and May 45(10%) while the lowest case was detected from July to October. Similarly, rubella IgM positivity rate was high in February 51%, April 47%, and March 39% and decreased to 15 and 17% in September and August respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Trends of rubella IgM positive cases by month, 2017&#x2013;2018, Liberia, <italic>N</italic>&#x2009;=&#x2009;472 and cumulative positivity rate&#x2009;=&#x2009;36%</p></caption><graphic xlink:href="12879_2019_4464_Fig2_HTML" id="MO2"/></fig></p>
      <p id="Par27">Rubella cases were reported from all counties of Liberia. Majority of the cases were reported from Montserrado 72 (15.3%), Lofa 68 (14.3%) and Margibi 66 (14.0%) while with the lowest number reported was in Rivercess 6 (1.3%). The national rubella IgM positivity rate was 36% which ranged from 14% in Rivercess County to 48% in Bomi County (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). However, the rubella IgM positive incidence rate was high in Bomi followed by Grand Kru and Margibi (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Laboratory results for rubella-specific immunoglobulin M antibody testing of suspected measles cases by county, 2017&#x2013;2018, Liberia</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">County</th><th rowspan="2"><sup>a</sup>Suspected measles cases</th><th rowspan="2">Rubella IgM tested</th><th colspan="4">Rubella IgM result</th></tr><tr><th>IgM +</th><th>IgM -</th><th>Indeterminate</th><th>Positivity %</th></tr></thead><tbody><tr><td>Montserrado</td><td>325</td><td>166</td><td>72</td><td>80</td><td>14</td><td>43</td></tr><tr><td>Lofa</td><td>165</td><td>152</td><td>68</td><td>77</td><td>7</td><td>45</td></tr><tr><td>Margibi</td><td>236</td><td>158</td><td>66</td><td>84</td><td>8</td><td>42</td></tr><tr><td>Bomi</td><td>92</td><td>85</td><td>41</td><td>42</td><td>2</td><td>48</td></tr><tr><td>Bong</td><td>163</td><td>86</td><td>33</td><td>51</td><td>2</td><td>38</td></tr><tr><td>Nimba</td><td>219</td><td>98</td><td>29</td><td>63</td><td>6</td><td>30</td></tr><tr><td>Sinoe</td><td>86</td><td>69</td><td>29</td><td>37</td><td>3</td><td>42</td></tr><tr><td>Grand Kru</td><td>134</td><td>82</td><td>26</td><td>55</td><td>1</td><td>32</td></tr><tr><td>Grand Gedeh</td><td>127</td><td>89</td><td>20</td><td>63</td><td>6</td><td>22</td></tr><tr><td>Maryland</td><td>119</td><td>77</td><td>20</td><td>54</td><td>3</td><td>26</td></tr><tr><td>Grand Bassa</td><td>118</td><td>55</td><td>19</td><td>32</td><td>4</td><td>35</td></tr><tr><td>Grand Cape Mount</td><td>60</td><td>42</td><td>19</td><td>22</td><td>1</td><td>45</td></tr><tr><td>River Gee</td><td>94</td><td>80</td><td>17</td><td>57</td><td>6</td><td>21</td></tr><tr><td>Gbarporlu</td><td>29</td><td>25</td><td>7</td><td>18</td><td>0</td><td>28</td></tr><tr><td>Rivercess</td><td>60</td><td>43</td><td>6</td><td>34</td><td>3</td><td>14</td></tr><tr><td>Total</td><td>2027</td><td>1307</td><td>472</td><td>769</td><td>66</td><td>36</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Suspected measles cases with known laboratory result, <italic>IgM</italic> Immunoglobulin M</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Map showing the distribution of rubella IgM positive cases and its positivity rate by district, 2017&#x2013;208, Liberia</p></caption><graphic xlink:href="12879_2019_4464_Fig3_HTML" id="MO3"/></fig>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Annualized Rubella IgM positive cases incidence rate by county, 2017&#x2013;2018, Liberia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>County</th><th>Mid-Year population<sup>a</sup></th><th>Rubella IgM positive cases</th><th>Annualized incidence rate per 100,000 population</th></tr></thead><tbody><tr><td>Bomi</td><td>91,593</td><td>41</td><td>22.4</td></tr><tr><td>Grand Kru</td><td>60,152</td><td>26</td><td>4.5</td></tr><tr><td>Margibi</td><td>232,918</td><td>66</td><td>3.4</td></tr><tr><td>Sinoe</td><td>124,747</td><td>29</td><td>3.8</td></tr><tr><td>Lofa</td><td>313,014</td><td>68</td><td>6.2</td></tr><tr><td>River Gee</td><td>82,132</td><td>17</td><td>6.1</td></tr><tr><td>Grand Cape Mount</td><td>153,386</td><td>19</td><td>21.6</td></tr><tr><td>Grand Gedeh</td><td>164,360</td><td>20</td><td>10.9</td></tr><tr><td>Maryland</td><td>176,733</td><td>20</td><td>14.2</td></tr><tr><td>Bong</td><td>366,547</td><td>33</td><td>5.7</td></tr><tr><td>Grand Bassa</td><td>253,001</td><td>19</td><td>2.3</td></tr><tr><td>Gbarporlu</td><td>103,502</td><td>7</td><td>2.7</td></tr><tr><td>Rivercess</td><td>88,758</td><td>6</td><td>10.3</td></tr><tr><td>Nimba</td><td>542,289</td><td>29</td><td>3.4</td></tr><tr><td>Montserrado</td><td>1,550,718</td><td>72</td><td>11.6</td></tr><tr><td>Total</td><td>4,303,851</td><td>472</td><td>5.5</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Projected from the 2008 population census [<xref ref-type="bibr" rid="CR26">26</xref>]</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p id="Par28">Our analysis uncovered that the rubella disease is circulating widely in Liberia and primarily infected young children under 15&#x2009;years of age. The study also revealed that the rubella IgM positive cases have also detected among women of childbearing age in 5% of rubella confirmed cases with 17% positivity rate among childbearing age groups. Detection of rubella IgM positive cases among women of reproductive age suggested the possibility of rubella infection during pregnancy that could potentially lead to CRS.</p>
      <p id="Par29">The rubella positivity rate (36%) in our finding was almost similar to study conducted in Zimbabwe (37.6%) [<xref ref-type="bibr" rid="CR27">27</xref>] and high as compared to similar other studies in the African region: for example the rubella IgM positivity rate was 30.2% in the Central Africa Republic [<xref ref-type="bibr" rid="CR28">28</xref>], 16.6% in C&#xF4;te d&#x2019;Ivoire [<xref ref-type="bibr" rid="CR29">29</xref>], 12.1&#x2013;15.3% in Ethiopia [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], 10.7% in Nigeria [<xref ref-type="bibr" rid="CR31">31</xref>] and in Cameroon 9.3% [<xref ref-type="bibr" rid="CR32">32</xref>]. The difference in positivity rate might be attributed to the nature of population settlement, topography, living conditions and study designs.</p>
      <p id="Par30">All age groups were affected while about 90% of rubella IgM positive cases were found among children under 15&#x2009;years old which is also similar to other findings in Cameroon [<xref ref-type="bibr" rid="CR32">32</xref>]. We further observed that the majority of rubella cases were reported among the younger age groups mainly 5&#x2013;9&#x2009;years with a median age of 7 years. This finding is similar with the study conducted on prolonged surveillance data from 40 countries in Africa in which 47% of rubella IgM positive cases detected among children 5&#x2013;9&#x2009;years old with an interquartile range of 4.2&#x2013;7&#x2009;years [<xref ref-type="bibr" rid="CR19">19</xref>]. Other findings from similar studies demonstrated in Sub-Saharan Africa countries also supported our result [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. For instance, rubella IgM positive cases contributed 43.5% in the Central Africa Republic and 43.0% in the Democratic Republic of Congo in children 5&#x2013;9&#x2009;Years [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] which are similar to our result. This might be because of the nature of the surveillance system. As measles surveillance is mainly focused on under 15&#x2009;years children and rubella in an adult is mostly clinically inapparent, the chance of missing rubella in adult and older age group is high.</p>
      <p id="Par31">In our findings, we observed that about 5% of IgM positive rubella cases were attributed to women of childbearing age. This is supported by other similar studies in Africa. The study conducted on measles case-based surveillance data from 40 countries in Sub-Saharan Africa indicated that women of reproductive age contributed 5% of all rubella positive cases which is comparable with our finding [<xref ref-type="bibr" rid="CR19">19</xref>]. In the Democratic Republic of Congo rubella in women of reproductive age contributed 3% of total confirmed rubella cases which are lower compared with our result. Rubella in women of childbearing age may suggest the possibility of rubella infection during pregnancy, which could potentially lead to CRS, occurs throughout the districts and remains largely undetected.</p>
      <p id="Par32">Although rubella infections were detected throughout the year, they were characterized by large peaks in the months from February to May, which corresponds with the dry and hot months in Liberia. A similar trend was observed in other countries in the tropical region, for instance, the highest number of rubella IgM positive cases were documented during the dry season in Ethiopia, Zimbabwe, and Niger [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. However, the reason why rubella infection increased to topmost during the dry and hot season was not clearly discussed. Some studies justified seasonal population migration from rural to urban areas was the main reason for the seasonal variation in rubella infections [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The case in Liberia was not clear and needs further study.</p>
      <p id="Par33">Our study has some limitations as we have depended on secondary data that was primarily collected to detect measles cases. As measles surveillance is mainly focused on detection and reporting of suspected-measles among children, mild rubella cases in adult or older age groups might be potentially underreported. Furthermore, the clinical manifestation of rubella cases may not meet suspected-measles case definition as 20&#x2013;50% of rubella infections do not include a rash [<xref ref-type="bibr" rid="CR40">40</xref>] and up to 50% of infections may be in-apparent [<xref ref-type="bibr" rid="CR3">3</xref>]. Measles surveillance is less sensitive for rubella detection [<xref ref-type="bibr" rid="CR17">17</xref>]. We also used only suspected measles cases with known laboratory result. Because of a shortage of the reagent, a significant number of measles suspected cases were not tested for both measles and rubella IgM in 2018. The system also relies mostly on health facilities and may have missed some community cases. Hence, the data we presented here might have represented small quota of possible rubella infections in Liberia.</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusions</title>
      <p id="Par34">This report provides a baseline and useful information on rubella epidemiology and transmission pattern in Liberia. Our finding demonstrated that rubella IgM positive cases had detected through the routine measles case-based surveillance system and widely circulating in Liberia. Rubella cases reported among all age groups including among infants under 1 year age and women of childbearing age. However, CRS has not detected and reported through the surveillance system. The ministry of the health of Liberia in collaboration with its partners should establish CRS surveillance according to WHO Guideline [<xref ref-type="bibr" rid="CR41">41</xref>]. CRS sentinel surveillance needs to be established in selected health facilities mainly at maternal and child health facilities. Rubella IgM positive cases among women of childbearing age need to be further investigated and closely followed up for an outcome in case of pregnancy during infection. Similarly, rubella cases among infants in under one-year-old should be investigated for CRS. The introduction of a single dose RCV as measles-rubella (MR) in the existing routine immunization program is important to prevent rubella virus transmission and possible CRS and its public health consequence. Further study is also important to describe rubella susceptibility profile in school-aged girls and women of childbearing age in Liberia.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>BCG</term>
          <def>
            <p id="Par5">Bacillus Calmette-Gu&#xE9;rin vaccine</p>
          </def>
        </def-item>
        <def-item>
          <term>CRI</term>
          <def>
            <p id="Par6">Congenital Rubella Illness</p>
          </def>
        </def-item>
        <def-item>
          <term>CRS</term>
          <def>
            <p id="Par7">Congenital Rubella Syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>ELISA</term>
          <def>
            <p id="Par8">Enzyme-Linked Immunosorbent Assay</p>
          </def>
        </def-item>
        <def-item>
          <term>EPI</term>
          <def>
            <p id="Par9">Expanded Program on Immunization</p>
          </def>
        </def-item>
        <def-item>
          <term>IDSR</term>
          <def>
            <p id="Par10">Integrated Diseases Surveillance and Response</p>
          </def>
        </def-item>
        <def-item>
          <term>IgM</term>
          <def>
            <p id="Par11">Immunoglobulin M</p>
          </def>
        </def-item>
        <def-item>
          <term>IPV</term>
          <def>
            <p id="Par12">Inactivated Polio Vaccine</p>
          </def>
        </def-item>
        <def-item>
          <term>NPHIL</term>
          <def>
            <p id="Par13">National Public Health Institute of Liberia</p>
          </def>
        </def-item>
        <def-item>
          <term>OPV</term>
          <def>
            <p id="Par14">Oral Polio Vaccine</p>
          </def>
        </def-item>
        <def-item>
          <term>QGIS</term>
          <def>
            <p id="Par15">Quantum Geographic Information System</p>
          </def>
        </def-item>
        <def-item>
          <term>RCV</term>
          <def>
            <p id="Par16">Rubella Containing Vaccine</p>
          </def>
        </def-item>
        <def-item>
          <term>WHO</term>
          <def>
            <p id="Par17">World Health Organization</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <p>We would like to thank the NPHIL for allowing us to use measles surveillance data for this analysis. We would also like to thank WHO, UNICEF and Centers for Diseases Control and Prevention (CDC) for supporting the immunization and surveillance activity in Liberia. The Stop Transmission of Polio Program significantly supported detection, verification and investigation of vaccine preventable diseases including rubella and routine immunization program. Finally, we would like to thank health facilities, surveillance officers and clinicians for detecting and timely reporting surveillance data with blood specimens.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>ABW cleaned, categorized and analyzed surveillance data, ABW interpreted the data and prepared manuscript, MSA helped data cleaning and analysis, prepared the map reviewed and supported preparation of the manuscript. TK supported the data analysis, RT, HK and JD contributed to the interpretation of the data, AB supported data analysis and discussion, JM, SA and TN participated in data interpretation and contributed on manuscript writing, GM, MK and JS helped manuscript writing, KY supported data cleaning and analysis, TNe contributed in data interpretation and manuscript writing, and MZG overseen the overall activity and reviewed the manuscript. All authors reviewed and approved the final version of the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>No budget allocated for these activities. Surveillance data were collected through routine surveillance. The surveillance stuffs who generated the data are a permanent staff of Ministry of Health of Liberia. The WHO provided technical support to the ministry of health and local health teams on the routine surveillance system. The opinions expressed by authors contributing to this article do not necessarily reflect the opinions of the WHO, Ministry of Health of Liberia and National Public Health Institute of Liberia.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>The datasets used to prepare this report are available at the National Public Health Institute of Liberia and can be obtained from corresponding author.</p>
    </notes>
    <notes>
      <title>Ethics approval and consent to participate</title>
      <p id="Par35">This work is a retrospective surveillance data analysis that is part of routine disease monitoring activity. The data we presented here was collected through the routine surveillance system. Blood specimen and demographic information were collected based on national IDSR technical guideline for surveillance purpose [<xref ref-type="bibr" rid="CR24">24</xref>]. Laboratory analysis was conducted aiming to detect measles and rubella cases as part of the routine activity. Permission was obtained from the National Public Health Institute of Liberia to analyze the secondary data. Name, pictures and any other information that discloses personal information of the patient was not included in this report. Hence, an ethical review was not sought and obtained for this work. Consent to participate in the study was not obtained as it is not applicable to this study.</p>
    </notes>
    <notes>
      <title>Consent for publication</title>
      <p id="Par36">As our report does not include individual data, consent for publication is not applicable for this article.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par37">The authors declare that they have no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">Rubing Chen, Suchetana Mukhopadhyay, Andres Merits, Bethany Bolling, Farooq Nasar, Lark L. Coffey, Ann Powers, Scott C. Weaver, Donald Smith PS and SS. Create one new unassigned family Matonaviridae to contain the genus Rubivirus, moved from the family Togaviridae 2018.013S. rubing.chen@gmail.com. <ext-link ext-link-type="uri" xlink:href="https://talk.ictvonline.org/files/ictv_official_taxonomy_updates_since_the_8th_report/m/animal-ssrna-viruses/8087">https://talk.ictvonline.org/files/ictv_official_taxonomy_updates_since_the_8th_report/m/animal-ssrna-viruses/8087</ext-link>. Accessed 05 Sept 2019.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>Rubella Fact Sheet</source>
          <year>2018</year>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Center for Disease Control And Prevention. Rubella Virus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Atlanta; 2015. p. 325&#x2013;40. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf">https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf</ext-link>. Accessed 15 Apr 2019.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Centers for Diseases Control and Prevention</collab>
          </person-group>
          <source>Last reviewed For Healthcare Professionals. Centers for diseases control and prevention</source>
          <year>2019</year>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khanal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bahl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sharifuzzaman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dhongde</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pattamadilok</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Reef</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Progress toward Rubella and congenital Rubella syndrome control &#x2014;South-East Asia region, 2000&#x2013;2016</article-title>
          <source>Morb Mortal Wkly Rep</source>
          <year>2020</year>
          <volume>67</volume>
          <issue>21</issue>
          <fpage>2016</fpage>
          <lpage>2020</lpage>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;(29):301&#x2013;16 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/wer/2011/wer8629.pdf?ua=1">https://www.who.int/wer/2011/wer8629.pdf?ua=1</ext-link>. Accessed 15 Apr 2019.</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>Congenital Rubella Syndrome</source>
          <year>2018</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <fpage>1</fpage>
          <lpage>16</lpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>FT Cutts</surname>
              <given-names>EV</given-names>
            </name>
          </person-group>
          <article-title>Modelling the incidence of congenital rubella syndrome in developing countries</article-title>
          <source>Int J Epidemiol</source>
          <year>1999</year>
          <volume>28</volume>
          <fpage>1176</fpage>
          <lpage>1184</lpage>
          <pub-id pub-id-type="doi">10.1093/ije/28.6.1176</pub-id>
          <pub-id pub-id-type="pmid">10661666</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">Centers for Disease Control and Prevention. Measles and rubella fact sheett. Ctr Dis Control Prev. 2017; <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/globalhealth/measles/default.htm">https://www.cdc.gov/globalhealth/measles/default.htm</ext-link>. Accessed 15 Apr 2019.</mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cutts</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Samuel</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS</article-title>
          <source>Bull World Health Organ</source>
          <year>1997</year>
          <volume>75</volume>
          <issue>1</issue>
          <fpage>55</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">9141751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>WHO-recommended standards for surveillance of selected vaccine-preventable diseases</source>
          <year>1999</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <fpage>23</fpage>
          <lpage>35</lpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambert</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Strebel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Orenstein</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Icenogle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Poland</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
          <article-title>Rubella</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>385</volume>
          <issue>9984</issue>
          <fpage>2297</fpage>
          <lpage>2307</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60539-0</pub-id>
          <pub-id pub-id-type="pmid">25576992</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strebel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dabbagh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gacic-Dobo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>SE Reef</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Progress toward control of Rubella and prevention of congenital Rubella syndrome &#x2014; worldwide, 2009</article-title>
          <source>MMWR</source>
          <year>2010</year>
          <volume>59</volume>
          <issue>40</issue>
          <fpage>1307</fpage>
          <lpage>1310</lpage>
          <pub-id pub-id-type="pmid">20948509</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strebel</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Gacic-dobo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reef</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cochi</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Global use of Rubella vaccines , 1980 &#x2013; 2009</article-title>
          <source>J Infect Dis</source>
          <year>2011</year>
          <volume>204</volume>
          <issue>Suppl 2</issue>
          <fpage>579</fpage>
          <lpage>584</lpage>
          <pub-id pub-id-type="doi">10.1093/infdis/jir447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>Measles and Rubella global update</source>
          <year>2018</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vanderende</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gacic-dobo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Diallo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Conklin</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Global routine vaccination coverage &#x2014; 2017</article-title>
          <source>MMWR</source>
          <year>2018</year>
          <volume>67</volume>
          <issue>45</issue>
          <fpage>1261</fpage>
          <lpage>1264</lpage>
          <pub-id pub-id-type="pmid">30439873</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grant</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Reef</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Dabbagh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Progress in Rubella and congenital Rubella syndrome control and elimination &#x2014; worldwide , 2000 &#x2013; 2016</article-title>
          <source>Morb Mortal Wkly Rep</source>
          <year>2020</year>
          <volume>66</volume>
          <issue>45</issue>
          <fpage>1256</fpage>
          <lpage>1260</lpage>
          <pub-id pub-id-type="doi">10.15585/mmwr.mm6645a4</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reef</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Redd</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Abernathy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zimmerman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Icenogle</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>The epidemiological profile of Rubella and congenital Rubella syndrome in the United States , 1998 &#x2013; 2004 : the evidence for absence of endemic transmission</article-title>
          <source>Clin Infect Dis</source>
          <year>2006</year>
          <volume>43</volume>
          <issue>Suppl 3</issue>
          <fpage>s116</fpage>
          <lpage>s132</lpage>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goodson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Masresha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dosseh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Byabamazima</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nshimirimana</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cochi</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rubella epidemiology in Africa in the Prevaccine era , 2002 &#x2013; 2009</article-title>
          <source>J Infect Dis</source>
          <year>2011</year>
          <volume>204</volume>
          <issue>Suppl 1</issue>
          <fpage>s2015</fpage>
          <lpage>s2225</lpage>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luce</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Masresha</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Katsande</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fall</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shibeshi</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>The Impact of Recent Rubella Vaccine Introduction in 5 Countries in The African Region</article-title>
          <source>J Immunol Sci</source>
          <year>2018</year>
          <volume>2</volume>
          <issue>16</issue>
          <fpage>108</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.29245/2578-3009/2018/si.1116</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">World Health Organization. Global measles and rubella strategic plan 2012&#x2013;2020. Geneva: World Health Organization; 2012.</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Liberia Ministry of Health</collab>
          </person-group>
          <source>EPI Comprehensive Multi Year Plan (cMYP) 2016 -2020</source>
          <year>2016</year>
          <publisher-loc>Monrovia</publisher-loc>
          <publisher-name>Republic of Liberia M</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">World Health Organization and United Nations Children&#x2019;s Emergency Fund. Liberia : WHO and UNICEF estimates of immunization coverage : 2017 revision. Geneva; 2018. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/immunization/monitoring_surveillance/data/lbr.pdf">https://www.who.int/immunization/monitoring_surveillance/data/lbr.pdf</ext-link>. Accessed 15 Apr 2019.</mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Ministry Of Health Liberia</collab>
          </person-group>
          <source>National Technical Guideline for integrated disease surveillance and response</source>
          <year>2016</year>
          <publisher-loc>Monrovia</publisher-loc>
          <publisher-name>WHO| Regional Office for Africa</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization Regional Office for Africa</collab>
          </person-group>
          <source>African regional guidelines for Measles and Rubella surveillance</source>
          <year>2015</year>
          <publisher-loc>Brazzaville</publisher-loc>
          <publisher-name>WHO Regional Office for Africa</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Census</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Results</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <source>Republic of Liberia 2008 population and housing census final results</source>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chimhuya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Manangazira</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mukaratirwa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nziramasanga</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Berejena</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shonhai</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trends of rubella incidence during a 5-year period of case based surveillance in Zimbabwe</article-title>
          <source>BMC Public Health</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>294):1</fpage>
          <lpage>294):8</lpage>
          <pub-id pub-id-type="doi">10.1186/s12889-015-1642-4</pub-id>
          <pub-id pub-id-type="pmid">25885586</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pagonendji</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Manikariza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rawago</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ouambita-mabo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Guifara</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidemiology of primary rubella infection in the Central African Republic : data from measles surveillance , 2007 &#x2013; 2014</article-title>
          <source>BMC Infect Dis</source>
          <year>2016</year>
          <volume>16</volume>
          <issue>505</issue>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1186/s12879-016-1842-2</pub-id>
          <pub-id pub-id-type="pmid">26729246</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitiku</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bedada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Masresha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kegne</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Nafo-Traor&#xE9;</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tesfaye</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Beyene</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The epidemiology of Rubella disease in Ethiopia : data from the measles case-based surveillance system</article-title>
          <source>J Infect Dis</source>
          <year>2011</year>
          <volume>204</volume>
          <issue>Suppl 1</issue>
          <fpage>239</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1093/infdis/jir120</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Getahun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beyene</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ademe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Teshome</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tefera</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidemiology of rubella virus cases in the pre-vaccination era of Ethiopia , 2009 &#x2013; 2015</article-title>
          <source>BMC Public Health</source>
          <year>2016</year>
          <volume>16</volume>
          <issue>1168</issue>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">26728978</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Umeh</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Onyi</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Case based rubella surveillance in Abia state, south EastNigeria, 2007&#x2013;2011</article-title>
          <source>PeerJ</source>
          <year>2014</year>
          <volume>2</volume>
          <fpage>e580</fpage>
          <pub-id pub-id-type="doi">10.7717/peerj.580</pub-id>
          <pub-id pub-id-type="pmid">25289179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mengouo</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Ndze</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Baonga</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kobela</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wiysonge</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of rubella infection in Cameroon : a 7-year experience of measles and rubella case-based surveillance , 2008 &#x2013; 2014</article-title>
          <source>BMJ</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>e012959</fpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomwalk</surname>
              <given-names>NE</given-names>
            </name>
          </person-group>
          <article-title>AAA. Prevalence of Rubella antibodies on the African continent</article-title>
          <source>Rev Infect Dis</source>
          <year>1989</year>
          <volume>11</volume>
          <issue>1</issue>
          <fpage>116</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1093/clinids/11.1.116</pub-id>
          <pub-id pub-id-type="pmid">2783785</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubella</surname>
              <given-names>FAKL-E</given-names>
            </name>
          </person-group>
          <article-title>World impact</article-title>
          <source>Rev Infect Dis</source>
          <year>1985</year>
          <volume>7</volume>
          <issue>Supplement 1</issue>
          <fpage>s29</fpage>
          <lpage>s36</lpage>
          <pub-id pub-id-type="pmid">4001731</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pukuta</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Waku-kouomou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Abernathy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Illunga</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Obama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mondonge</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genotypes of Rubella virus and the epidemiology of Rubella infections in the Democratic Republic of the Congo , 2004 &#x2013; 2013</article-title>
          <source>J Med Virol</source>
          <year>2017</year>
          <volume>88</volume>
          <issue>10</issue>
          <fpage>1677</fpage>
          <lpage>1684</lpage>
          <pub-id pub-id-type="doi">10.1002/jmv.24517</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitiku</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bedada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Masresha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kegne</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Nafo-Traor&#xE9;</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tesfaye</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Beyene</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The epidemiology of Rubella disease in Ethiopia : data from the measles case-based surveillance system</article-title>
          <source>J Infect Dis</source>
          <year>2011</year>
          <volume>1899</volume>
          <issue>Suppl 1</issue>
          <fpage>239</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1093/infdis/jir120</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fatiregun</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Fagbamigbe</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Adebowale</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of rubella disease in south-west nigeria : trends and projection from measles case- based surveillance data Epidemiology of rubella disease in south-west Nigeria : trends and projection from measles case-based surveillance data</article-title>
          <source>South Afr J Infect Dis</source>
          <year>2014</year>
          <volume>29</volume>
          <issue>2</issue>
          <fpage>60</fpage>
          <lpage>64</lpage>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wesolowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Metcalf</surname>
              <given-names>CJE</given-names>
            </name>
            <name>
              <surname>Eagle</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kombich</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grenfell</surname>
              <given-names>BT</given-names>
            </name>
          </person-group>
          <article-title>Quantifying seasonal population fluxes driving rubella transmission dynamics using mobile phone data</article-title>
          <source>PNAS</source>
          <year>2015</year>
          <volume>112</volume>
          <issue>35</issue>
          <fpage>11114</fpage>
          <lpage>11119</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1423542112</pub-id>
          <pub-id pub-id-type="pmid">26283349</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bharti</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tatem</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Grais</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Djibo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>BTG. Explaining seasonal fluctuations of measles in Niger using nighttime lights imagery</article-title>
          <source>Science</source>
          <year>2014</year>
          <volume>334</volume>
          <issue>6061</issue>
          <fpage>1424</fpage>
          <lpage>1427</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1210554</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Lanzieri</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Redd</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abernathy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Icenogle</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Rubella</article-title>
          <source>VPD surveillance Manua. Atlanta: Centers for Disease Control and Prevention</source>
          <year>2011</year>
          <fpage>1</fpage>
          <lpage>12</lpage>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>Guidelines for surveillance of congenital rubella syndrome and rubella</source>
          <year>1999</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <fpage>1</fpage>
          <lpage>41</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31533638</article-id>
      <article-id pub-id-type="pmc">6751661</article-id>
      <article-id pub-id-type="publisher-id">4405</article-id>
      <article-id pub-id-type="doi">10.1186/s12879-019-4405-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Detecting influenza and emerging avian influenza virus by influenza and pneumonia surveillance systems in a large city in China, 2005 to 2016</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Guo</surname>
            <given-names>Xiaorong</given-names>
          </name>
          <address>
            <email>1226723191@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Yang</surname>
            <given-names>Dong</given-names>
          </name>
          <address>
            <email>411700379@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Liu</surname>
            <given-names>Ruchun</given-names>
          </name>
          <address>
            <email>lrc8180@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Yaman</given-names>
          </name>
          <address>
            <email>34929709@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Qingqing</given-names>
          </name>
          <address>
            <email>156074854@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>Xinrui</given-names>
          </name>
          <address>
            <email>xinrui_ma@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Yelan</given-names>
          </name>
          <address>
            <email>88290139@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Heng</given-names>
          </name>
          <address>
            <email>83302140@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Xixing</given-names>
          </name>
          <address>
            <email>1049820294@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Zhao</surname>
            <given-names>Benhua</given-names>
          </name>
          <address>
            <email>benhuazhao@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0710-5086</contrib-id>
          <name>
            <surname>Chen</surname>
            <given-names>Tianmu</given-names>
          </name>
          <address>
            <phone>+86-13661934715</phone>
            <email>13698665@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2264 7233</institution-id><institution-id institution-id-type="GRID">grid.12955.3a</institution-id><institution>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, </institution><institution>Xiamen University, </institution></institution-wrap>4221-117 South Xiang&#x2019;an Road, Xiang&#x2019;an District, Xiamen, Fujian Province People&#x2019;s Republic of China </aff>
        <aff id="Aff2"><label>2</label>Changsha Center for Disease Control and Prevention, Changsha, Hunan People&#x2019;s Republic of China </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2193 0096</institution-id><institution-id institution-id-type="GRID">grid.223827.e</institution-id><institution>Division of Public Health, School of Medicine, </institution><institution>University of Utah, </institution></institution-wrap>Salt Lake City, UT USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>9</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2019</year>
      </pub-date>
      <volume>19</volume>
      <elocation-id>825</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>3</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>8</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2019</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Detecting avian influenza virus has become an important public health strategy for controlling the emerging infectious disease.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">The HIS (hospital information system) modified influenza surveillance system (ISS) and a newly built pneumonia surveillance system (PSS) were used to monitor the influenza viruses in Changsha City, China. The ISS was used to monitor outpatients in two sentinel hospitals and to detect mild influenza and avian influenza cases, and PSS was used to monitor inpatients in 49 hospitals and to detect severe and death influenza cases.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">From 2005 to 2016, there were 3,551,917 outpatients monitored by the ISS system, among whom 126,076 were influenza-like illness (ILI) cases, with the ILI proportion (ILI%) of 3.55%. After the HIS was used, the reported incident cases of ILI and ILI% were increased significantly. From March, 2009 to September, 2016, there were 5,491,560 inpatient cases monitored by the PSS system, among which 362,743 were pneumonia cases, with a proportion of 6.61%. Among pneumonia cases, about 10.55% (38,260/362,743) of cases were severe or death cases. The pneumonia incidence increased each year in the city. Among 15 avian influenza cases reported from January, 2005 to September, 2016, there were 26.7% (4/15) mild cases detected by the HIS-modified ISS system, while 60.0% (9/15) were severe or death cases detected by the PSS system. Two H5N1 severe cases were missed by the ISS system in January, 2009 when the PSS system was not available.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">The HIS was able to improve the efficiency of the ISS for monitoring ILI and emerging avian influenza virus. However, the efficiency of the system needs to be verified in a wider area for a longer time span in China.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Avian influenza virus</kwd>
        <kwd>Influenza surveillance system</kwd>
        <kwd>Pneumonia surveillance system</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011438</institution-id>
              <institution>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics</institution>
            </institution-wrap>
          </funding-source>
          <award-id>SKLVD2018KF001, SKLVD2018KF002</award-id>
          <principal-award-recipient>
            <name>
              <surname>Zhao</surname>
              <given-names>Benhua</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par5">In recent years, reports about human cases of infected emerging avian influenza virus has become more and more common [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. Human infected H5N1 virus was first reported in 1997 in Hong Kong, China, and then was spread widely in mainland China [<xref ref-type="bibr" rid="CR5">5</xref>] as well as many other countries in Southeast Asia [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], West Asia [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], and Africa [<xref ref-type="bibr" rid="CR10">10</xref>]. Thereafter, human cases infected with emerging influenza viruses were reported in the subsequent years, especially in China. For example, H7N9 was reported in 2013 [<xref ref-type="bibr" rid="CR11">11</xref>], H5N6 in 2014 [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR15">15</xref>], H10N8 in 2013 [<xref ref-type="bibr" rid="CR1">1</xref>], and H9N2 in 2013 in Hunan province, China [<xref ref-type="bibr" rid="CR16">16</xref>]. It is important to detect these emerging viruses in and out of China.</p>
      <p id="Par6">There are currently two main surveillance systems focused on detecting / monitoring the virus in China. One is China&#x2019;s national sentinel surveillance system for influenza-like illness (ILI) in sentinel hospitals across 31 provinces in mainland China. The sentinel hospitals are accounted for 2.5% of all hospitals in China [<xref ref-type="bibr" rid="CR17">17</xref>]. The other one is the national pneumonia surveillance system, which was built by the Chinese Center for Disease Control and Prevention (CDC) in 2004. The system is mainly to monitor pneumonia of unknown etiology (PUE) to facilitate timely detection of novel respiratory pathogens, such as severe acute respiratory syndrome (SARS) and avian influenza [<xref ref-type="bibr" rid="CR18">18</xref>]. The two systems have played significant roles in monitoring the activity of influenza, controlling and preventing emerging avian influenza [<xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR19">19</xref>].</p>
      <p id="Par7">Traditionally, the number of ILI cases was counted manually by influenza surveillance staff. Therefore, the hospital information system (HIS) has been used for recording and monitoring the outpatients in most hospitals in China [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The PUE surveillance system was not (and is still not) used consistently because most cases on community-acquired pneumonia met the PUE criteria, but were not reported to the PUE system [<xref ref-type="bibr" rid="CR18">18</xref>]. The PUE surveillance system was not sensitive enough to detect the emerging avian influenza virus.</p>
      <p id="Par8">To explore a new way to monitor influenza virus by using HIS and improve the sensitivity of detecting emerging avian influenza virus, we modified the influenza surveillance system (ISS) and built a pneumonia surveillance system (PSS) in Changsha City, China. In this study, we separately reported the roles of the ISS and the PSS systems in detecting influenza and emerging avian influenza virus.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Study area</title>
        <p id="Par9">Changsha (27&#xB0;51&#x2032;~&#x2009;28&#xB0;41&#x2032; N, 111&#xB0;53&#x2032;~&#x2009;114&#xB0;15&#x2032; E), a large city with 7.04 million people in central south China, is the capital of Hunan Province. It includes 6 districts, 2 counties, and 1 county-level city. There are a total of 4586 hospitals, clinics, and public health departments all over the city. In this study, there were 49 secondary and tertiary hospitals included into the PSS system and 2 tertiary hospitals into the ISS system, respectively. The two hospitals in ISS system were also included in the PSS. The locations of the selected hospitals were shown in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Locations of 49 hospitals in pneumonia surveillance system and 2 hospitals influenza surveillance system in Changsha City, China. The map depicted in this figure was taken from Wikimedia Commons (<ext-link ext-link-type="uri" xlink:href="http://commons.wikimedia.org/wiki/Main_Page">http://commons.wikimedia.org/wiki/Main_Page</ext-link>). PSS, pneumonia surveillance system; ISS, influenza surveillance system</p></caption><graphic xlink:href="12879_2019_4405_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>The modified influenza surveillance system</title>
        <p id="Par10">The ISS, based on two sentinel hospitals (hospitals A and B), was set up in Changsha in September 2005. Hospital A, which is located in the south urban area of the city, is a tertiary hospital with more than 2700 staffs and 1839 hospital beds. Hospital B, which is located in the north urban area of the city, is also a tertiary hospital with more than 1700 staffs and 1593 hospital beds. Both hospitals have the administrative department that is in charge of the routine surveillance. Hospital A is a municipally designated hospital for the diagnosis and treatment of tuberculosis.</p>
        <p id="Par11">In 2006 and 2008, the ISS system became a branch of Hunan provincial and national influenza surveillance network respectively. In February, 2012, the HIS was adopted for the surveillance in hospital A, and was modified after June, 2013. The ISS in Changsha underwent five stages (stage 1: week 39, 2005 to week 52, 2005; stage 2: week 1, 2006 to week 52, 2007; stage 3: week 1, 2008 to week 5, 2012; stage 4: week 6, 2012 to week 24, 2013; stage 5: week 25, 2013 to week 41, 2016.). During stage 1 to 3, the two sentinel hospitals registered ILI cases manually in five outpatient departments, including outpatient and emergency departments of respiratory medicine, outpatient and emergency departments of pediatrics, and fever clinic. During stage 4 to 5, hospital B remained the manual surveillance in the same outpatient departments. ILI case was defined as &#x201C;fever (axillary temperature &#x2265; 38&#xB0;C) + cough or sore throat&#x201D; [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p>
        <p id="Par12">Differently, in hospital A, HIS was adopted into the ISS during stage 4 to 5 and was also named as &#x201C;HIS (stage 1)&#x201D; and &#x201C;HIS (stage 2)&#x201D; respectively. During stage 4, all outpatient departments of the hospital were included in the ISS, and the computer would emerge a popup window by HIS with the question that &#x201C;ILI or not&#x201D; if physicians diagnosed one of the 108 influenza-associated diseases based on the International Classification of Diseases 10th Revision (ICD-10). The physician should answer the question to continue the later part to treat the diseases from the patients. But we found that some ILI cases could still be missed probably because of the misunderstanding of the definition of ILI of the physician, especially if the physician was not in the department with the ISS system during stage 1 to 3. Therefore, during stage 5, the question was changed to three options: a) fever (axillary temperature&#x2009;&#x2265;&#x2009;38&#x2009;&#xB0;C), b) cough, c) sore throat. The procedure of HIS would count the ILI automatically by computing the number of &#x201C;a) + b)&#x201D;, &#x201C;a) + c)&#x201D;, and &#x201C;a) + b) + c)&#x201D;.</p>
        <p id="Par13">During the 5 stages, the patients who visited the outpatient departments of the two hospitals and were identified as potential ILI cases, were calculated every week. At least 5&#x2013;20 throat swab samples of ILI cases per hospital per week were collected for testing the influenza virus by reverse transcription polymerase chain reaction (RT-PCR) and / or cell culture in the laboratory of Changsha CDC. The criteria for including ILI patients who were chosen to collect the samples were: a) the patients were in three days after illness onset date; b) the patients had no history of using antivirals. These sample selection and laboratory surveillance procedures were based on the National Influenza Surveillance Program (2010 edition and 2017 edition) which was announced by the National Health Commission of the People&#x2019;s Republic of China. This system may monitor influenza and emerging avian influenza cases with mild symptoms or at the early stage of the infection (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Data of the system from week 39, 2005 to week 41, 2016 were collected in our study. Because H1N1pdm was firstly emerged in 2009 [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], the virus was not tested in ISS stages 1 and 2 (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Flowchart of detecting influenza and avian influenza virus by influenza surveillance system and pneumonia surveillance system in Changsha City, China. PSS, pneumonia surveillance system; ISS, influenza surveillance system; ILI, influenza-like illness; PCR, polymerase chain reaction</p></caption><graphic xlink:href="12879_2019_4405_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Outcomes during different surveilled stages of influenza surveillance system in Changsha City, China</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Sentinel hospitals</th><th rowspan="2">Stages</th><th rowspan="2">Surveilled patients</th><th rowspan="2">ILI</th><th rowspan="2">ILI%</th><th rowspan="2">Number of tested specimens</th><th colspan="10">Number of positive</th></tr><tr><th>H3N2</th><th>H1N1</th><th>H1N1pdm</th><th>A (untyped)</th><th>B</th><th>H5N1</th><th>H5N6</th><th>H7N9</th><th>H9N2</th><th>Total</th></tr></thead><tbody><tr><td rowspan="6">Hospital A</td><td>1</td><td>8203</td><td>188</td><td>2.29</td><td>30</td><td>0</td><td>1</td><td>NA</td><td>0</td><td>0</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>1</td></tr><tr><td>2</td><td>123,731</td><td>2100</td><td>1.70</td><td>721</td><td>53</td><td>20</td><td>NA</td><td>0</td><td>8</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>81</td></tr><tr><td>3</td><td>503,835</td><td>17,190</td><td>3.41</td><td>2692</td><td>47</td><td>31</td><td>188</td><td>59</td><td>64</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>389</td></tr><tr><td>4</td><td>379,441</td><td>10,014</td><td>2.64</td><td>641</td><td>41</td><td>0</td><td>31</td><td>0</td><td>12</td><td>0</td><td>NA</td><td>1</td><td>0</td><td>85</td></tr><tr><td>5</td><td>1,163,601</td><td>66,779</td><td>5.74</td><td>3534</td><td>178</td><td>0</td><td>124</td><td>1</td><td>202</td><td>0</td><td>1</td><td>0</td><td>2</td><td>508</td></tr><tr><td>Total</td><td>2,178,811</td><td>96,271</td><td>4.42</td><td>7618</td><td>319</td><td>52</td><td>343</td><td>60</td><td>286</td><td>0</td><td>1</td><td>1</td><td>2</td><td>1064</td></tr><tr><td rowspan="6">Hospital B</td><td>1</td><td>7754</td><td>452</td><td>5.83</td><td>29</td><td>0</td><td>1</td><td>NA</td><td>0</td><td>0</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>1</td></tr><tr><td>2</td><td>177,460</td><td>2089</td><td>1.18</td><td>596</td><td>50</td><td>30</td><td>NA</td><td>0</td><td>1</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>81</td></tr><tr><td>3</td><td>479,086</td><td>13,045</td><td>2.72</td><td>2626</td><td>58</td><td>52</td><td>171</td><td>46</td><td>73</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>400</td></tr><tr><td>4</td><td>174,345</td><td>2382</td><td>1.37</td><td>651</td><td>43</td><td>0</td><td>30</td><td>0</td><td>8</td><td>0</td><td>NA</td><td>0</td><td>0</td><td>81</td></tr><tr><td>5</td><td>534,461</td><td>11,837</td><td>2.21</td><td>3393</td><td>151</td><td>0</td><td>66</td><td>0</td><td>172</td><td>0</td><td>0</td><td>0</td><td>0</td><td>389</td></tr><tr><td>Total</td><td>1,373,106</td><td>29,805</td><td>2.17</td><td>7295</td><td>302</td><td>83</td><td>267</td><td>46</td><td>254</td><td>0</td><td>0</td><td>0</td><td>0</td><td>952</td></tr><tr><td rowspan="5">Total</td><td>1</td><td>15,957</td><td>640</td><td>8.12</td><td>59</td><td>0</td><td>2</td><td>NA</td><td>0</td><td>0</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>2</td></tr><tr><td>2</td><td>301,191</td><td>4189</td><td>2.87</td><td>1317</td><td>103</td><td>50</td><td>NA</td><td>0</td><td>9</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>162</td></tr><tr><td>3</td><td>982,921</td><td>30,235</td><td>6.13</td><td>5318</td><td>105</td><td>83</td><td>359</td><td>105</td><td>137</td><td>0</td><td>NA</td><td>NA</td><td>0</td><td>789</td></tr><tr><td>4</td><td>553,786</td><td>12,396</td><td>4.01</td><td>1292</td><td>84</td><td>0</td><td>61</td><td>0</td><td>20</td><td>0</td><td>NA</td><td>1</td><td>0</td><td>166</td></tr><tr><td>5</td><td>1,698,062</td><td>78,616</td><td>7.95</td><td>6927</td><td>329</td><td>0</td><td>190</td><td>1</td><td>374</td><td>0</td><td>1</td><td>0</td><td>2</td><td>897</td></tr><tr><td/><td>Total</td><td>3,551,917</td><td>126,076</td><td>3.55</td><td>14,913</td><td>621</td><td>135</td><td>610</td><td>106</td><td>540</td><td>0</td><td>1</td><td>1</td><td>2</td><td>2016</td></tr></tbody></table><table-wrap-foot><p><italic>ILI</italic> influenza-like illness, <italic>NA</italic> not available</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec5">
        <title>The new pneumonia surveillance system</title>
        <p id="Par14">The PSS was built in Changsha in March, 2009. Pneumonia related inpatient departments in all 49 hospitals (excluding the primary health care centers and private clinics) in Changsha were enrolled into the system. This system monitors pneumonia cases among inpatient population. The public health staff in the surveillance hospitals would count the total number of monitored inpatients, pneumonia cases, severe or death pneumonia cases diagnosed by physicians and then they reported to CDC monthly. When cases were suspected as infected with avian influenza virus by clinicians, the throat swab or lower respiratory tract samples of the suspicious patients (either pneumonia cases, severe or death pneumonia cases) were collected for testing the virus by RT-PCR in the laboratory of Changsha CDC. All the surveillance procedures were performed in every month of each year. However, because H5N6 was first emerged in 2014 and H7N9 in 2013 in China [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], the viruses were not tested from ISS stage 1 to 4, and from ISS stage 1 to 3, respectively (Table <xref rid="Tab1" ref-type="table">1</xref>). The PSS system may monitor influenza and emerging avian influenza cases with severe symptoms or death (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). In this study, we collected the data of the system from March, 2009 to September, 2016.</p>
      </sec>
      <sec id="Sec6">
        <title>Statistical methods</title>
        <p id="Par15">The sentinel hospitals A and B are located in the south and north in the same city. We assumed that the outpatients were from the same age group. Therefore, three indicators (<italic>d</italic><sub>1</sub>, <italic>d</italic><sub>2</sub> and <italic>d</italic><sub>3</sub>) were used to compare the difference between the two hospitals among the five stages. They were the differences of weekly number of monitored outpatients, ILI, and ILI% of the two hospitals, and were expressed as follows:
<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {d}_1={x}_A-{x}_B $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:math><graphic xlink:href="12879_2019_4405_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {d}_2={y}_A-{y}_B $$\end{document}</tex-math><mml:math id="M4" display="block"><mml:msub><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:math><graphic xlink:href="12879_2019_4405_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equc"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {d}_3={z}_A-{z}_B $$\end{document}</tex-math><mml:math id="M6" display="block"><mml:msub><mml:mi>d</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>A</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:math><graphic xlink:href="12879_2019_4405_Article_Equc.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par16"><italic>x</italic><sub><italic>A</italic></sub>, <italic>x</italic><sub><italic>B</italic></sub>, <italic>y</italic><sub><italic>A</italic></sub>, <italic>y</italic><sub><italic>B</italic></sub>, <italic>z</italic><sub><italic>A</italic></sub> and <italic>z</italic><sub><italic>B</italic></sub> refer to weekly number of monitored outpatients of hospital A, weekly number of monitored outpatients of hospital B, weekly ILI of hospital A, weekly ILI of hospital B, weekly ILI% of hospital A, and weekly ILI% of hospital B.</p>
        <p id="Par17">The Analysis of variance (ANOVA) was employed to show the <italic>d</italic><sub>1</sub>, <italic>d</italic><sub>2</sub> and <italic>d</italic><sub>3</sub> among the five surveillance stages of the two sentinel hospitals. If there is a statistical significance, the Least Significant Difference (LSD) method will be adopted to conduct the multiple comparisons between any two stages. <italic>P</italic>&#x2009;&lt;&#x2009;&#xA0;0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Results</title>
      <sec id="Sec8">
        <title>Influenza surveillance system</title>
        <p id="Par18">From week 39 (from 26th September to 2nd October) in 2005 to week 41 (from10<sup>th</sup> October to 16th October) in 2016, a total of 3,551,917 outpatients were monitored by the ISS system, among whom 126,076 were ILI cases, with the ILI% of 3.55% (Table <xref rid="Tab1" ref-type="table">1</xref>). From the two sentinel hospitals, the total monitored outpatients numbers were 2,178,811 and 1,373,106, ILI were 96,271 and 29,805, and ILI% were 4.42 and 2.17%, respectively (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
        <p id="Par19">The results of ANOVA showed that the <italic>d</italic><sub>1</sub>, <italic>d</italic><sub>2</sub> and <italic>d</italic><sub>3</sub> were significantly different among the five surveillance stages (<italic>P</italic>&#x2009;&lt;&#x2009;&#xA0;0.001). The results of multiple comparisons by LSD method showed a significant difference in the number of outpatients monitored weekly between hospital A and B between any two stages except between stage 1 and 3. The weekly ILI in hospital A during stage 4 and 5 were shown to be statistically significant compared to hospital B, but no statistical significance during the stages from 1 to 3. The weekly numbers of ILI% in hospital A were shown significance to hospital B during almost all stages except between stage 3 and 4 (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). These results indicated that HIS could improve the efficiency of ISS system in monitoring ILI and ILI% significantly (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Multiple comparisons of surveilled patients, ILI and ILI% among different stages between two sentinel hospitals based on Least Significant Difference method</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Dependent variables</th><th>Stages (I)</th><th>Stages (J)</th><th>Mean difference (I-J)</th><th>
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="20">Surveilled patients</td><td>Stage 1</td><td>Stage 2</td><td>548.7(<sup>a</sup>)</td><td>0.006</td></tr><tr><td/><td>Stage 3</td><td>&#x2212;83.6</td><td>0.667</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;&#x2009;2856.6(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;3583.7(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 2</td><td>Stage 1</td><td>&#x2212;&#x2009;548.7(<sup>a</sup>)</td><td>0.006</td></tr><tr><td/><td>Stage 3</td><td>&#x2212;&#x2009;632.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;&#x2009;3405.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;4132.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 3</td><td>Stage 1</td><td>83.66</td><td>0.667</td></tr><tr><td/><td>Stage 2</td><td>632.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;&#x2009;2773.0(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;3500.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 4</td><td>Stage 1</td><td>2856.6(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>3405.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>2773.0(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;727.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 5</td><td>Stage 1</td><td>3583.7(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>4132.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>3500.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 4</td><td>727.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td rowspan="20">ILI</td><td>Stage 1</td><td>Stage 2</td><td>&#x2212;19.0</td><td>0.557</td></tr><tr><td/><td>Stage 3</td><td>&#x2212;38.2</td><td>0.222</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;126.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;334.6(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 2</td><td>Stage 1</td><td>19.0</td><td>0.557</td></tr><tr><td/><td>Stage 3</td><td>&#x2212;19.3</td><td>0.156</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;&#x2009;107.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;315.7(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 3</td><td>Stage 1</td><td>38.2</td><td>0.222</td></tr><tr><td/><td>Stage 2</td><td>19.3</td><td>0.156</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;88.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;&#x2009;296.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 4</td><td>Stage 1</td><td>126.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>107.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>88.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;208.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 5</td><td>Stage 1</td><td>334.6(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>315.7(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>296.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 4</td><td>208.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td rowspan="20">ILI%</td><td>Stage 1</td><td>Stage 2</td><td>&#x2212;5.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>&#x2212;5.9(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;6.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;8.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 2</td><td>Stage 1</td><td>5.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>&#x2212;0.6(<sup>a</sup>)</td><td>0.029</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;0.8(<sup>a</sup>)</td><td>0.018</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;3.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 3</td><td>Stage 1</td><td>5.9(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>0.6(<sup>a</sup>)</td><td>0.029</td></tr><tr><td/><td>Stage 4</td><td>&#x2212;0.2</td><td>0.452</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;2.5(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 4</td><td>Stage 1</td><td>6.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>0.8(<sup>a</sup>)</td><td>0.018</td></tr><tr><td/><td>Stage 3</td><td>0.2</td><td>0.452</td></tr><tr><td/><td>Stage 5</td><td>&#x2212;2.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td>Stage 5</td><td>Stage 1</td><td>8.4(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 2</td><td>3.1(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 3</td><td>2.5(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr><tr><td/><td>Stage 4</td><td>2.3(<sup>a</sup>)</td><td>&lt;&#x2009; 0.001</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> The mean difference is significant at the 0.05 level. ILI, influenza-like illness</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Temporal distributions of weekly monitored outpatients, ILI and ILI% of two sentinel hospitals in Changsha City form week 39, 2005 to week 41, 2016. <bold>a</bold>, temporal distributions of weekly monitored outpatients; <bold>b</bold>, temporal distributions of weekly ILI; <bold>c</bold>, temporal distributions of weekly ILI%</p></caption><graphic xlink:href="12879_2019_4405_Fig3_HTML" id="MO3"/></fig></p>
        <p id="Par20">The seasonality of ILI in hospital A matched the activity of influenza virus better than hospital B after the use of HIS (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Two ILI peaks were almost recorded in each year from the ISS system during stages 4 and 5 in hospital A. One peak was recorded in the alternation of winter to spring, and the other one was in summer (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). However, the seasonality of ILI was not shown in hospital B. Because of the HIS, the proportion of tested sample descended in hospital A. However, the proportion of positive samples almost had same tendency in the two hospitals (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). The inpatient cases on pneumonia ascended after &#x201C;HIS (stage 1)&#x201D; in hospital A (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Temporal distributions of weekly ILI and weekly number of estimated influenza cases in two sentinel hospitals in Changsha City form week 39, 2005 to week 41, 2016. <bold>a</bold> temporal distributions of weekly ILI and influenza cases in hospital A; <bold>b</bold> temporal distributions of weekly ILI and influenza cases in hospital B. The estimated influenza cases&#x2009;=&#x2009;the number of ILI cases &#xD7; the proportion of positive samples</p></caption><graphic xlink:href="12879_2019_4405_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Temporal distributions of weekly proportion of tested samples and weekly proportion of positive samples in two sentinel hospitals in Changsha City, week 39, 2005 to week 41, 2016. <bold>a</bold> Hospital A; <bold>b</bold> Hospital B</p></caption><graphic xlink:href="12879_2019_4405_Fig5_HTML" id="MO5"/></fig>
<fig id="Fig6"><label>Fig. 6</label><caption><p>Temporal distributions of pneumonia cases in 49 hospitals and two influenza surveillance sentinel hospitals in Changsha City, March, 2009 to September, 2016. <bold>a</bold> 49 hospitals; <bold>b</bold> hospital A; <bold>c</bold> hospital B</p></caption><graphic xlink:href="12879_2019_4405_Fig6_HTML" id="MO6"/></fig></p>
        <p id="Par21">There was a total of 14,913 throat swabs collected from the two hospitals during the five surveillance stages, among which 2016 were tested positive to influenza or avian influenza virus. Among the positive results, there were 621 with H3N2, 135 with H1N1 (seasonal influenza virus), 610 with H1N1pdm (influenza A / H1N1 from 2009), 106 with untyped influenza A, 540 with B, 1 with H5N6, 1 with H7N9, and 2 with H9N2 virus. The numbers of influenza virus from the two hospitals were similar during the five stages. However, the outcomes of monitoring avian influenza virus were different between the two hospitals. In stage 4, one mild H7N9 case was captured in hospital A when the HIS was adopted at HIS (stage 1). In stage 5, one mild H5N6 case and two mild H7N9 cases were captured in hospital A when the HIS was adopted at HIS (stage 2) (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
      </sec>
      <sec id="Sec9">
        <title>Pneumonia surveillance system</title>
        <p id="Par22">From March, 2009 to September, 2016, there were 5,491,560 inpatients monitored by the PSS system and 362,743 pneumonia cases, with the rate of 6.61%. About 10.55% (38,260/362,743) of the cases reported on pneumonia were severe or death cases. The incidence of pneumonia increased each year in Changsha (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). The seasonality of pneumonia was observed in spring (Fig. <xref rid="Fig6" ref-type="fig">6</xref>a).</p>
        <p id="Par23">We collected 3401 throat swab or lower respiratory tract samples, among which 2094 were tested positive to influenza or avian influenza virus. Among the positive results, 78 were H3N2, 17 were seasonal H1N1, 1871 were H1N1pdm, 103 were untyped influenza A, 16 were B, 1 was H5N6, and 8 were H7N9 virus. The activity of H7N9 virus and that of seasonal viruses especially H1N1pdm were observed in 2014 (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Outcomes of pneumonia surveillance system in Changsha City, China</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Year</th><th rowspan="2">Surveilled patients</th><th rowspan="2">Number of pneumonia cases</th><th rowspan="2">Number of severe / death cases</th><th rowspan="2">Number of tested specimens</th><th colspan="10">Number of positive</th></tr><tr><th>H3N2</th><th>H1N1</th><th>H1N1pdm</th><th>A (untyped)</th><th>B</th><th>H5N1</th><th>H5N6</th><th>H7N9</th><th>H9N2</th><th>Total</th></tr></thead><tbody><tr><td>2009</td><td>394,683</td><td>27,388</td><td>1892</td><td>2944</td><td>69</td><td>17</td><td>1794</td><td>102</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1982</td></tr><tr><td>2010</td><td>650,244</td><td>30,503</td><td>3431</td><td>136</td><td>1</td><td>0</td><td>9</td><td>1</td><td>6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>17</td></tr><tr><td>2011</td><td>748,361</td><td>34,602</td><td>4537</td><td>142</td><td>0</td><td>0</td><td>29</td><td>0</td><td>5</td><td>0</td><td>0</td><td>0</td><td>0</td><td>34</td></tr><tr><td>2012</td><td>820,482</td><td>39,831</td><td>4890</td><td>10</td><td>3</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>3</td></tr><tr><td>2013</td><td>883,769</td><td>47,283</td><td>6250</td><td>29</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td></tr><tr><td>2014</td><td>798,792</td><td>62,726</td><td>7041</td><td>81</td><td>5</td><td>0</td><td>21</td><td>0</td><td>4</td><td>0</td><td>0</td><td>7</td><td>0</td><td>37</td></tr><tr><td>2015</td><td>672,289</td><td>67,205</td><td>5765</td><td>16</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>2016</td><td>522,940</td><td>53,205</td><td>4454</td><td>43</td><td>0</td><td>0</td><td>18</td><td>0</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>20</td></tr><tr><td>Total</td><td>5,491,560</td><td>362,743</td><td>38,260</td><td>3401</td><td>78</td><td>17</td><td>1871</td><td>103</td><td>16</td><td>0</td><td>1</td><td>8</td><td>0</td><td>2094</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec10">
        <title>Emerging avian influenza cases</title>
        <p id="Par24">There were 15 avian influenza cases reported from January, 2005 to September, 2016 (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>). Four cases were mild ones that were detected by the ISS system. Nine cases were severe or death cases that were detected by the PSS system. Two H5N1 severe cases were missed by both systems in January, 2009 when the PSS system was not available. Two H5N6 cases, of which one was mild case reported by the ISS system in 2014 and the other was severe case reported by the PSS system in 2016, were detected in Changsha. Nine H7N9 cases were reported by the two systems. One of them was mild case and was detected by the ISS system in 2013 and the other eight were severe / death cases detected by the PSS system in 2014. Two H9N2 cases were mild cases and were detected by the PSS system in 2016.
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Avian influenza cases detected by different ways in Changsha City, China</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Avian influenza virus</th><th>Category of cases</th><th>Detected by ISS system</th><th>Detected by PSS system</th><th>Other ways</th><th>Total</th></tr></thead><tbody><tr><td rowspan="2">H5N1</td><td>Mild cases</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Severe / death cases</td><td>0</td><td>0</td><td>2</td><td>2</td></tr><tr><td rowspan="2">H5N6</td><td>Mild cases</td><td>1</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Severe / death cases</td><td>0</td><td>1</td><td>0</td><td>1</td></tr><tr><td rowspan="2">H7N9</td><td>Mild cases</td><td>1</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Severe / death cases</td><td>0</td><td>8</td><td>0</td><td>8</td></tr><tr><td rowspan="2">H9N2</td><td>Mild cases</td><td>2</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Severe / death cases</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td rowspan="2">Total</td><td>Mild cases</td><td>4</td><td>0</td><td>0</td><td>4</td></tr><tr><td>Severe / death cases</td><td>0</td><td>9</td><td>2</td><td>11</td></tr></tbody></table><table-wrap-foot><p><italic>ISS</italic> influenza surveillance system, <italic>PSS</italic> pneumonia surveillance system</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Discussion</title>
      <p id="Par25">The avian influenza viruses have spread to many countries including China, Thailand [<xref ref-type="bibr" rid="CR26">26</xref>], Vietnam [<xref ref-type="bibr" rid="CR27">27</xref>], Cambodia [<xref ref-type="bibr" rid="CR28">28</xref>], Turkey [<xref ref-type="bibr" rid="CR8">8</xref>], the Republic of Azerbaijan [<xref ref-type="bibr" rid="CR9">9</xref>], Indonesia [<xref ref-type="bibr" rid="CR29">29</xref>], and Egypt [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. To control the transmission of the disease, surveillance systems with high sensitivity and specificity need to be created. The surveillance system is commonly used for monitoring ILI for detecting avian influenza virus [<xref ref-type="bibr" rid="CR30">30</xref>]. In Egypt, clinicians refer all persons with ILI and&#x2009;&lt;&#x2009;2-week history of poultry contact to one of the Chest and Fever hospitals throughout the country. The respiratory samples of ILI cases are collected to test influenza virus. Daily respiratory samples are also collected from 2 ILI cases and from all patients admitted with severe acute respiratory infection (defined as hospitalization occurring within 2&#x2009;weeks of onset of fever and cough) in 8 sentinel sites [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
      <p id="Par26">In Changsha City, the ISS and PSS are different with the surveillance systems in Egypt. The ISS focuses on detecting mild cases while the PSS focuses on severe or death cases infected with influenza and emerging avian influenza viruses (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Therefore, the two systems together could monitor the viruses with different symptoms. The PSS, which covered by all secondary and tertiary hospitals in the city, is built primarily to monitor pneumonia cases. Therefore, the PSS could provide us with the data to estimate the burden of pneumonia and the pathogen spectrum of pneumonia including influenza and emerging avian influenza viruses.</p>
      <p id="Par27">According to our results, we found that the efficiency for monitoring ILI and emerging avian influenza virus was improved after the HIS was used in hospital A. The differences of ILI were significant between stages 1 to 3 and stages 4 to 5, and between hospital A and hospital B after the HIS was used. All the mild emerging avian influenza cases (H5N6, H7N9, H9N2) were detected in the hospital A where the HIS was adopted. These results would encourage a higher coverage of the HIS and the quality of the influenza surveillance in China, to reduce the repetitive work of doctors and avoid bias from the manual counting. Moreover, the probability of finding out influenza and avian influenza virus would be higher than the existing surveillance system because more ILI cases would be recorded by HIS.</p>
      <p id="Par28">Because the ISS only focuses on the mild cases or the early stage of the infection, the surveillance of severe influenza or avian influenza cases is dependent on the PSS. The PSS is a system built in Changsha City and covers all the hospitals that have inpatient departments. Because the PSS focuses on pneumonia cases instead of PUE cases, the system might be more sensitive in detecting influenza virus and emerging avian influenza virus. The PSS has not only given us a way to estimate the disease burden of pneumonia cases in the city, but also has played an important role in controlling and preventing seasonal influenza each year, the pandemic of influenza A (H1N1) in 2009, and the emerging avian influenza such as H5N6 and H7N9 by detecting the severe cases of the infection with these viruses.</p>
      <p id="Par29">Co-infection of seasonal and avian influenza viruses was commonly observed [<xref ref-type="bibr" rid="CR31">31</xref>]. However, the co-infection was not observed by the ISS in our study. But the activity of H7N9 virus and that of seasonal viruses especially H1N1pdm were observed by the PSS in 2014. This difference might be due to the limited number of reported avian influenza cases in the PSS.</p>
      <sec id="Sec12">
        <title>Limitations</title>
        <p id="Par30">This study has several limitations. Firstly, in the surveillance procedure of the two systems, the tested samples were not chosen randomly, which might affect the surveillance outcomes and thus might impact our findings. Secondly, although the two systems have run stably for a long time and covered a large population, the number of avian influenza cases was limited. It still needs a longer time and a larger population to assess the sensitivity and specificity of the systems. In addition, the ISS system only covers two sentinel hospitals, and the coverage of the system should be improved. The missing PSS data in hospital B from late 2015 to 2016 might underestimate the ability of the PSS system in detecting the viruses. Limited by the small number of reported avian influenza cases in PSS, the co-infection of seasonal and avian influenza viruses might not be observed apparently. Our findings also showed that the number of severe pneumonia cases decreased significantly in late 2014 in Hospital A (Fig. <xref rid="Fig6" ref-type="fig">6</xref>). The reason for the decrease remains unclear, but the decrease might slightly affect the results of detecting influenza cases.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>Conclusions</title>
      <p id="Par31">The HIS seems to be able to improve the efficiency of the ISS for monitoring ILI and emerging avian influenza virus. Although the PSS could monitor some emerging avian influenza viruses, the efficiency of the system needs to be verified in a wider area and in a longer time span in China.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>Xiaorong Guo, Dong Yang, and Ruchun Liu contributed equally to this study.</p>
      </fn>
      <fn>
        <p>Benhua Zhao and Tianmu Chen senior authors contributed equally to this study.</p>
      </fn>
    </fn-group>
    <ack>
      <p>We thank the staff members at the hospitals, local health departments, and municipal- and county-level CDCs in Changsha City for their valuable assistance in coordinating data collection. We thank Miss Mikah Ngwanguong Hannah in Medical College, Xiamen University for her English language editing.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>TC, BZ, and RL designed the research; RL, DY, YL, YLL, HZ, and XZ collected the data; TC, and XG conceived the experiments, TC, XG, DY and RL conducted the experiments and analyzed the results; TC, QH and XM wrote the manuscript. All authors read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>This study was partly supported by the Open Research Fund of State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics (SKLVD2018KF001 and SKLVD2018KF002). The funding body had no role in the study design, collection, analysis, interpretation of data and in writing the manuscript.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.</p>
    </notes>
    <notes>
      <title>Ethics approval and consent to participate</title>
      <p id="Par43">This effort of outbreak control and investigation was part of CDC&#x2019;s routine responsibility in Changsha City; therefore, institutional review and informed consent were waived by Medical Ethics Committee of Changsha Center for Disease Control and Prevention on the following grounds: (1) all data analyzed were anonymized.; (2) neither medical intervention nor biological samples were involved; (3) study procedures and results would not affect clinical management of patients in any form.</p>
    </notes>
    <notes>
      <title>Consent for publication</title>
      <p id="Par44">Not applicable.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par45">No authors declare a conflict of interest.</p>
    </notes>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ANOVA</term>
          <def>
            <p id="Par32">Analysis of variance</p>
          </def>
        </def-item>
        <def-item>
          <term>CDC</term>
          <def>
            <p id="Par33">Center for Disease Control and Prevention</p>
          </def>
        </def-item>
        <def-item>
          <term>HIS</term>
          <def>
            <p id="Par34">Hospital information system</p>
          </def>
        </def-item>
        <def-item>
          <term>ICD-10</term>
          <def>
            <p id="Par35">International Classification of Diseases 10th Revision</p>
          </def>
        </def-item>
        <def-item>
          <term>ILI</term>
          <def>
            <p id="Par36">Influenza-like illness</p>
          </def>
        </def-item>
        <def-item>
          <term>ISS</term>
          <def>
            <p id="Par37">Influenza surveillance system</p>
          </def>
        </def-item>
        <def-item>
          <term>LSD</term>
          <def>
            <p id="Par38">Least Significant Difference</p>
          </def>
        </def-item>
        <def-item>
          <term>PSS</term>
          <def>
            <p id="Par39">Pneumonia surveillance system</p>
          </def>
        </def-item>
        <def-item>
          <term>PUE</term>
          <def>
            <p id="Par40">Pneumonia of unknown etiology</p>
          </def>
        </def-item>
        <def-item>
          <term>RT-PCR</term>
          <def>
            <p id="Par41">Reverse transcription polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>SARS</term>
          <def>
            <p id="Par42">Severe acute respiratory syndrome</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and epidemiological characteristics of a fatal case of avian influenza a H10N8 virus infection: a descriptive study</article-title>
          <source>Lancet</source>
          <year>2014</year>
          <volume>383</volume>
          <issue>9918</issue>
          <fpage>714</fpage>
          <lpage>721</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60111-2</pub-id>
          <pub-id pub-id-type="pmid">24507376</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Symptoms seem to be mild in children infected with avian influenza a (H5N6) and other subtypes</article-title>
          <source>J Infec</source>
          <year>2015</year>
          <volume>71</volume>
          <issue>6</issue>
          <fpage>702</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jinf.2015.09.004</pub-id>
          <pub-id pub-id-type="pmid">26380897</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tsang</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human infection with influenza a(H7N9) virus during 3 major epidemic waves, China, 2013-2015</article-title>
          <source>Emerg Infect Dis</source>
          <year>2016</year>
          <volume>22</volume>
          <issue>6</issue>
          <fpage>964</fpage>
          <lpage>972</lpage>
          <pub-id pub-id-type="doi">10.3201/eid2206.151752</pub-id>
          <pub-id pub-id-type="pmid">27191934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cowling</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wardrop</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsang</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global epidemiology of avian influenza a H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data</article-title>
          <source>Lancet Infect Dis</source>
          <year>2016</year>
          <volume>16</volume>
          <issue>7</issue>
          <fpage>e108</fpage>
          <lpage>e118</lpage>
          <pub-id pub-id-type="doi">10.1016/S1473-3099(16)00153-5</pub-id>
          <pub-id pub-id-type="pmid">27211899</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Continual antigenic diversification in China leads to global antigenic complexity of avian influenza H5N1 viruses</article-title>
          <source>Sci Rep</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>43566</fpage>
          <pub-id pub-id-type="doi">10.1038/srep43566</pub-id>
          <pub-id pub-id-type="pmid">28262734</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beigel</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Farrar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Hayden</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Hyer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lochindarat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>TH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Avian influenza a (H5N1) infection in humans</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <issue>13</issue>
          <fpage>1374</fpage>
          <lpage>1385</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra052211</pub-id>
          <pub-id pub-id-type="pmid">16192482</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza AV</collab>
            <name>
              <surname>Abdel-Ghafar</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Chotpitayasunondh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Hayden</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Naghdaliyev</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peiris</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Shindo</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Update on avian influenza A (H5N1) virus infection in humans</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>358</volume>
          <issue>3</issue>
          <fpage>261</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra0707279</pub-id>
          <pub-id pub-id-type="pmid">18199865</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oner</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Bay</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arslan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akdeniz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sahin</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Cesur</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Epcacan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Deger</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kizilyildiz</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Avian influenza a (H5N1) infection in eastern Turkey in 2006</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>355</volume>
          <issue>21</issue>
          <fpage>2179</fpage>
          <lpage>2185</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa060601</pub-id>
          <pub-id pub-id-type="pmid">17124015</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilsdorf</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boxall</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gasimov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Agayev</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mammadzade</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ursu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gasimov</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mardel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jankovic</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two clusters of human infection with influenza a/H5N1 virus in the republic of Azerbaijan, February-march 2006</article-title>
          <source>Euro Surveill</source>
          <year>2006</year>
          <volume>11</volume>
          <issue>5</issue>
          <fpage>122</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="doi">10.2807/esm.11.05.00620-en</pub-id>
          <pub-id pub-id-type="pmid">16757853</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kayali</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kandeil</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>El-Shesheny</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kayed</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Gomaa</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Maatouq</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Shehata</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Moatasim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Bagato</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Active surveillance for avian influenza virus, Egypt, 2010-2012</article-title>
          <source>Emerg Infect Dis</source>
          <year>2014</year>
          <volume>20</volume>
          <issue>4</issue>
          <fpage>542</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.3201/eid2004.131295</pub-id>
          <pub-id pub-id-type="pmid">24655395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jie</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human infection with a novel avian-origin influenza a (H7N9) virus</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <issue>20</issue>
          <fpage>1888</fpage>
          <lpage>1897</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1304459</pub-id>
          <pub-id pub-id-type="pmid">23577628</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ou</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical, epidemiological and virological characteristics of the first detected human case of avian influenza a(H5N6) virus</article-title>
          <source>Infect Genet Evol</source>
          <year>2016</year>
          <volume>40</volume>
          <fpage>236</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1016/j.meegid.2016.03.010</pub-id>
          <pub-id pub-id-type="pmid">26973295</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mok</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Da Guan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>XQ</given-names>
            </name>
            <name>
              <surname>Lamers</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XB</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>QL</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>ZT</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic characterization of highly pathogenic avian influenza a(H5N6) virus, Guangdong, China</article-title>
          <source>Emerg Infect Dis</source>
          <year>2015</year>
          <volume>21</volume>
          <issue>12</issue>
          <fpage>2268</fpage>
          <lpage>2271</lpage>
          <pub-id pub-id-type="doi">10.3201/eid2112.150809</pub-id>
          <pub-id pub-id-type="pmid">26584075</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>ZF</given-names>
            </name>
            <name>
              <surname>Mok</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Peiris</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <article-title>Human infection with a novel avian influenza a(H5N6) virus</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>373</volume>
          <issue>5</issue>
          <fpage>487</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc1502983</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human infection with a novel, highly pathogenic avian influenza a (H5N6) virus: Virological and clinical findings</article-title>
          <source>J Infect</source>
          <year>2016</year>
          <volume>72</volume>
          <issue>1</issue>
          <fpage>52</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jinf.2015.06.009</pub-id>
          <pub-id pub-id-type="pmid">26143617</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detection and genetic characteristics of H9N2 avian influenza viruses from live poultry Markets in Hunan Province, China</article-title>
          <source>PloS one</source>
          <year>2015</year>
          <volume>10</volume>
          <issue>11</issue>
          <fpage>e0142584</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0142584</pub-id>
          <pub-id pub-id-type="pmid">26554921</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ip</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bao</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detection of mild to moderate influenza a/H7N9 infection by China's national sentinel surveillance system for influenza-like illness: case series</article-title>
          <source>Bmj</source>
          <year>2013</year>
          <volume>346</volume>
          <fpage>f3693</fpage>
          <pub-id pub-id-type="doi">10.1136/bmj.f3693</pub-id>
          <pub-id pub-id-type="pmid">23798720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Havers</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Use of National Pneumonia Surveillance to Describe Influenza A(H7N9) Virus Epidemiology, China, 2004&#x2013;2013</article-title>
          <source>Emerg Infect Dis</source>
          <year>2013</year>
          <volume>19</volume>
          <issue>11</issue>
          <fpage>1784</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.3201/eid1911.130865</pub-id>
          <pub-id pub-id-type="pmid">24206646</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shay</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influenza-associated mortality in temperate and subtropical Chinese cities, 2003&#x2013;2008</article-title>
          <source>Bull World Health Organ</source>
          <year>2012</year>
          <volume>90</volume>
          <issue>4</issue>
          <fpage>279</fpage>
          <lpage>288B</lpage>
          <pub-id pub-id-type="doi">10.2471/BLT.11.096958</pub-id>
          <pub-id pub-id-type="pmid">22511824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Duan</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Multi personal computer storage system: solution of sea capacity PACS storage</article-title>
          <source>Chin Med J</source>
          <year>2003</year>
          <volume>116</volume>
          <issue>5</issue>
          <fpage>650</fpage>
          <lpage>653</lpage>
          <pub-id pub-id-type="pmid">12875670</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>A study on building data warehouse of hospital information system</article-title>
          <source>Chin Med J</source>
          <year>2011</year>
          <volume>124</volume>
          <issue>15</issue>
          <fpage>2372</fpage>
          <lpage>2377</lpage>
          <pub-id pub-id-type="pmid">21933571</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transmissibility of the influenza virus during influenza outbreaks and related asymptomatic infection in mainland China, 2005-2013</article-title>
          <source>PLoS One</source>
          <year>2016</year>
          <volume>11</volume>
          <issue>11</issue>
          <fpage>e0166180</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0166180</pub-id>
          <pub-id pub-id-type="pmid">27880774</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>QP</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Szot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>The transmissibility estimation of influenza with early stage data of small-scale outbreaks in Changsha, China, 2005-2013</article-title>
          <source>Epidemiol Infect</source>
          <year>2017</year>
          <volume>145</volume>
          <issue>3</issue>
          <fpage>424</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="doi">10.1017/S0950268816002508</pub-id>
          <pub-id pub-id-type="pmid">27834157</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cowling</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Chuang</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Tsang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>The effective reproduction number of pandemic influenza: prospective estimation</article-title>
          <source>Epidemiology</source>
          <year>2010</year>
          <volume>21</volume>
          <issue>6</issue>
          <fpage>842</fpage>
          <lpage>846</lpage>
          <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181f20977</pub-id>
          <pub-id pub-id-type="pmid">20805752</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Nishiura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Seto</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Cowling</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Years of life lost in the first wave of the 2009 influenza a(H1N1) pandemic in Hong Kong</article-title>
          <source>Am J Epidemiol</source>
          <year>2013</year>
          <volume>178</volume>
          <issue>8</issue>
          <fpage>1313</fpage>
          <lpage>1318</lpage>
          <pub-id pub-id-type="doi">10.1093/aje/kwt120</pub-id>
          <pub-id pub-id-type="pmid">23978528</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ungchusak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Auewarakul</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dowell</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Kitphati</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Auwanit</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Puthavathana</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Uiprasertkul</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boonnak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pittayawonganon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>NJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Probable person-to-person transmission of avian influenza a (H5N1)</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <issue>4</issue>
          <fpage>333</fpage>
          <lpage>340</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa044021</pub-id>
          <pub-id pub-id-type="pmid">15668219</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dinh</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Tien</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Hien</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>le TQ</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Phong le</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tuan le</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Van Tan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Van Tu</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk factors for human infection with avian influenza a H5N1, Vietnam, 2004</article-title>
          <source>Emerg Infect Dis</source>
          <year>2006</year>
          <volume>12</volume>
          <issue>12</issue>
          <fpage>1841</fpage>
          <lpage>1847</lpage>
          <pub-id pub-id-type="doi">10.3201/eid1212.060829</pub-id>
          <pub-id pub-id-type="pmid">17326934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ly</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Van Kerkhove</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Achenbach</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Holl</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Buchy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sorn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Seng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Uyeki</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Sok</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk factors associated with subclinical human infection with avian influenza a (H5N1) virus--Cambodia, 2006</article-title>
          <source>J Infect Dis</source>
          <year>2009</year>
          <volume>199</volume>
          <issue>12</issue>
          <fpage>1744</fpage>
          <lpage>1752</lpage>
          <pub-id pub-id-type="doi">10.1086/599208</pub-id>
          <pub-id pub-id-type="pmid">19416078</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Naipospos</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Vijaykrishna</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Usman</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Hassan</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Dao</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Bui</surname>
              <given-names>NA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam</article-title>
          <source>Virology</source>
          <year>2006</year>
          <volume>350</volume>
          <issue>2</issue>
          <fpage>258</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="doi">10.1016/j.virol.2006.03.048</pub-id>
          <pub-id pub-id-type="pmid">16713612</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Refaey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Azziz-Baumgartner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Amin</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Fahim</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roguski</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Elaziz</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Iuliano</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Salah</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Uyeki</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Lindstrom</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased number of human cases of influenza virus a(H5N1) infection, Egypt, 2014-15</article-title>
          <source>Emerg Infect Dis</source>
          <year>2015</year>
          <volume>21</volume>
          <issue>12</issue>
          <fpage>2171</fpage>
          <lpage>2173</lpage>
          <pub-id pub-id-type="doi">10.3201/eid2112.150885</pub-id>
          <pub-id pub-id-type="pmid">26584397</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durand</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Glew</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kasper</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trock</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Bresee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Donis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Uyeki</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Widdowson</surname>
              <given-names>M-A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Timing of influenza a(H5N1) in poultry and humans and seasonal influenza activity worldwide, 2004&#x2013;2013</article-title>
          <source>Emerg Infect Dis</source>
          <year>2015</year>
          <volume>21</volume>
          <issue>2</issue>
          <fpage>202</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.3201/eid2102.140877</pub-id>
          <pub-id pub-id-type="pmid">25625302</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
